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Abstract
Three new fluonmetnc assays were developed for the detection of pyroglutamyl ammopeptidase type-II 
(PAPII) activity Two of these assays are based on hydrolysis of the TRH substrate analogue pGlu-His- 
Pro-MCA, while the third, a continuous assay, exploits the ability o f the enzyme to hydrolyse the 
substrate pGlu-MCA
Following solubilisation o f PAPII from the membrane fraction o f bovme brain, using trypsin, the 
enzyme was purified 3,000-fold, with an overall yield of 24%, using a range o f conventional 
chromatographic techniques
By gel filtration chromatography, a relative molecular mass o f 214,000 Da was determined for the 
enzyme The purified PAPII was found to be relatively labile However, the presence of 1% v/v BSA was 
shown to greatly improve its stability Optimal enzyme activity was observed at 45 °C A pH optimum 
of 6 8-7 6 was observed for the enzyme, with rapid inactivation occurring below pH 4 0 and above pH 
9 2
Purified PAPII was strongly inhibited by the transition metals Cd2+, Hg2+ and Zn2+, while activation 
was observed m the presence of Co2+ The enzyme was identified as a metallopeptidase on the basis of its 
inhibition, in a time dependent manner, by metal-complexing agents and its subsequent reactivation in 
the presence o f metal ions, including Zn2+, N i2+ and Co2+ Inhibition by cysteine protease inhibitors 
and activators and by the senne protease inhibitor AEBSF, was also observed
Substrate specificity studies revealed that, with the exception of pGlu-Phe-Pro-NH2 , pGlu-MCA and 
pGlu-BNA, the purified enzyme cleaves N-terminal pyroglutamic acid from only tn- and tetrapeptides 
with a His residue m the penultimate position A number of N-terminal pyroglutamyl peptides of varying 
length were shown to competitively inhibit the enzyme Of these, LHRH and LHRH 1-5, although not 
substrates for the enzyme, were found to be potent inhibitors, with Kj values o f 8|xM and 11 (iM 
respectively
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Introduction
1 .1  Pyroglutamic Acid
Pyroglutamic acid (pGlu, Glp, <Glu), also known as pyrrolidone carboxylic acid (PCA, pyr) and 5-oxo- 
L-prohne is a cyclical ammo acid with unique properties Structurally, it may be considered to be an 
internally cyclised glutamic acid (see figure 1 1) The presence of the internal amide bond which forms 
between nitrogen-1 and carbon-5 chemically defines pyroglutamic acid as 2-carboxy y-butyrolactam The 
internal linkage is neutral and functionally, acts as an amide (Abraham and Podell, 1981)
Glutamic Acid Pyroglutamic Acid Glutamine
COOH
H2N  C  H
CH,
CH?
COOH
-CH2 
\
0 = C .  HC— COOH
\  /
NH
H2C-
/
COOH
H2N  C  H
CH,
CH,
h 2n o
Figure 1.1 Structures o f  pyroglutamic acid and its two possible amino acid precursors, glutamic acid  
and glutamine
Pyroglutamic acid can be formed non-enzymatically by heating glutamic acid at 150°-160°C However, y- 
denvatives of glutamic acid, for example glutamine, y-esters of glutamic acid and y-glutamyl peptides, 
cyclise much more rapidly than glutamic acid itself The non-enzymatic cyclisation of glutamine is 
substantial even at 37°C, 10% being converted to pyroglutamic acid after 24 hours (Orlowski and 
Meister, 1971)
The enzymatic synthesis of pyroglutamic acid, by a range of enzymes, has been demonstrated and is 
reviewed by Orlowski and Meister (1971) and Abraham and Podell (1981) The first indication of the 
enzymatic synthesis of pyroglutamic acid was the discovery o f D-Glutamic acid cyclotransferase, an 
enzyme found in kidney and liver which is capable of converting D-glutamic acid to D-pyroglutamic acid 
Orlowski and Meister (1971) suggest that the role of this enzyme may be to detoxify D-glutamic acid, 
present m the diet or formed by bacterial metabolism in the intestine D-glutamic acid is one of the most 
abundant bacterial D-amino acids and is a very poor substrate for D-amino acid oxidase L-glutamic acid 
cyclotransferase (L-glutamic acid dehydrase) has been found in a variant of Pseudomonas cruciviae (Akida 
et a l , 1959)
Glutamine synthetase, distributed widely in plants and animals, in the presence of ArI P and Mg2+, 
catalyses the synthesis of L-gluumine and D-glutamine Irom the respective optical isomers of glutamic 
acid y-glutamylcysteine synthetase can also catalyse the formation ol pyroglutamic acid in die presence
of ATP, L-cysteine and Mg2+, through the formation of the intermediate L-y-glutamyl-L-cysteme 
However, it is unlikely that this relatively slow reaction can be o f any physiological significance 
(Orlowski and Meister, 1971)
L-glutamme cyclotransferase, discovered m Papaya latex by Messer (1963), catalyses the conversion of 
glutamine and glutaminyl peptides to pyroglutamic acid and pyroglutamyl peptides respectively This 
enzyme has not yet been found in animal tissue, however, the conversion o f glutamine to pyroglutamic 
acid by a two step enzyme catalysed reaction has been observed Glutamine can be converted to y- 
glutamyl-glutamine by the enzyme y-glutamyl transpeptidase (y-glutamyl transferase) and subsequently 
converted to pyroglutamic acid by y-L-glutamyl cyclotransferase (y-glutamyl lactamase), (Orlowski et 
a l , 1969) This enzyme is widely distributed m animal tissues with relatively high levels of activity in 
kidney, liver, brain and skm In man, the highest levels of activity are found in the brain Orlowski and 
Meister (1971) suggest that this wide distribution implies metabolic significance for this enzyme A 
mammalian glutaminyl cyclase, capable of converting glutaminyl peptides into pyroglutamyl peptides 
was identified by Fischer and Spiess (1987)
It has been clearly demonstrated that exogenous pyroglutamic acid is not utilised in protein biosynthesis 
Instead, N-terminal pyroglutamic acid must be formed by cyclisation of the amino-termmal residue (i e 
glutamine or glutamic acid) It is most likely formed either late in protein translation or immediately 
prior to secretion o f the completed protein from the cell (Abraham and Podell, 1981)
Pyroglutamic acid is present at the N-terminus of many proteins and bioactive peptides with diverse 
biological functions (see table 1 1) The activity of some bioactive peptides is dependent on the presence 
of this N-terminal residue (Abraham and Podell, 1981) As a free acid, pyroglutamic acid has been found 
in the tissue of patients with Hawkinsmuna disease (Borden et a l , 1992) An increased level o f the free 
acid has been shown in the plasma of patients with Huntington's disease (Uhlhass and Lange, 1988) It 
has been found to prevent scopolamine-induced amnesia and electroconvulsive shock in rats (Spignoli et 
a l , 1987) and to improve learning and age associated memory loss (Gnoli et a l , 1990) In addition to the 
aforementioned physiological significance of pyroglutamic acid, its presence at the N-terminus of 
polypeptides may confer resistance to non-specific proteolytic degradation
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T able 1.1 Some Peptides and Proteins with an N-terminal pGlu Residue
Peptide / Protein Sequence
TRH pGlu-His-Pro-NH2
TRH-Like Peptides
Prostate (Fertilisation Promoting Peptide) pGlu-Glu-Pro-NH2
Testis pGlu-Phe-Pro-NH2
Alfalfa pGlu-Tyr-Pro-NH2
Neurotensin pGlu-Leu-T yr-Glu-Asn-
Bombesm pGlu-Gln-Arg-Leu-Gly-
Eledoisin pGlu-Pro-Ser-Lys-
Anorexogemc Peptide pGlu-His-Gly-OH
Fastigiatine pGlu-Glu-Gln-OH
Fibnnopeptidase B
Human pGlu-Gly-Val-Asp(NH2)-
Reindeer pGIu-Leu-Ala-Asp-
Bovme pGlu-Phe-Pro-Thr-Asp-
Physalaemin pGlu-Ala-Asp(OH)-Pro-
Peptides From Snake Venoms pGlu-Asp(NH2)-Trp
pGlu-Glu(NH2)-Trp
Eiseine pGlu-Glu-Ala-OH
Gastrin
Human pGlu-Gly-Pro-Trp-Leu-
Porcine pGIu-Gly-Pro-Trp-Met-
Vasoactive Polypeptide pGlu-Val-Pro-Trp-
Heavy Chain From Human Pathological IgG pGlu-Val-Thr-
Heavy Cham of Human 7G Immunoglobulin pGlu-Val-Gln-Leu-
Heavy Chains o f Rabbit Anti-Hapten Antibodies pGlu-Ser-Leu-GIu-Glu-
Heavy Chains of Rabbit IgG pGlu-Ser-Val-Glu-Glu-
Mouse X Chains pGlu-Ala-V al-Val-
a2-CB 1 of Rat Skm Collagen pGIu-Tyr-Ser-Asp-Lys-
Human apoLp-Gln-II pGlu-Ala-Lys-Glu-Pro-
Thymic Factor from Porcine Serum pGlu-Ala-Lys-Ser-Gln-
Hypertrehalosaemic Neuropeptide pGlu-Val-Asn-Phe-Ser-
Peptide Inhibiting Epidermal Mitosis pGlu-Glu-Asp-Cys-Lys-OH
Colon Mitosis Inhibitory Peptide pGlu-GIu-His-Gly-OH
Caerulem pGlu-Gln-Asp-Tyr(S03H)-
Levitide pGlu-Gly-Met-Ile-Gly-Thr-
Porcine Pancreatic Spasmolytic Polypeptide pGlu-Lys-Pro-Ala-Ala-
Human Monocyte Chemoattractant pGlu-Pro-Asp-Ala-Ile-
Growth Hormone From Tilipia pGlu-Gln-Ile-Thr-Asp-
( Iakcn from Awad6 el al (1994) and subsequently modified)
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1.2 Pyroglutamyl Aminopeptidases
Aminopeptidases (EC 3 411  1-14) are N-temunal exopeptidases involved m protein modification and m 
particular, protein and peptide metabolism They exhibit specificity for the hydrolysis o f peptide bonds 
which contain the ammoacyl residue present at the N-termmus of polypeptides Omega peptidases (EC 
3 4 19) are exopeptidases capable o f removing terminal residues that (a) lack a free a-amino or a -  
carboxyl group (l e the pyroglutamyl and ammoacylamide groups), or (b) are linked through a sissile 
bond that involves a carboxyl or ammo group that is not attached to an a-carbon (McDonald and Barrett, 
1986)
\
Pyroglutamyl Aminopeptidases (PAPs) represent one class of omega peptidases which specifically 
remove the L-pyroglutamyl residue from the amino-termmus of polypeptides by hydrolysis (see figure 
1 2) Pyroglutamyl aminopeptidase has also been referred to as pyrrolidonyl peptidase, pyrrohdone 
carboxyl peptidase, pyrrohdone carboxylyl peptidase, pyrrolidonecarboxylate peptidase, pyroglutamyl 
arylamidase, pyroglutamate aminopeptidase, pyroglutamyl peptidase, L-pyroglutamyl peptide hydrolase, 
PYRase and 5-oxoprolyl-peptidase (Awad6 et a l , 1994) To date, two classes of pyroglutamyl 
aminopeptidase have been characterised The first includes bacterial pyroglutamyl aminopeptidase and 
animal type-I pyroglutamyl aminopeptidase (PAPI), a soluble enzyme with biochemical characteristics 
similar to the bacterial PAPs The second class includes animal type-II pyroglutamyl aminopeptidase 
(PAPII), a membrane bound enzyme and serum PAP, also known as Thyrolibermase (Bauer et a l , 1981) 
Enzymes from these two classes present distinct differences m their cellular and subcellular localisation, 
molecular weights and enzymatic properties
O / Cll2
n c h 2 / c h 2.V /  R'
'C CH2\  /  t  PAP v / • +
H N - C H  / C H H 20  W  H2N — CH— C — -
C — NH c - - -  , \  O
|| || COOH
O O
Pyroglutamyl-peptide Pyroglutamic acid n-1 peptide
Figure 1.2 Hydrolysis of pGlu from  the N-terminus o f  L-pGlu-proteins or L-pGlu-peptides by PAP
1.2.1 Class-I: Animal PAPI and Bacterial PAPs
PAP activity was originally discovered in a strain o f Pseudomonas fluorescens  by Doolittle and 
Armentrout (1968) and subsequently in a number o f other species o f bacteria including Bacillus, 
Streptococcus, Staphlococcus, Micrococcus, Sarcima, Citrobacter Klebsiella, Enterobacter, Arizona, 
Neisseria and some strains of Escherichia (Szewczuk and Mulczyk, 1969) Shortly thereafter the enzyme 
was found to be present in a wide range of animal, plant and human tissues (Armentrout, 1969, Szewczuk 
and Kwiatkowska, 1970)
0
4
1 .2 .1 .1  B iochem ical and B iophysical C haracteristics o f C lass-I PAPs
With the exception o f the Klebsiella coacae enzyme, which is associated with the particulate fraction 
(Kwiatkowska et a l , 1974), all o f the bacterial PAPs studied to date have been shown to be soluble 
protems located m the cell cytosol (Tsuru et a l , 1978, Awad6 et a l , 1992) The hydrophobic character of 
four bacterial PAPs (based on the ammo acid sequence deduced from cDNA) indicates that the charge of 
these enzymes is uniformly distributed along the polypeptide This is consistent with the observation that 
the enzymes are soluble proteins (Kyte and Doolittle, 1982) Mammalian PAPI (EC 3 4 19 3), like its 
bacterial counterpart, is also a soluble cytosolic enzyme (Mudge and Fellows, 1973, Browne and 
O'Cumn, 1983, Lauffart et a l , 1988, Cummins and O'Connor, 1996) The enzyme has been found to be 
present in all mammalian tissues tested, with the exception of blood (Szewczuk and Kwiatkowska, 1970) 
The regional distribution o f the enzyme m the supernatant fractions o f rat brain reveals less than a two 
fold variation m regions from lowest to highest concentrations (Friedman and Wilk, 1986)
The mammalian PAPI is a monomeric enzyme with a molecular weight of 22,000 to 25,000 Daltons 
(Da) (Mudge and Fellows, 1973, Browne and O'Cumn, 1983, Mantle et a l , 1991, Cummins and 
O'Connor, 1996) The molecular weight o f the bacterial enzyme, under non-denatunng conditions, has 
been shown to vary from 50,000 to 91,000 Da These molecular weights represent multimenc forms of 
the enzyme with an average subunit molecular weight of approximately 25,000 Da, virtually the same as 
for the mammalian PAPI The genes for bacterial PAP from four sources are either 639 or 645 
nucleotides long, encoding for 213 or 215 ammo acids with deduced molecular weights o f 22,441 to 
23,777 Da (Awadd et a l , 1994)
PAPI and bacterial PAPs are members of the cysteine proteinase family The cysteine residue at the active 
site of the enzyme is very labile and thus, a thiol-reducmg agent such as DTT or 2-mercaptoethanol is 
required for enzyme activity The enzymes are very sensitive to sulphydryl-blocking reagents such as N- 
ethylmaleimide, 2-iodoacetamide, lodoacetate and p-hydroxymercunbenzoate and also to trace amounts of 
heavy metals such as Hg2+, Zn2+, and Cu2+ (Doolittle and Armentrout, 1968, Tsuru et a l , 1978, Bauer 
and Kleinhauf, 1980, Browne and O'Cumn, 1983, Cummins and O’Connor, 1996) The active site 
cysteine has been identified by site directed mutagenesis following cloning of the gene from Bacillus 
amylohquefaciens (Yoshimoto et a l , 1993)
Both the animal PAPI and the bacterial PAPs are unstable and heat sensitive enzymes, being rapidly 
inactivated at temperatures above 50°C Stabilisation of the enzyme has been achieved using the 
reversible inhibitor 2-pyrrohdone (Armentrout and Doolittle, 1969, Szewczuk and Kwiatkowska, 1970, 
Mudge and Fellows, 1973) or by the addition of BSA to the purified enzyme (Cummins and O'Connor, 
1996) Optimal enzyme activity is expressed at pH 8 5 lor purified mammalian PAPI (Lauffart el a l , 
1988, Mantle et a l , 1991, Cummins and O'Connor, 1996) and at pH 7 0 to 9 0 for bacterial PAP 
(Doolittle and Armentrout, 1968, Kwiatkowska et a l , 1974, Awad6 et a l , 1992)
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A distinctive feature of PAPI and bacterial PAPs is a broad substrate specificity These enzymes have 
been shown to cleave N-terminal pGlu from a range of biologically active peptides including TRH, Acid 
TRH, LHRH, Neurotensin and Bombesin (Browne and O'Cuinn, 1983, Cummins and O'Connor, 1996) 
pGlu-Pro bonds are not normally hydrolysed by either bacterial or animal PAPI (Doolittle, 1970, Browne 
and O'Cuinn, 1983, Cummins and O'Connor, 1996) However, the enzyme from the particulate fraction 
of Klebsiella coacae was found to be capable o f hydrolysing the pGlu-Pro bond (Kwiatkowska et a l , 
1974) Initial PAP assays were based on the cleavage of L-pyroglutamyl dipeptides such as L-pGlu-L-Ala 
and monitoring the ammo acid release by the nmhydnn method (Doolittle and Armentrout, 1968) The 
development of the colounmetnc and fluonmetnc substrates L-pGlu-BNA (Szewczuk and Kwiatowska, 
1970), L-pGlu-pNA and L-pGlu-MCA (Fujiwara and Tsuru, 1978) resulted in PAP assays with greatly 
increased sensitivity
PAPI levels in mammals are developmentally regulated In mouse brain, the specific activity is highest 
on the 13th foetal day and declines thereafter until the 20th-22nd postnatal day with a plateau around birth 
(Faivre-Bauman et a l , 1981) Similarly, in rat bram, lung and gut, highest levels of enzyme activity 
were observed m the late foetal stages with a subsequent decrease over the next two weeks to adult levels 
(Fuse et a l , 1990)
There is clear evidence that PAPI is regulated in some cells and tissues The activity if PAPI in CH3 
cells (a clonal line of rat anterior pituitary cells) was elevated following exposure for three days to 5- 
oxoprolmal (a specific PAPI inhibitor) This increase was due to an increase m Vmax and was not 
blocked by a protein synthesis inhibitor This mode o f inhibition may be due to a decrease in the 
degradation of PAPI (Friedman et a l , 1986) The thyroid hormone L-3,5,3'-tniodothyronme (T3 ) 
produced a dose-dependent increase in the specific activity o f PAPI in CH3 cells following three days of 
exposure This increase was blocked by cycloheximide, indicating that the increase was due to enzymatic 
induction The increase was found to be cell specific smce T3 did not alter the specific activity of PAPI in 
the cell line AT-20 (Suen and Wilk, 1987) Chronic, but not acute administration of T3 also elevated 
PAPI m selected bram regions o f the rat (Suen and Wilk, 1989a) An effect similar to that produced by 
T3 was also elicited by sodium butyrate This short chain fatty acid elevated PAPI three-fold in GH3 cells 
(Suen and Wilk, 1989b) However, a number o f reports suggest that PAPI is not regulated by thyroid 
status PAPI levels m rat brain, adenohypophysis and liver have been shown to be unaffected by 
administration of T3 or tetraiodothyromne (T4 ) (Bauer, 1987a, Emerson et al, 1987, Scharfmann et a l ,
1990)
1 .2  1 .2  Inhibitors o f C lass-I I’APs
Potent and specific (both reversible and irreversible) inhibitors of PAPI have been described Active site 
directed inhibitors were first synthesised by Fujiwara et al (1981a, 1981b, 1982), for the D 
amyfohquefaciens enzyme lliese were pGlu-chloromethyl ketone (pGCK), Z-pCrlu chloromethyl ketone
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(Z-pGCK) and Z-pGlu-diazomethyl ketone (Z-pGDK) The chloromethyl ketone denvatives are highly 
potent irreversible inhibitors A three-fold molar excess of inhibitor to enzyme was sufficient to 
inactivate the enzyme by 95% after only one minute incubation This inhibitor was found to be very 
unstable, therefore the Z-pGCK derivative was prepared Although this inhibitor inacuvated the enzyme at 
a ten-fold slower rate, it was nonetheless, quite potent
Aldehydes interact with cysteine protease forming hemiacetal adducts The aldehyde derivative of  
pyroglutamate, 5-oxoprolinal is a potent and specific competitive inhibitor in vitro with a of 20- 
26nM 5-oxoprolmal is also active w  vivo when administered to mice, however its potency is relatively 
weak in vivo , possibly due to rapid metabolism (Friedman et a l , 1985)
pGlu-diazomethyl ketone (PDMK) is an irreversible PAPI inhibitor It is very potent in vivo as well as 
in vitro One hour following mtrapentonal administration of 0 1 mg/kg to mice, the brain enzyme was 
totally inhibited, and after 24 hours the enzyme was still 50% inhibited Since it is an irreversible 
inhibitor, restoration of enzyme activity requires the synthesis of new enzyme (Wilk et a l , 1985)
2-pyrrohdone is a pyroglutamyl substrate analogue which acts as a reversible, non-competitive inhibitor 
of PAPI As mentioned earlier, 2-pyrrolidone has been used to stabilise both the microbial and 
mammalian PAPI
1 .2 .1 .3  Physiological Role and C urrent Uses o f C lass-I PAPs 
As previously mentioned, PAPI has been shown to act on many different substrates having an N-terminal 
pGlu, including TRH Despite earlier interest m the role of PAPI in TRH metabolism, it appears that 
this enzyme is not involved m the control o f TRH levels in vivo (Mendez et a l , 1990, Salers et a l ,
1991) The role o f PAPI still remains unclear It has been proposed that it may contribute to the final 
stages of intracellular catabolism of peptides to free ammo acids which are then released to the cellular 
pool (Mantle et a l , 1990, 1992) Thus the enzyme may, at least in part, be involved in the regulation of 
the cellular pool o f free pGlu (Awad6 et a l , 1994) As described in section 1 1, free pGlu is known to 
have pharmacological properties, thus a specific pathway may exist to generate this molecule The source 
of free pGlu that is associated with the aforementioned diseases remains unknown, but the involvement of 
PAPI remains a possibility
As with the mammalian PAPI the role of the bacterial PAP remains unclear This enzyme may be 
involved in the utilisation of peptides as a source of nutrients as suggested in the case of Pseudomonas 
fluorescens, which was shown by Doolittle and Armentrout (1968) to be capable of growing with free 
pGlu as the sole source of carbon and nitrogen Such a role for the enzyme is weakened by the 
observation that it is not commonly found in bacteria, and even within the same species some strains 
possess PAP activity while others lack the enzyme (Szewczuk and Mulczyk, 1969) Awad6 et al (1994)
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proposed that the high accumulation of peptides with an N-termmal pGlu may abnormally acidify the cell 
cytoplasm They therefore postulated that bacterial PAP may be involved m detoxification
The discovery of PAP was initially associated with the search for an enzyme capable of opening 
pyrrohdone rings (Doolittle and Armentrout, 1968), thus exposing an a-amino acid, m order to facilitate 
protein sequencing by conventional methods Nowadays, even though enzymatic and chemical methods 
are available to open pyrrohdone rings and mass spectrometry is available to overcome sequencing 
difficulties associated with N-termmal pGlu residues, researchers still use PAP (typically commercial calf 
liver PAPI or bacterial PAP) to confirm the presence of this residue Since PAP activity is present in 
some bacterial strains but is absent in others, specific PAPI assays have been used in bacterial diagnostic 
kits (Awad6 et a l , 1994)
1.2.2 Class-II: Animal PAPII and Serum PAP
In the late 1970s a pyroglutamyl ammopeptidase, capable of cleaving the pGlu-His bond of TRH was 
partially purified from rat serum (Taylor and Dixon, 1978) and porcine serum (Bauer and Nowak, 1979) 
Unlike PAPI which is inhibited by sulphydryl-blockmg reagents (see section 1 2  11), the serum enzyme 
was not strongly affected by these substances While DTT and EDTA are necessary for expression of 
PAPI activity, the serum enzyme was inhibited in their presence The molecular weight of the enzyme 
was found to be approximately 260,000 Da, an order of magnitude greater than the soluble PAPI In 
addition to these differences, Bauer and Nowak (1979) observed that the serum enzyme catalysed the 
degradation of pGlu-BNA extremely poorly while this is an excellent substrate for PAPI In 1981, Bauer 
et al reported that the serum PAP had a narrow substrate specificity cleaving only TRH or closely related 
peptides and thus proposed the name "Thyrolibennase" for the enzyme
While several authors had reported that PAP activity was associated, at least m part, with the particulate 
fraction of brain (Schock, 1977, Hayes et a l , 1979, Griffiths et a l , 1979, Greaney et a l , 1980), Browne 
et al (1981) were the first to demonstrate the existence of two distinct pyroglutamyl aminopeptidases m 
guinea pig brain They found the particulate enzyme to have a high molecular weight (approximately
180,000 Da) and to be optimally active only in the absence of DTT and EDTA, while the soluble PAPI 
required these substances for optimal activity This particulate enzyme has since become known as 
pyroglutamyl ammopeptidase type-II (PAPII, EC 3 4 19 6), to distinguish it from the soluble PAPI (EC 
3 4 19 3) (McDonald and Barrett, 1986)
1 .2 .2  1 R egional D istribution o f PAPII
Although PAPII has been shown to be present in many mammalian tissues, it appears to be mainly a 
CNS enzyme with highest levels of activity in the brain (see table 12  2 1) (Friedman and Wilk, 1986, 
Vargas et a l , 1987, 1992a) Following cloning of a cDNA encoding the rat brain enzyme by Schauder et 
al (1994), die analysis ol northern blots confirmed the heterogeneous distribution of PAPII mRNA
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levels in rat Highest transcription levels were found m brain with lower levels m pituitary, lung and 
liver Kidney was not found to contain detectable levels o f mRNA Within the brain the distribution of 
PAPII is heterogeneous In rabbit and rat brain highest levels o f activity are found in the olfactory bulb 
while lowest levels are found in the adenohypophysis or hypophysis (see table 1 2  2 2) Although PAPII 
levels in rabbit spinal cord are lower than in brain, significant differences in enzyme distribution exist 
within this region The activity was found to be highest m the thoracic segments (in particular T1 and T2 
regions) while PAPII activity was not detected in the sacral segments S3 and S4 (Vargas et a l , 1992a) 
The specific activity of PAPII was found to be higher in rabbit retinal membranes than in any other non- 
CNS tissues and the specific activity in Y79 retinoblastoma cells was found to be greater than the highest 
activity found in other cell lmes by approximately one order of magnitude (Wilk et a l , 1988) Studies on 
primary cell cultures of rodent brain have shown that whrie a relauvely high level o f PAPII activity is 
found on neuronal cells, glial cells are almost devoid o f activity In the pituitary, PAPII is localised 
preferentially on lactotrophs (Bauer et a l , 1990, Cruz et a l , 1991) The heterogeneous distribution of 
PAPII highlights another distinct difference between this enzyme and the cytosolic PAPI which is 
distributed quite homogeneously (see section 1 2  1)
Table 1.2.2.1 Distribution o f PAPII in Rabbit and Rat
Organ PAPII Specific Activity^
Rabbit3 Ratb
Brain 100 100
Testis 6 54 -
Spleen 2 88 2 7
Prostate 2 69 -
Adrenal 1 92 -
Heart 0 96 s a
Skeletal Muscle 0 77 s a
Lung 0 58 27
Serum 0 38 27
Kidney 0 38 s a
Liver s a 2 5
Thymus s a -
Pancreas s a -
a Taken from Vargas et al (1992a) and subsequently modified 
b Taken from Friedman and Wilk (1986) and subsequently modified 
t  Specific activity is presented as a percentage of that m brain 
"s a " denotes sub-assay levels present, indicates value not determined
I
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Table 1.2.2.2 Distribution o f PAPII in Rabbit and Rat Brain Regions
Region PAPII Specific Activity t
Rabbit Rat
Olfactory Bulb 100 100
Posterior part of Cerebral Cortex 99 -
Hippocampus 76 79 8
Cerebellar Vermis 71 -
Cerebellar Hemisphere 57 -
Nucleus Accumbens-lateral Septum 33 44 2
Mesencephalon 29 -
Median Eminence 23 -
Hypothalamus minus Median Eminence 19 -
Pons 17 -
Medulla Oblongata 14 17 7
Adenohypophysis - 7 9
Hypophysis 3 5 -
Serum 0 3 1 7
Taken from Vargas el al (1992a) and subsequently modified 
t  Specific activity is presented as a percentage of that m the olfactory bulb 
- indicates value not determined
1 .2 .2 .2  Subcellu lar D istribution  o f PAPII
Studies on the subcellular distribution of PAPII have demonstrated that, within the CNS, the enzyme is 
located on the synaptosomal membranes (O'Connor and O'Cuinn, 1984, Horsthemke et a l , 1984, Torres 
et a l , 1986, O'Leary and O'Connor, 1995a) It has been clearly demonstrated that PAPII is an integral 
(intrinsic) membrane protein which is not dissociated from the plasma membrane by successive washing 
with high or low ìomc-strength buffers or by alkali treatment (O'Connor and 0'Cumn, 1984, Friedman 
and Wilk, 1986, Charli et a l , 1988, O'Leary and O'Connor, 1995a) The topographical organisation of 
PAPII on the membrane was investigated by Charli et al (1988) using rat bram synaptosomes and 
primary cultures o f foetal cortical cells These authors reported the following findings, (1) enzyme 
activity was detected on intact cells using a non-penetrating substrate, (2) the activity is not increased by 
homogenisation, solubilisation or permeablisation and (3) PAPII activity is greatly decreased by trypsin 
treatment of intact cells Based on these findings they concluded that PAPII is an ectoenzyme (ì e an 
integral membrane protein with an extracellularly localised active site) This classification was 
corroborated by the findings of Bauer et al (1990) and Cruz et al (1991) who found TRII to be degraded 
(at the pGlu-His bond) extracellularly by intact neuronal cells in culture Analysis of the ammo acid 
sequence, deduced from the cDNA encoding PAPII from rat brain by Schauder et al (1994), revealed a 
stretch of 22 hydrophobic amino acids near the amino-tenninus of the enzyme This is consistent with a
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transmembrane-spannmg domain, the aminotenmnus of the enzyme located mtracellularly and the bulk of 
the enzyme, including the active site, located extracellularly This confirms the classification of PAPII as 
an ectoenzyme
1 .2 .2 .3  B iochem ical and B iophysical C haracteristics o f  C lass-II PAPs
PAPII has been purified from a number of sources including rat liver and guinea pig, rat, porcine, rabbit 
and bovine brain Solubilisation o f the enzyme from the plasma membrane has been achieved using the 
proteolytic enzymes papain (O'Connor and O'Cuinn, 1984, Scharfmann et a l , 1989) and trypsin (Wilk 
and Wilk, 1989a,b, Bauer, 1994) Solubilisation was achieved usmg the non-ionic detergent Triton X-100 
by O'Leary and O'Connor (1995a), although a detrimental effect of detergents on PAPII activity has been 
reported by a number o f investigators (O'Connor and 0'Cumn, 1984, Wilk and Wilk, 1989a, Bauer, 
1994)
As mentioned earlier PAPII and serum PAP differ from the soluble PAPI with respect to their molecular 
weights Both enzymes are o f relatively large molecular size with estimates of 230,000 - 240,000 Da for 
PAPII (O'Connor and O'Cumn, 1984, Wilk and Wilk, 1989a, Bauer, 1994, O'Leary and O'Connor, 
1995a) and 260,000 Da for the serum enzyme (Taylor and Dixon, 1978, Bauer and Nowak, 1979) Suen 
and Wilk (1990) reported a 48,000 Da subunit of PAPII from Y-79 human retinoblastoma cells This was 
determined by immunoblot analysis of SDS PAGE gels using polyclonal antibodies raised to the 
enzyme This is consistent with a pentamenc structure for the enzyme Following 200,000-fold  
purification of PAPII from porcine brain, Bauer (1994) demonstrated a single band with an approximate 
molecular weight of 116,000 Da by SDS PAGE under reducing or non-reducing conditions This 
indicates that, under native conditions, the enzyme exists as a dimer consisting of two identical subunits 
which are not linked covalently The enzyme was identified as a glycoprotein by lectin-bmdmg analysis 
and by the reduction of the molecular mass to 97,000 Da upon treatment of the denatured enzyme with 
endoglycosidase-F/N-glycosidase F In its native form, however, the enzyme was found to be only 
partially deglycosylated and retained full enzymatic activity (Bauer, 1994) These findings are consistent 
with those of Schauder et al (1994), who calculated the mass of the enzyme to be 117,302 Da based on 
the ammo acid sequence deduced from cDNA encoding rat brain PAPII These authors also identified 12 
putaUve glycosylation sites m the extracellular domain of the enzyme
Maximal activity of serum PAP was observed at incubation temperatures between 40°C and 50°C Above 
50°C the enzyme is rapidly and irreversibly inactivated (Bauer and Nowak, 1979) A broad pH optimum 
of 6 5 to 8 0 has been reported for the serum enzyme (Taylor and Dixon, 1978, Bauer and Nowak, 1979) 
while a slightly narrower pH optimum of 7 0 to 7 5 has been reported for PAPII (Wilk and Wilk 
1989a,b)
Inhibition of PAPII and serum PAP by chelating agents such as EDTA, EGTA, 8-hydroxyquinoline, 
1, 10-phenanthroline, imidazole and sodium cyanide has been observed by all groups working on these
enzymes (Taylor and Dixon, 1978, Bauer and Nowak, 1979, Yamada and Mon, 1990, O'Connor and 
O'Cumn, 1984, 1985, Garat et a l , 1985, Wilk and Wilk, 1989a, Bauer, 1994, O'Leary and O'Connor, 
1995a) The insensitivity of the enzymes to specific cysteine- and serine-protease inhibitors led to the 
assumption that PAPII and serum PAP are metallopeptidases Czekay and Bauer (1993) demonstrated a 
tune dependent inhibition of PAPII with chelators and the subsequent reactivation of the EDTA-treated 
enzyme with Zn2+, Ni2+ and Co2+ Modification studies on PAPII by these authors and by O'Connor 
and O'Cumn (1987) have identified a tyrosine and a glutamic acid residue at the active site o f the enzyme 
The basic ammo acids histidine and arginine were also found to be essential for activity The presence of 
these ammo acids is a common feature of metallopeptidases Furthermore, the ammo acid sequence 
deduced by Schauder et al (1994) from cDNA encoding PAPII has been shown to contain the His-Glu- 
Xaa-Xaa-His consensus sequence o f the zinc-dependent metallopeptidase family, in the extracellular 
domain of the enzyme These features are m complete agreement with the classification of PAPII as a 
zinc-metallopepudase
1 .2 .2 .4  C loning o f the PAPII Gene
Recently Schauder et al (1994) have reported the cloning of a cDNA encoding rat bram PAPII and the 
transient transfection of COS-7 cells with this DNA leading to the expression of an active ectopeptidase 
which displayed the characteristics of PAPII The data obtained at the molecular level were found to be 
totally compatible with data previously obtained by biochemical studies Some of these findings have 
been mentioned earlier including, the heterogeneous tissue distribution of the enzyme (section 1 2  2 1), 
its identification as an ectoenzyme (section 1 2 2 2), its molecular weight and identification as a 
glycoprotein and its identification as a zinc-metallopeptidase (section 1 2 2 3) The authors have identified 
putative sulphanation and phosphorylation sites which may be important for intracellular sorting and 
trafficking and for regulation
Southern blot analysis indicated that the enzyme is present as a single-copy gene This supports the 
proposal that serum PAP and PAPII (which exhibit almost identical chemical characteristics) are derived 
from the same gene (O'Connor and O'Cumn, 1984, Wilk, 1986, Bauer, 1987b, Scharfmann et a l , 1990, 
Yamada and Mon, 1990) It is possible that the serum enzyme is secreted from the liver and may be 
formed by alternative splicing (Schauder et a l , 1994)
Significant homology was observed between the ammo acid sequence of the rat PAPII and those of rat 
ammopeptidase N (34%) and mouse ammopeptidase A (32%), both of which have been identified as 
membrane-anchored zmc-metallopeptidases While the trans-membrane portions were found to be 
completely different, sequences in the extracellular domain displayed a high degree of homology Two 
stretches, each with seven amino acids are completely conserved indicating that these enzymes share a 
common anccstry (Schauder el a l , 1994)
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1 .2 .2 .5  Substrate Specificity  of C lass-II PAPs
Probably the most interesting feature of PAPII and serum PAP is their extraordinarily high degree of 
substrate specificity Both enzymes have been shown to remove the N-termmal pGlu from only TRH or 
closely related peptides O'Connor and O'Cuinn (1984,1985) and Elmore et al (1990) demonstrated that, 
of a range of N-termmal pGlu peptides tested, only TRH (pGlu-His-Pro-NH2), Acid TRH (pGlu-His- 
Pro), LHRH 1-3 (pGlu-His-Trp), pGlu-His-Gly and pGlu-His-Pro-Gly were cleaved by the gumea pig 
bram enzyme Substitution of pGlu by Glu or of His by either Phe or N-Val m the TRH sequence 
abolished the susceptibility of the peptide to hydrolysis Some tolerance to substitution of the Pro-NH2 
residue was observed as indicated by the observation that -Trp, -Gly and -Pro-Gly in this position 
permitted enzyme activity Although the enzyme was found to be capable of hydrolysing pGlu-His-Pro- 
Gly, the extended substrates pGlu-His-Pro-Gly-NH2 and pGlu-His-Pro-Gly-Lys were not hydrolysed 
Similarly, while LHRH 1-3 is hydrolysed, extending the sequence to LHRH 1-5 (pGlu-His-Trp-Ser-Lys) 
abolished enzyme activity (Elmore et a l , 1990) Studies with rabbit bram PAPII, using various synthetic 
pyroglutamyl peptidyl naphtylamides were earned out by Wilk and Wilk (1989a,b) These authors found 
only pyroglutamyl-histidyl tnpeptide denvatives to be hydrolysed When a benzyloxycarbonyl (Z, cpZ) 
group is added to the pyroglutamyl nng of the TRH analogue pGIu-His-Pro-NA the resulting peptide is 
not cleaved Other five-membered heterocyclic rings can substitute for the pyroglutamyl ring but 
hydrolysis is not observed if  pGlu is substituted with a six-membered heterocyclic nng (Lanzara et a l ,
1989) Similar substrate specificity has been observed for PAPII from rat liver (Scharfmann et a l , 1989) 
and bovme bram (O'Leary and O'Connor, 1995a) and for porcine serum PAP (Bauer et a l , 1981) These 
observations suggest that the specificity of the enzyme is restncted to tnpeptides, tnpeptide amides and 
tetrapeptides with the pGlu-His sequence at the amino-temunus Due to its high degree of specificity for 
TRH, Bauer et al (1981) proposed the name "Thyroliberinase" for the serum enzyme Wilk (1986) 
proposed that PAPII may be the first true neuropeptide specific peptidase to be charactensed
The affinity of PAPII and serum PAP for TRH is quite consistent among the vanous sources tested 
Ki/Km values from 25jxM to 56|iM have been reported for TRH, with the majority of these falling 
within the range 40|iM  to 50|xM (Taylor and Dixon, 1978, Bauer et a l , 1981, O'Connor and O'Cuinn, 
1985, Scharfmann et a l , 1989, Yamada and Mori, 1990, Bauer, 1994, O'Leary and O'Connor, 1995a) 
With the exception o f pGlu-His (which was shown to be a non-competitive inhibitor), all of the 
pyroglutamyl peptides tested by Elmore et al (1990) were found to be competitive inhibitors of PAPII It 
is interesting to note that the peptides pGlu-His-Pro, pGlu-His-Gly and pGlu-His-Pro-Gly each displayed 
higher Kl values than the corresponding amides, suggesting that the enzyme prefers an amide group at the 
carboxy-termmus of the peptide substrate (Elmore et a l , 1990) The decapeptide LHRH, although not a 
substrate for the enzyme has been shown to be a strongly competitive inhibitor of PAPII, displaying a K, 
value (20[iM) lower than the enzymes K, for TRH (40(iM) (O'Connor and O'Cuinn, 1985) A similar 
finding was observed by Bauer et al (1981) for the serum enzyme However, in a recent report O'Leary 
and O'Connor (1995a) found die inhibition o f bovine bram PAPII with LHRH to be non-competitive 
with a of 820|iM, considerably higher than the Km oi TRH (50jjM)
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1 . 2 . 2 . 4  A ssays for C lass-II PAPs
The determination o f PAPII and serum PAP activity has been achieved by many researchers using 
radiolabelled TRH (for example, [3H-Pro]TRH, [pGlu-14C]TRH or [3H-His]TRH ) as a substrate A 
number of variations of the assay have been described m which, following hydrolysis of the substrate, the 
degradation products are separated by paper chromatography, thin layer chromatography, column 
chromatography, lmmunoaffinity or HPLC (Bauer, 1976, Taylor and Dixon, 1978, Garat et a l , 1985, 
O'Connor and O'Cuinn, 1984,1985, Friedman and Wilk, 1986, Coggins et a l , 1987a, Bauer et a l ,
1990) Following metabolite separation, the enzyme activity of the sample is quantified by measuring the 
radioactivity to determine either the amount of TRH remaining or the amount of pGlu, His-Pro-NH2 or 
His-Pro diketopiperazme produced
In 1986, Friedman and Wilk developed a coupled enzyme assay for the detection of PAPII based on the 
cleavage of the synthetic substrate pGlu-His-Pro-2NA m the presence of excess dipeptidyl aminopeptidase 
type IV (DAPIV) The assay is based on the following reaction sequence
p a p h
pGlu-His-Pro-2NA ----------------------►- pGlu + His-Pro-2NA
DAPIV
His-Pro-2NA ----------------------- ►  His-Pro + 2NA
The inclusion of Z-Pro-Prolmal, a specific prolyl endopeptidase inhibitor, m the assay mixture blocks the 
cleavage o f the Pro-2NA bond and the inclusion of PDMK prevents the cleavage o f the substrate by 
PAPI PAPII activity could thus be quantified by measuring the amount of 2NA released A modification 
o f this procedure was described by O'Leary and O'Connor (1995a) who used the substrate pGlu-His-Pro- 
MCA Although DAPIV is not commercially available and must therefore be purified for use m the 
assay, this coupled enzyme assay is less labour-intensive and more economical than the radiolabelled 
assays It has the added advantage of avoiding the use of radioactivity
A number o f researchers have reported that the PAPI substrates pGlu-BNA, pGlu-pNA and pGIu-MCA are 
not hydrolysed by PAPII or serum PAP (O'Connor and O'Cuinn, 1985, Garat et a l , 1985, Wilk arid 
Wilk, 1989a) However, Bauer et al (1981) reported that the serum enzyme cleaves pGlu-BNA, albeit at a 
rate 200-times slower than the calf liver PAPI Czekay and Bauer (1993) and Bauer (1994) demonstrated 
similar slow hydrolysis of the substrate with PAPII from porcine and rat brains The use of this 
fluorogemc substrate facilitates the continuous monitoring of PAPII activity m purified samples with 
high levels o f activity
Due to the unique substrate specificity of class-II PAPs for only TRH or closcly related peptides, a brief 
discussion on TRH is warranted
1 4
1 .3  Thyrotropin-Releasing Hormone (TRH)
It has been recognised since the early 1950s that the hypothalamus exerts an important influence on the 
regulation o f the pituitary-thyroid axis (Reichhn et a l , 1978) In 1969, following rigorous chemical 
analysis o f large numbers of ovine and porcine hypothalamic fragments, the structure of TRH was 
elucidated in the laboratories of Guillemin and Schally (B0ler et a l , 1969, Burgus et a l , 1969) Working 
independently, they reported that TRH was a weakly basic tnpeptide with the ammo acid sequence 
pyroglutamyl-histidyl-proline amide (pGlu-His-Pro-NH2) (see figure 1 3  1) TRH has a strict 
conformational requirement for biological activity and almost any departure from its native structure 
results in substantial if not complete loss of activity (Guillemin and Burgus, 1972)
Figure 1.3 1 Structure o f  Thyrotropin-Releasing Hormone (TRH)
(p G lu ---------------  H is  Pro-N H 2)
1.3.1 Neuroendocrine Role of TRH
The most obvious effect o f TRH (also known as Thyrotropm-Releasing Factor or Thyroliberin), and that 
from which it derives its name(s), is the ability to stimulate the release o f thyrotropin (Thyroid- 
Stimulating Hormone (TSH)) from the anterior pituitary (adenohypophysis) via binding to high affinity 
receptors (Jackson, 1982) TRH is released from the hypothalamic neurons into the hypothalamo- 
hypophyseal portal vessels that carry blood between the hypothalamus and the anterior pituitary The 
anterior pituitary contains several different types of endocrine cells TRH receptors are located on two 
pituitary cell types thyrotrophs (TSH-releasing cells) and mammotrophs (lactotrophs, prolactin-releasmg 
cells) Binding of TRH to the receptors on these cells stimulates the release of TSH and prolactin (see 
figure 1 3  1 1 )
TSH stimulates the thyroid gland to produce and release the thyroid hormones, tetraiodothyromne (T4) 
and triiodothyronine (T3) It is composed of two different, noncovalcntly associated glycoprotein subunits 
termed a-subumt and TSHB (Pierse and Parsons, 1981) Each subunit is encodcd by a separate gene 
located on diifercnt chromosomes in humans and mice (Chm, 1986) Coordinate regulaUon of expression 
ol the I SI I subunit genes results in nearly balanced production ol (he subunit proteins However the a-
subunit is often synthesised and released in excess Only the heterodimer can act in the endocnne system 
(Chin et a l , 1993) It is well known that TRH release at the hypothalamus and TSH synthesis by the 
pituitary thyrotroph are directly regulated by the thyroid hormones in a negative fashion (Hershman and 
Pekary, 1985) Thyroid hormones rapidly (within hours) decrease a-subunit and TSH6 subunit mRNAs 
in pituitary tissue in a time- and dose- dependent fashion (Chin et a l , 1985) The mechanism of thyroid 
hormone action proposed by Chin et al (1993) is as follows Thyroid hormones enter the cell via a 
passive mechanism (T4 can be monodeiodmated to T3 m certain cell types), and move from the 
cytoplasm to the nucleus where they interact with high affinity receptors (TRs) The TRs interact with 
target DNAs by association with specific receptors thus resulting in activation or repression of specific 
genes
Figure 1.3.1.1 The Hypothalamic-Pituitary-Thyroid (HPT) Axis
<±> Positive Influence 
©  Negative Influence
Rather than having a restricted endocrine function in stimulating die release of TSH and prolactin, TRH 
appears to have much more widespread effects on the release of other hormones such as growth hormone 
(GII), a-melanocyte-stimulating hormone, vasopressin, somatostatin, insulin and glucagon as well as 
noradrenaline and adrenaline (For review, see Griffiths, 1985 and 1987 )
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In its amino acid sequence and its biological activity, TRH exhibits no species specificity and it is readily 
active m all mammalian species studied including humans (Fleischer and Guillemin, 1976) TRH-like 
immunoreactivity or biological activity is widely distributed throughout the CNS, gastrointestinal tract 
and the body fluids of mammalian species (see table 13  2 1) (for review see Jackson, 1982) An 
investigation into the distribution of TRH in rat CNS showed that, while the highest concentration of 
TRH is in the hypothalamus, more than 70% of the total brain TRH is located extrahypothalamicly 
(Leppaluoto et a l , 1978) where it has a wide distribution (see table 13 2 2)
1.3.2 Regional Distribution of TRH
Table 1.3.2.1 Distribution o f TRH in Tissues and Body Fluids o f  Various Animal Species
Species Tissue/Body Fluid
TRH Concentration 
(fmol/mg protein)
Human Cerebellum 15
Hypothalamus 1,093
Placenta 54 6
Pineal Gland 71 7
Peripheral Blood 78 pg/ml
Rat Cerebellum 31 5
Hypothalamus 2,208
Caecum 91
Rectum 27 6
Pancreas 93 8
Retina 828
Peripheral Blood 77 pg/ml
Hypophyseal Portal Plasma 801 pg/ml
Frog Brain 6 9
Skin 2 6
Blood 227 ng/ml
Monkey Cerebellum, Anterior 2 3
Hypothalamus, Anterior 151
Chicken Hypothalamus 938 - 1,352
Snake Hypothalamus 10,844 - 20,171
Salmon Hypothalamus 5,188 - 7,284
Taken from Prasad (1985)
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Table 1.3.2.2 TRH Distribution in Rat Brain
Bram Area
TRH Concentration 
(pg/mg tissue)
Extrahypothalamic Bram
Brainstem 5
Cerebellum 2
Diencephalon 6
Olfactory Lobe 6
Cerebral Cortex 2
Hypothalamic-Pituitary Complex
Dorsal Hypothalamus 49
Ventral Hypothalamus 64
Stalk Median Eminence 3,570
Posterior Pituitary 115
Anterior Pituitary 10
Taken from Jackson and Reichhn (1974)
1.3.3 Neuroregulatory Role of TRH
Information processing in the bram largely involves chemical communication among neurons through 
substances called neuroregulators These substances may be subdivided into those that convey information 
between adjacent nerve cells (neurotransmitters) and those that amplify or dampen neuronal activity 
(neuromodulators) Although TRH was first classified as a hormone through its effect on the pituitary, it 
possesses many characteristics which suggest that m addition to its neuroendocrine role, TRH may 
function as a neurotransmitter or neuromodulator The following features provide a formidable list of 
criteria consistent with such a neuronal role
- its extrahypothalamic location m the bram
- its localisation at the synaptic level
- its release at synaptic terminals
- its attachment to high affinity receptors that show a remarkable degree of anatomical 
localisation
- its specific effects on neuronal activity
- its stimulation of a wide range of centrally mediated behavioural effects (see table 13 3)
- the presence of brain peptidases capable of its inactivation
For a more complete review of this topic, see Griffiths (1985) and Prasad (1985)
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Table 1.3.3 Examples ofC N S effects ofTRH, resulting from  direct application to specific brain 
regions or from intracerebroventricular injections
♦ Reversal of narcotic / alcohol-induced sedation
♦ Reversal of natural sedation (hibernation)
♦ Thermoregulation induction of hypo- or hyper-thermia (depending on species)
♦ Wet-dog shaking activity - Symptoms similar to those produced by opiate 
withdrawal
♦ Locomotor activity
♦ Forepaw tremor (rats)
♦ Muscle tone improvement (antagonism of induced relaxation)
♦ Cardiovascular effects increased blood pressure and heart rate, increased cerebral 
blood flow
♦ Respiratory effects increased respiratory rate and minute volume
♦ Gastrointestinal effects increased or decreased motility (depending on species), 
increased gastric acid secretion and gastric emptying, increased pancreatic 
exocrine secretion
♦ Anorexic effects decreased food and water intake
♦ Antinociceptive action
♦ Increased catecholamine release from adrenal medulla
♦ Blood glucose hyperglycemia m rats, hypoglycemia in mice
♦ Anticonvulsant activity
Taken from Griffiths (1987)
1.3.4 Biosynthesis of TRH
Despite some initial confusion about the mechanism of TRH biosynthesis, the isolation of a cDNA from 
amphibian skin (a tissue rich m the tnpeptide), showed that TRH is derived from a high molecular weight 
precursor (Richter et al, 1984) The rat preprohormone TRH precursor (prepro-TRH) contains five copies 
of the progenitor sequence Gln-His-Pro-Gly These are flanked by pairs of basic residues (typical 
prohormone processing signals), Lys-Arg at the ammo end and Lys-Arg or Arg-Arg at the carboxyl end, 
and are separated from each other by intervening peptides that are not related to the TRH sequence (Lee et 
al, 1988) The human TRH cDNA encodes six copies of the TRH progenitor sequence, m contrast to the 
five copies present m the rat (Yamada et al, 1990) The intervening (connectmg) sequences are numbered 
Psl to Ps6
Considerable effort has been devoted to elucidating the processing pattern of the TRH prohormone in 
various regions of the bram and m peripheral tissues Based on the deduced ammo acid sequence of rat pro- 
TRH, proteolytic processing is expected to produce TRH plus several non-TRH peptides Although the 
major pathway of pro-TRH processing in the hypothalamus has been shown to involve nearly complete 
proteolytic cleavage at all ol the basic residues that flank the TRH progenitor sequence, some studies have 
shown the presence of extended forms of'l R1I m the hypothalamus Peptides extended at the N-termindl
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or C-termmal of TRH occur in similar concentrations in bovine hypothalamus, while only C-terminally 
extended forms of the tripeptide occur in rat hypothalamus Similarly, small amounts of C-terminally 
extended forms of TRH (such as TRH-Ps4) have been detected m spmal cord as a result of incomplete 
processing of the TRH precursor molecule Pro-TRH has been shown to be processed differently in the 
olfactory bulb with TRH-Ps4 and TRH-Ps5 as major end-products, demonstrating tissue-specific 
processing of the precursor (For a more complete review of this topic see Ladram et a l , 1994)
It has recently been demonstrated that Ps4 possesses biological activities in vitro and in vivo (Bulant et 
a l , 1990, Carr et a l , 1992) It has been shown to potentiate TRH induced release of TSH and prolactin 
Specific binding sites for this TRH-potentiating peptide (distinct from TRH receptors) have been 
demonstrated m the pituitary A general property of prohormone proteins is that they have the potential 
to produce a number of regulatory peptides endowed with similar or different bioactivities The precise 
function(s) of intervening sequences withm the precursor molecule is currently a matter of speculation It 
has long been assumed that they are functionally unimportant throw away peptides or that they may 
participate m the processing or intracellular routing of the prohormone Pro-TRH is an example of a 
prohormone which yields a true hormone TRH and a biologically active connecting peptide Ps4, that act 
m a synergistic manner on the same target cells to modulate hormone release For more extensive reviews 
on this topic, see Ladram et a l , 1994 and O'Leary and O'Connor, 1995b
Mams et al (1990) have suggested that the maturation of pro-TRH is a sequential phenomenon starting 
m the endoplasmic recticulum after cleavage of the signal sequence Then, pro-TRH travels through the 
Golgi complex, where it undergoes enzymatic modifications such as phosphorylation, glycosylation, 
endoproteolysis, exoproteolysis and sulphation The terminal step, amidation, uses the glycine residue as 
an amide donor and is catalysed by peptidylglycine a-amidatmg monooxygenase (PAM) Cyclisation of 
the ammo terminal glutamine residue to pyroglutamate is cyclised by a glutamine cyclase-like enzyme 
(Busby et a l , 1987) Following processing in the Golgi complex, terminal maturation of TRH occurs m 
large dense core vesicles (secretory granules) The subsequent release of the mature TRH and prohormone 
related peptides at the synapse has been shown to involve voltage sensitive Ca2+ channels and protein 
kinase-C (Loudes et a l , 1988)
1.3.5 TRH Receptors
The action of TRH on target cells, such as those of the anterior pituitary, is mediated through its 
interaction with highly specific membrane-bound receptors Recent cloning and sequencing of the TRH 
receptor (TRH-R) from anterior pituitary cells of different species has revealed that it is a member of the 
seven-transmembrane-spannmg, GTP-bmdmg protein-coupled family of receptors or GPCRs The mouse 
pituitary TRH-R mRNA encodes for a 393 amino acid GPCR (Straub et a l , 1990) which bears 
significant homology with sequences observed for the cloned TRH-R from humans, 398 ammo acids 
(Duthie et a l , 1993, Matre et a l , 1993) and for rats, 412 and 387 ammo acids (two isofonns of this 
receptor, generated by alternative splicing, have been cloned and sequenced), (de la Pena et a l , 1992a and
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1992b) The major sequence variation between species and isoforms was seen to occur within the 
intracellular carboxy-terminal tail of the TRH-R (Momson et a l , 1994), a portion of the receptor 
sequence known to contain several senne and threonine residues which are potential sites for regulatory 
phosphorylation by kinase enzymes, including protein kinase C (Kikkawa el a l , 1989)
TRH-Rs have been shown to be widely distributed throughout the CNS and peripheral tissues Virtually 
all brain tissues tested have been shown to contain detectable levels of TRH-Rs However, major species 
differences have been observed in both absolute and relative TRH-R bmding in different bram regions 
Several bram regions have been shown to exhibit binding equal to or exceeding that m the anterior 
pituitary gland of the same species including the amygdala, hypothalamus and nucleus accumbens (Taylor 
and Burt, 1982) A study of the distribution of mRNA encoding the TRH-R m rat bram and pituitary by 
in situ hybridisation has shown even distribution of the TRH-R mRNA throughout the anterior lobe of 
the pituitary, thyrotrophs and mammotrophs, but no hybridisation was detected in the posterior lobe In 
virtually every area demonstrating TRH-R mRNA expression, prohormone or TRH immumoreactivity 
has previously been described The presence of TRH-Rs in the same regions which synthesise TRH 
precursors suggests a local action of TRH (Zabavmk et a l , 1993) Recently, the direct TRH precursor, 
TRH-Gly, has been shown to interact directly with the TRH-R in vitro, causing the release of TSH and 
prolactin (Yamada et a l , 1995)
TRH-R mRNA has also been shown to be widely distributed throughout rat peripheral tissues, albeit at a 
considerably lower concentration than m the pituitary, as is TRH itself The rank order of the expression 
in these tissues (quantified by Northern blot analysis) was bram, uterus, thymus, testis, submandibular 
gland, heart and adrenal gland Although TRH is distributed widely m the digestive organs such as liver, 
intestine and pancreas, strong signals of TRH-R mRNA were not detected m these tissues The wide 
distribution of TRH and TRH-Rs in peripheral tissues suggests a role for TRH not only m the CNS but 
also m these tissues (Fukusumi et a l , 1995)
Down regulation of receptors is an important mechanism for diminishing cell responsiveness to many 
hormones, neurotransmitters and growth factors The number of receptors on the surface membrane of 
cells may be decreased by the action of the receptor ligand (homologous down regulation) or by the action 
of other extracellular regulatory factors that interact with other cell receptors (heterologous down 
regulation) Homologous down regulation of TRH-Rs by TRH as well as heterologous down regulation 
by other extracellular molecules such as thyroid hormones, epidermal growth factor and vasoactive 
intestinal peptide have been reported' Importantly, the decrease m the number of TRH-Rs causes 
adenohypophyseal cells to exhibit a less marked response to TRH Down regulation caused by TRH is 
not due to rapid receptor internalisation, but rather to a slow decrease in TRH-Rs with a half-time of 12 
hours It has been proposed that homologous down regulation is caused by a TRH induced increase in the 
rate of mRNA turnover due to decreased mRNA stability and to increases in the degrading activity of an 
RNAase (for review, see Gershengom, 1993)
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1.3.6 Therapeutic Applications of TRH
Diagnostically, intravenous (1 v ) administration of TRH has been used to assess the integrity of the 
hypothalamic-pituitary-thyroid axis in clinical conditions associated with disturbances in the thyroid 
hormone levels However, with the introduction of sensitive assays for TSH, the need for the TRH test 
has declined, except m cases where the capacity of the pituitary to secrete TSH is being examined 
Interestingly, the potential therapeutic applications of TRH that have attracted the most attention are not 
based on its endocrine properties, but on its broad spectrum of stimulatory actions within the CNS (see 
table 13  3) (Griffiths, 1987) These CNS-mediated effects provide the rationale for the use of TRH m the 
treatment of brain and spinal injury and certain CNS disorders such as Alzheimer's disease and motor 
neuron disease (MND) The endocrine actions of TRH such as stimulation of the pituitary-thyroid axis, 
resulting in hyperthyroidism, are regarded as adverse side effects m the treatment of CNS-related 
conditions The beneficial effects of TRH on CNS disorders and trauma appear to be due partly to its 
ability to potentiate other neurotransmitter systems and to reverse or attenuate certain actions of secondary 
injury factors that occur as a result of CNS trauma The exact mechanism by which TRH improves these 
conditions is still not fully understood (Kelly, 1995)
TRH was initially used to treat brain and spinal injury because of its ability to antagonise the damaging 
actions of endogenous opioids (which contribute to secondary tissue damage after CNS trauma), without 
reducing opioid analgesia The basis of the neuroprotective actions of TRH has now been extended to 
include us ability to antagonise the actions of other secondary injury factors such as leukotnnes and 
platelet-activating factor, as well as to restore magnesium homeostasis, improve bioenergetic status and 
decrease tissue oedema after brain injury (Faden and Salzman, 1992)
The use of TRH m the treatment of certain kinds of memory dysfunction, including Alzheimer's disease, 
is based on its ability to potentiate the activity of several neurotransmitter systems that are involved in 
memory, including cholinergic, noradrenergic, serotonergic and dopaminergic systems (Horita et a l , 
1986) Intrapentoneal (i p ) administration of TRH has been shown to protect against disruption of 
memory in animals (Stwertka et a l , 1991) In a pilot study involving Alzheimer's disease patients, i v 
administration of TRH significantly improved arousal and modestly improved semantic memory (Mellow 
et a l , 1989) Recently, TRH has been shown to increase memory retention and retrieval in rats through 
activation of N-methyl-D-aspartate (NMDA) -receptor mediated processes (Kasparov and Chizh, 1992)
MND is characterised by progressive loss of voluntary motor function and is invariably fatal Gradual 
degradation of the large motor neurons m the cerebral cortex, brain stem and cervical and lumbar spinal 
cord occurs Death usually occurs from respiratory failure due to bulbar or diaphragmatic involvement 
Evidence showing that TRH has neurotrophic (neuron-growth promoting) and neuroregulatory effects m 
the motor neurons, together with its apparent beneficial effects in the human spinocerebellar 
degenerations, would seem to indicate a possible role tor TRH m the management of MND Clinical 
trials using TRH m the treatment of MND patients have showed promising results (For review sec 
Kelly, 1995 )
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There are a number of other conditions for which TRH may have potential beneficial effects, including 
cerebral ischaemia (stroke), Down's syndrome, schizophrenia, depression, epilepsy, reversal of narcotic 
overdose and haemorrhagic, endotoxic and anaphylactic shock For more comprehensive reviews on these 
and other clinical applications of TRH see Griffiths (1987), Holaday et al (1989) and Kelly (1995)
1.3.7 TRH Analogues
In addition to its hormonal actions, the mam drawbacks to using TRH as therapeutic agent m the 
treatment of CNS disorders are (l) its rapid enzymatic degradation and hence its relatively short half-life 
(see section 13 8) and (n),its relative inability to cross the blood-bram barrier (only about 0 2% of an 
i v injected dose has been detected in cerebrospinal fluid) (Nagai et a l , 1980) Several strategies are 
currendy being investigated m an attempt to overcome these disadvantages and to capitalise on the 
neuroregulatory effects of TRH These include the following (i) TRH analogues, (11) peptide mimetics, 
(m) microspheres, ( i v ) intrathecal drug delivery systems and (v) inhibitors of TRH-specific peptidases 
For a review of these topics, see Kelly (1995)
In an attempt to overcome the susceptibility of TRH to enzymatic degradation, various analogues have 
been prepared and evaluated The chemical structures of some of these analogues are shown m figure 
1 3 7 2 All of the analogues shown are agonists of TRH that are capable of binding to and activating 
TRH-Rs Studies in vitro have shown that methylation of prolmamide m TRH, as seen m RX77368 and 
RX74355, protects against deamidation by prolyl endopeptidase Alternatively, replacement of the 
pyroglutamyl residue with, for example, a six-membered ring as seen in the case of CG3509, CG3703 
and TA-0910, confers resistance to the action of the PAPs (Griffiths et a l , 1989)
The ability of TRH or its analogues to bind to central or pituitary receptors is dependent on the three- 
dimensional conformation of the peptide and the interplay of a variety of forces such as electrostatic 
interactions Comparative conformation-activity relationships for hormonally and centrally acting TRH 
analogues now indicate that certain conformations are preferred at the CNS receptor, while others are 
preferred at the pituitary receptor This is not to suggest that pituitary and CNS TRH-Rs are, 
intrinsically, chemically different It could be that factors closely associated with TRH-Rs in the 
membrane, influence the binding of ligands to the receptor It is also a possibility that more than one 
type of TRH-R exists (Ward et a l , 1987)
The TRH analogue [3-MeHis] TRH is the most potent analogue in stimulating the release of TSH from 
the pituitary However, although it has a very high affinity for central TRH-Rs, it is experimentally less 
active in the brain than TRH (Ward et a l , 1987) In contrast, several analogues that have a much lower 
affinity for TRH-Rs, but that are much more stable to degradation by brain peptidases show enhanced 
central activity over TRI1 The analogue TA-0910, administered either orally or intravenously exerts CNS 
effects 100 or 30 times, respectively, as potent as TRH In contrast, its ISH-releasing action is only
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i/so1*1 that of TRH, indicating a successful dissociation between the CNS and hormonal actions Its 
resistance to degradation by serum PAP also contributes to its pharmacological potency (Chishima, 
1994) RX77368, the most enzymatically stable analogue, is excreted 60% unchanged and would be 
expected to have greatest activity by virtue of this fact RX77368 generally vanes m potency between 2 
and 220 times that of TRH despite a relatively low affinity for TRH-Rs compared with that of [3-MeHis] 
TRH (Metcalf, 1982)
Quantitative structure-activity relationship (QSAR) studies reveal that TRH and its analogues can be 
fitted into three well defined classes (P,C and Y) depending on the relative position of the nngs (see figure 
13 7 1) The P conformer has the rings onentated like the three blades of a propeller, m C conformers 
they are positioned like a cup The Y class has the two nngs m close proximity (the subscripts describe 
which ones) Hence there are three subclasses, Y 12, Y13 and Y23 (Ward el a l , 1987, Griffiths et a l , 
1989) The Y23 confirmation (that predicted for RX77368) is the most active in the brain while the P 
conformation (that predicted for [3-MeHis] TRH) is the most active in the pituitary The distinction 
between the two accounts for the fact that [3-MeHis] TRH is more potent than TRH in the pituitary but 
less potent m the brain (Gnffiths et a l , 1989)
Figure 1.3 7 1 Conformational preferences o f  TRH and its analogues, showing the relative 
positions o f  the rings l=pGlu, 2=His, 3=Pro-NH2
Figure 1.3.7.2 Chemical structures ofTR H  and some o f  its analogues, showing various 
modifications to the tripeptide pGlu-His-Pro-NH2
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In addition to the susceptibility of TRH to enzymatic degradation, the low lipophilicity of TRH may also 
be a reason for the limited ability of the peptide to penetrate the blood-brain barrier A possible approach 
to diminish these delivery problems is denvadsation of the peptide to produce prodrugs or transport forms 
which are more lipophilic than the parent peptide and more resistant to degradation by enzymes present at 
the mucosal barrier or in the blood At the same time, the prodrug denvatives should be capable of 
releasing the parent peptide spontaneously or enzymatically in the blood following their absorption 
(Bundgaard and Moss, 1989 and 1990, Moss and Bundgaard, 1992) N-acylation of the imidazole group of 
the histidine residue of TRH has resulted in denvatives which are much more lipophilic than TRH itself 
These denvatives are totally resistant to degradation by serum PAP, thus prolonging their half-life in 
vivo On the other hand, they are readily bioreversible as the parent TRH is formed quantitatively from 
the denvatives by spontaneous hydrolysis or by plasma esterase-catalysed hydrolysis (Bundgaard and 
Moss, 1990)
For more extensive reviews on TRH analogues and their therapeutic uses, see Griffiths (1987), Gnffiths 
et al (1989) and Shanf (1993)
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1.3.8 Enzymatic Inactivation of TRH
As for other biologically active substances, highly efficient and specific degradation and / or elimination 
mechanisms must exist in order to terminate the action of TRH Inactivation of TRH through energy 
dependent uptake mechanisms has not been demonstrated, while m contrast, its rapid in vitro inactivation 
has been reported by a number of investigators In general, degradative enzymes may play an important 
part m controlling hormone action Initially by regulating the amount of the hormone available for 
release at its site of production or the amount actually reaching its site of action, then by controlling the 
duration of action through inactivation at the receptor sites in particular target tissues and finally by 
removal of the hormone from the general circulation so that too large a response to the hormone is 
prevented (Griffiths and Kelly, 1979)
Due to its unique structural features such as the blocked N- and C- termini, combined with the internal 
proline residue, TRH is resistant to general proteolytic attack (Burgus and Guillemin, 1970) Two 
pathways exist for the primary inactivation of TRH in vitro, (a) cleavage of the pGlu-His bond by 
pyroglutamyl aminopeptidases (PAPs) and (b) cleavage of the C-termmal amide by prolyl endopeptidase 
(PE) (see figure 13  8)
Following primary inactivation of TRH by PAP, the metabolite His-Pro-NH2 1S formed Spontaneous 
and non-enzymatic cyclisation of this metabolite to His-Pro diketopiperazine (cyclo His-Pro), has been 
reported at neutral and alkaline pH (Peterkofsky et a l , 1982, Prasad et a l , 1982) Cyclo His-Pro, which 
does not appear to be further degraded by any enzymatic mechanism, is itself reported to posses endocrine 
activity (Brabant et a l , 1981, Melmed et a l , 1982) as well as numerous CNS actions (Peterkofsky et a l , 
1982, Prasad et a l , 1982) The conversion of TRH to cyclo His-Pro thus represents an instance of the 
biotransformation of a peptide (Griffiths and McDermott, 1984) Any enzyme capable of converting His- 
Pro-NH2 to a metabolite other than cyclo His-Pro must therefore be considered to be a regulator of its 
formation, by competing with the biotransformation process Dipeptidyl aminopeptidases (DAPs) have 
been described (type-II, EC 3 4 14 2, m the soluble fraction and type-IV, EC 3 4 14 5, m the particulate 
fraction), which are capable of competing with the spontaneous cyclisation process to produce His-Pro 
from His-Pro-NH2 (Bauer and Kleinkauf, 1980, Browne and O'Cuinn, 1983, O'Connor and O'Cuinn, 
1986) His-Pro itself has been shown to modify behavioural activity affecting motor output and 
emotional responses Binding to high- and low- affinity sites in fresh rat brain slices has also been 
demonstrated (Coggins et a l , 1986 and 1987a,b) An mudopeptidase capable of cleaving His-Pro-NH2 at 
the His-Pro bond has also been reported (Matsui et a l , 1979, Torres et a l , 1986) The proposed 
subcellular localisation of this enzyme in the particulate fraction has not been definitively demonstrated
PE (EC 3 4 21 26), also known as prolyl oligopeptidase and post-prolme-cleavmg enzyme, has been 
described predominantly as a soluble, cytoplasmic enzyme However, its presence in serum and in the 
particulate fraction of tissue homogenates, including synaptosomal membranes, has also been 
demonstrated (Dalma/ et a l , 1986, Maes et a l , 1994, O'Leary et a l , 1996) PE has been identified as a 
serine protease (Yoshunoto et a l , 1977), with a sulphydryl group necessary for expression of enzyme
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activity (Browne and O'Cuinn, 1983) The enzyme has been shown to have a broad substrate specificity 
In addition to its ability to deamidate TRH to acid TRH, PE has been shown to hydrolyse a wide range of 
naturally occurring peptides at the carboxyl side of proline, including oxytocin, angiotensin, bradykmm, 
substance P, neurotensin, vasopressin and LHRH (for review, see 0'Cumn et a l , 1990) The cleavage of 
TRH by PE may also be considered to be a biotransformation since acid TRH is reported to produce a 
"wet dog shaking” effect following mtraventricular injection (Boschm et a l , 1980) Acid TRH may be 
further metabolised by PAP and subsequently to its substituent ammo acids by the action of 
lmidopeptidase For a more comprehensive review of TRH metabolism see O’Cuinn et al (1990)
Figure 1.3.8 Possible Degradation Pathways o f TRH
(TRH) 
pGIu-His-Pro-NH2
Pyroglutamyl
Aminopeptidase
pGlu + His-Pro-NH2
Spontaneous
Non-Enzymatic
Cyclisation
His-Pro 
diketopiperazine
Dipeptidyl
Aminopeptidase
His-Pro + NH3
Inudopeptidase
t
His + Pro
(Acid TRH) NH 
pGIu-His-Pro 3
Pyroglutamyl
Aminopeptidase
pGlu + His-Pro
lmidopeptidase
r
His + Pro
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1.4 Physiological Role of Class-II PAPs
1.4.1 In Vivo Degradation of TRH
Given that many putative neurotransmitters can be degraded by more than one peptidase and that many 
peptidases are capable of hydrolysing more than one neuropeptide, some guidelines are necessary for the 
identification of the inactivating peptidase for each neuropeptide Schwartz et al (1981) and Loh et al 
(1984) have provided the following guidelines (slightly modified by O'Cuinn et a l , 1990) for the 
identification of neuropeptide-inactivating peptidases
- that the enzyme should be active at physiological pH
- that the hydrolysis products should be biologically inactive or at least should not exhibit the 
same biological activity as the parent molecule in the context of neurotransmission
- that the inactivating enzyme should be strategically located to hydrolyse synaptically released 
neuropeptides (application of this criterion may confer anatomical specificity on the peptidase 
where only one neuropeptide is acting as a neurotransmitter)
- that enzymatic inhibition would protect synaptically released neuropeptides
- that enzyme inhibition would produce the biological actions of neuropeptides
- that enzyme activity might exhibit adaptive change to modified neurotransmission
- that substrate specificity would account for increased biological activity of synthetic analogues
Due to their intracellular localisation, neither PAPI nor cytosolic PE can be important for the 
inactivation of TRH after its release Moreover, since uptake of TRH by energy-dependent processes has 
not been demonstrated, these enzymes are apparently not even important for the inactivation of TRH at 
secondary control levels (Bauer, 1987b) Charli et al (1987) showed that TRH levels were unaffected by 
in vitro treatment of rat hypothalamic slices with the PE inhibitor Z-Pro-Pro-Prohnal and the PAPI 
inhibitor PDMK or by the in vivo administration of these inhibitors This suggests that PAPI and PE are 
not involved m regulating intracellular levels of TRH
The identification of PAPII as an ectoenzyme localised on the synaptosomal membrane of neuronal cells, 
combined with its unique substrate specificity, suggests a role for this enzyme in the termination of TRH 
mediated neurotransmission Support for this possibility is provided by the observation that 3H-TRH 
degradation by neuronal cells in primary culture was not inhibited by PAPI or PE inhibitors while 
LHRH, a competitive inhibitor of PAPII, reduced the ability of these cells to degrade 3H-TRH (Bauer et 
a l , 1990) Further support was provided by the observation that N-l-carboxy-2-phenyl ethyl (Nim 
benzyl)-histidyl-BNA (CPHNA), a reversible inhibitor of PAPII (K,=8fiM) and only slightly inhibitory 
to PAPI, effected a 2-fold recovery of TRH released basally or by K+ stimulation of rat hypothalamic 
slices The involvement of PAPII m the termination of TRH neurotransmission is further supported by 
the observation that the effect of CPHNA was found to be greater m regions with higher PAPII activity 
(a 5-fold increase m TRH recovery was observed for olfactory bulb slices) It is also noteworthy that these 
significant effects were observed despite only a 40% inhibition of the enzyme (Charli et a l , 1989)
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1.4.2 Regulation of PAPII Activity In Vivo
A mandatory prerequisite for a regulatory function of PAPII is that the enzyme itself is regulated by some 
other mechanism
1 .4 .2 .1  Short Term  R egulation of PAPII by Phosphorylation
As mentioned previously in section 1 2  24 , cloning of a cDNA encodmg rat brain PAPII has revealed a 
number of putative phosphorylation sites which the authors proposed may be important for regulation of 
the enzyme (Schauder et a l , 1994) Suen and Wilk (1990 and 1991) proposed that PAPII is subject to 
short-term regulation by protein kinase C-mediated phosphorylation 12-0-tetradecanoyl phorbol 13- 
acetate (TPA) directly activates the Ca2+ and phospholipid dependent protein kinase C The authors 
observed that exposure of Y-79 human retinoblastoma cells to TPA decreased the activity of the enzyme 
in a time- and concentration- dependent manner Enzyme activity was shown to decrease to 10% of 
control levels within 15 minutes and subsequently return to 70% of control levels m 1 hour Pretreatment 
of cells with the protein kinase C inhibitor H-7 [l-(5-isoqumohnylsulphonyl)-2-methyl piperazine 
dihydrochlonde] or sphmgosme was shown to prevent the inactivation of PAPII by TPA The 
inactivation of the enzyme was shown to follow the same time-course as translocation and activation of 
protein kmase C It was demonstrated that inactivation of PAPII was not due to dissociation or 
internalisation of the enzyme but due to a time-dependent phosphorylation of a 48,000 Da subunit of the 
enzyme (Suen and Wilk, 1990)
A second phase of decreasing levels of PAPII activity has been observed after longer exposure of cells to 
TPA After 1 hour, enzymatic activity has been shown to slowly and progressively decline, eventually 
reaching 15% of the control after 7 hours Cotreatment of cells with H-7 prevented the second phase of 
inactivation It has been demonstrated that this second phase of PAPII inactivation after exposure to TPA 
is due to the inhibition of enzyme synthesis (Suen and Wilk, 1991)
1 .4 .2 .2  R egulation o f PAPII by Thyroid Horm ones
Considering the implication of PAPII m TRH metabolism, the most obvious question would be whether 
or not the enzyme is regulated by thyroid hormones As previously mentioned, TRH release at the 
hypothalamus and TSH synthesis by the pituitary thyrotroph are regulated by thyroid hormones (T3 and 
T4) in a negative fashion (see section 13 1) In addition, heterologus down-regulation of TRH-Rs by 
these hormones has been reported (see section 1 3 5) The activities of PAPII and serum PAP are also 
stringently controlled by thyroid hormones A number of investigators have studied the effect of these 
hormones by monitoring enzyme levels following the induction of hypo- or hyper- thyroidism in 
animals Hypothyroidism can be induced by treatment with the mild goitrogenic agent propylthiouracil 
(PTU), by feeding the animals on a low iodine diet or by thyroidectomy Hyperthyroidism can be induced 
by treatment with T3 or T4 At this point it should be noted that in vitro, T3 itself does not affect the 
activity of PAPII (Bauer, 1987a)
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The effect of thyroid hormones on serum PAP levels has been clearly demonstrated by a number of 
investigators Induction of hypothyroidism causes a slow decrease, over several weeks, m serum PAP 
levels while induction of hyperthyroidism causes a more rapid, dose-related increase m the level of the 
enzyme, after a 24 hour lag phase (Bauer, 1976, Emerson and Wu, 1987, Ponce et a l , 1988, Scharfmann 
et a l , 1990) A significant sex difference was also observed, with euthyroid female rats showing only 
85% of the enzymatic activity of euthyroid males (Bauer, 1976) Yamada and Mon (1990) reported that m 
human serum, neither hypo- nor hyper- thyroidism caused a significant change m serum PAP activity 
The difference between human and rat serum remains to be elucidated
The regulation of membrane bound PAPII by thyroid hormones has been shown to be tissue specific 
While, like serum PAP, the adenohypophyseal enzyme is regulated by thyroid hormones and a significant 
sex difference is observed, no such hormonal regulation is observed for PAPII from kidney, lung, 
hypothalamus and vanous brain regions (Bauer, 1987a,1988, Emerson and Wu, 1987, Ponce, 1988, Suen 
and Wilk, 1989) However, Scharfmann et al (1990) showed that liver PAPII is regulated m a similar 
manner to the serum enzyme, providing further evidence that serum PAP may be a secreted form of the 
liver enzyme Suen and Wilk (1989) reported that PAPII levels in rat brain frontal cortex are elevated 
following chronic T3 treatment, an effect which may have been obscured m previous studies using whole 
brain homogenates
Schomburg and Bauer (1995) earned out an extensive investigation into the effects of thyroid hormones 
on the mRNA levels of the TRH-R, PAPII and TSH m rat pituitary TRH-R mRNA was found 
exclusively in the adenohypophysis, with none detected in postenor pituitary including the intermediate 
lobe Transcripts of PAPII were found in both parts of the pituitary but T3-induced alterations were 
observed only m the antenor pituitary While transenpts of preproTRH, TRH-R and PAPII were all 
detected m the hypothalamic tissue preparations, T3-mduced alterations in these mRNA levels were not 
observed by Northern blot analysis
In agreement with previous reports, the authors observed a reduction m length of the TSHB mRNA 
transenpts 4 hours after a single injection of T3, followed by a slow decrease in the TSHB mRNA levels, 
reaching minimum levels after 48 hours Newly synthesised TSHB transenpts of the onginal size were 
detected after 96 hours although the concentration was still below control levels indicating that euthyroid 
conditions were not yet reached Under these conditions, no profound changes in the a-subumt mRNA 
levels were observed
The steady state mRNA levels of the TRH-R changed much more rapidly under these conditions A 
decrease to 60% of control levels was observed 2 hours after injection with minimal levels (35% of 
control) being observed after a further 2 hours and basal levels being regained only 24 hours after T3 
injection
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Steady state mRNA levels of PAPII also changed rapidly in response to T3 injection with a 5-fold 
increase being observed after 4 hours and maximal levels (>10-times above control levels), being 
observed after 6-24 hours Basal levels were observed 96 hours after injection Previous investigations by 
this group demonstrated a rapid increase in the activity of PAPII when pituitary cell aggregates were 
cultured m the presence of T3 They noted that the observed lag phase of 5 hours is remarkably short in 
view of the considerable cellular trafficking that is required before the enzyme is finally expressed on the 
cell surface (Bauer et a l , 1990)
Schomburg and Bauer (1995) also studied the response to an induced hypothyroid state by treating 
euthyroid rats with PTU After 1 day of treatment, adenohypophyseal transcript levels of PAPE decreased 
to 40% of control values and declined further to 15% within 3-4 days TRH-R mRNA levels increased 
slowly After 1 day of PTU treatment no change was observed but after 4 days, transcript levels were 
elevated to 200% of the control value TSHB transcript concentrations changed in parallel with TRH-R 
levels, reachmg 330% of control values within 4 days of PTU treatment
Analysis of T3 induced changes suggests that the relatively slow decline in TSHB levels is secondary in 
time to the acute pretranslational regulation of the TRH-R and PAPII The fast alterations of the 
transcript concentrations occur m mirror image to, and precede the corresponding changes in TRH-R and 
PAPII activity, suggesting that the controlled balance of these factors is of critical importance for an 
adequate adenohypophyseal response (Schomburg and Bauer, 1995)
1 .4 .2 .3  R egulation of, PA PII by Estrogens
As mentioned earlier, a significant sex difference was observed in the levels of PAP m rat serum (Bauer, 
1976) Similarly, adenohypophyseal PAPII levels m male rats was found to be 3-fold higher than m 
female rats (Bauer, 1988) Following ovariectomy, the activity rapidly increases within a few days, 
reachmg the value of male rats withm 3 weeks Subsequent treatment with estradiol benzoate causes the 
PAPII levels to return to basal levels Likewise, the activity of the adenohypophyseal enzyme of normal 
male rats decreases as a result of estradiol benzoate treatment The inverse effect of thyroid hormones and 
estradiol was demonstrated by administering T3 alone, or m combination with estradiol benzoate to 
female rats With T3 alone, a 36-fold increase in enzyme activity was observed withm 3 days, whereas for 
the same time penod, only a 16-fold increase was observed when both hormones were given These 
effects are specific for estradiol since other stenods have no effect on PAPII activity (Bauer, 1988) 
Northern blot analysis has shown that male rats contain more transcripts for adenohypophyseal PAPII 
than female rats, therefore the effect of estrogens is probably exerted at the level of transcription Since an 
inverse relationship between TRH-R levels and PAPII levels is expected, it is not surprising that the 
adenohypophysis of female rats contains considerably more transcripts for the TRH-R than those of males 
(Schomburg et a l , 1993)
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Serum PAP (which is moderately regulated by thyroid hormones and estrogens) might modulate the 
adenohypophyseal TRH levels by controlling the amount of TRH reaching this region via the 
hypothalamo-hypophyseal portal blood system Alternatively, this enzyme may serve a scavenger 
function to ensure that TRH released into the peripheral circulation or produced peripherally does not 
reach the TRH responsive target of the anterior pituitary (Bauer, 1995) At the pituitary level, the specific 
location of PAPII on lactotrophs (Bauer et a l , 1990) and the stringent control by estradiol and thyroid 
hormones might indicate that the adenohypophyseal enzyme could modulate the stimulatory effect of 
TRH on prolactin release by determining the availability and / or the duration of action of TRH on these 
target cells Prolactin secretion might be modulated by an alternative feedback mechanism through the 
integrative function of PAPII according to the hormonal conditions of the body (Bauer, 1995) In 
agreement with the proposed function of bram PAPII in the inactivation of synaptically released TRH (in 
order to clear the target site for the transmission of the next TRH signal), the activity of the enzyme 
should not be a limiting factor, and therefore it is not surprising that the activity of the bram enzyme is 
not influenced by hormonal manipulation of the animals (Bauer, 1988)
1.4.3 Ontogenesis of Class-II PAPs
The developmental pattern of PAPII occurs in a region specific manner In rat serum, PAP activity is 
absent at birth and appears on the 20th postnatal day, mcreasmg thereafter, reaching adult levels on day 
45 Rat liver PAPII follows the same ontogenic pattern as the serum enzyme, once again suggesting that 
the serum enzyme may be a secreted form of the liver enzyme (Scharfmann and Aratan-Spire, 1991) The 
developmental pattern of the adenohypophyseal enzyme in rat has been shown to be somewhat similar to 
that of the liver and serum enzymes Enzyme activity was shown to be absent at birth, first appearing on 
the 8th postnatal day, mcreasmg until day 28 and subsequently declining until adult levels were reached 
(Vargas et a l , 1992b) This ontogenic pattern correlates well with that of TSH (peak serum and pituitary 
levels between postnatal days 8 and 28) and thyroid hormones (peak serum values between postnatal days 
12 and 28) (Gayo et a l , 1986) The parallelism between PAPII and T3 or T4 ontogenesis suggests that 
these hormones are involved in the development of PAPII activity m these regions because of their 
known stimulatory actions on enzyme activity m these regions (see section 14  2 2) (Vargas et a l , 
1992b) Bauer et al (1990) reported that adenohypophyseal PAPII is preferentially if not exclusively 
localised on prolactin cells The coincident developmental patterns of prolactin cells and 
adenohypophyseal PAPII is m agreement with PAPII being synthesised in these cells (Vargas et a l , 
1992b)
Adenohypophyseal PAPII development is clearly delayed as compared to the bram enzyme In rat 
hypothalamus, PAPII activity has been detected on the 16th foetal day A sharp increase (7-fold) occurs 
between foetal day 22 and postnatal day 8 with a subsequent decrease thereafter until adult levels are 
reached PAPII m cortex tissue shows a similar developmental pattern to that in hypothalamus (Vargas el 
a l , 1992b, de Gandanas et a l , 1994) In contrast, olfactory bulb has been shown to present two peaks of 
PAPII activity A 2-fold increase from days 1-3 followed by a decrease at day 5 and a 2 4-fold increase on
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day 22 followed by a subsequent decrease to adult levels has been observed A biphasic ontogeny m this 
area has also been observed for TRH and TRH rnRNA levels (with a first peak at postnatal day 5 and a 
second one between days 20-30) (Vargas et a l , 1992b) and also for cyclo His-Pro (Lamberton et a l , 
1984)
Vargas et al (1992b) surmised that the ontogenesis of adenohypophyseal PAPII occurs in parallel to 
neurogenesis of the median eminence and development of the hypothalamic-adenohypophyseal axis 
PAPII development m brain occurs before or during synaptogenesis in a region specific manner, leading 
to the ultimate regional distribution of the enzyme attained m the adult animal
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Materials and Methods
2.1 Materials
Sigm a Chem ical Com pany (Poole. D orset. E nglandV
AG-25 Silver Stain Kit 
Ala-MCA
7-Ammo-4-Methyl-Coumarm (MCA) 
Ammonium Persulphate 
Bacitracin
Benzamidine 
Blue Dextran
Bovine Serum Albumin (BSA)
Bowman-Birk, trypsin / Chymotrypsin inhibitor 
Calcium Sulphate (CaSC>4 2H2O)
Cadmium Sulphate (CdSC>4 8/3H2O)
CDTA
Cellulose Type 50 
CHAPS
Cobalt Sulphate (C0SO4 H2O)
5,5-Dithio-bis 2-mtrobenzoic Acid 
Dithiothreitol (DTT)
EDTA
EGTA
Eledoism
N-Ethylmaleimide
Glycme
8-Hydroxyqumolme 
Imidazole 
2-Iodoacetamide 
Iodoacetate
Lauryl Sulphate (SDS)
Luhbenn (LHRH)
Magnesium Sulphate (MgSÜ4 7H2O) 
Manganese Sulphate (M11SO4 H2O) 
2-Mercaptoethanol
Mercunc Sulphate (HgS04) 
N,N'-Methylene-Bisacrylamide 
MW-GF-200 Marker Kit 
Nickel Sulphate (N1SO4 6H20 )
Neurotensm
pGlu-ßNA
pGlu-Glu-Pro-NH2
pGlu-His-Gly
pGlu-His-Gly-NH2
pGlu-His-Pro
pGlu-pNA
1,10-Phenanthrolme
Phenylmethylsulphonylfluonde(PMSF)
Phospholipase C
Potassium Phosphate (Monobasic) 
Potassium Phosphate (Dibasic)
Pro-MCA 
Puromycm 
Pyroglutamic Acid 
Saponin 
Sephadex G-25
Silver Stain SDS PAGE High MW Standard 
-Kit
Sodium Chloride (NaCl)
Sodium Dexoycholate 
TEMED
Thioglycohc Acid 
Tnzma Base 
Trypsin
Trypsin Inhibitor from Soybean 
Zinc Sulphate (Z11SO4 7H2O)
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Bachem Feinchemikalein AG (Buhendorf. Switzerland'):
Cyclo(His-Pro)
Gly-Pro-MCA
His-Pro-OH
pGlu-Ala-OH
pGlu-Gly-OH
pGlu-His-Pro-Gly-OH
pGlu-MCA
pGlu-Phe-OH
pGlu-Val-OH
pGlu-His-Pro-MCA
Thyroliberin (TRH) 
Z-Gly-Pro-MCA
BDH  C hem icals Ltd. (Poole. D orset. England!:
Copper Sulphate (CUSO4)
M erck Chem ical Com pany ^Frankfurt. Germ anvi: 
Anunonium Sulphate
Di-Sodium Hydrogen Phosphate (Na2HPC>4)
Potassium Chlonde (KCl)
Sodium Hydroxide (NaOH)
Pharm acia Fine Chem ical Com pany (U ppsala. Sw edeni.
Acetic Acid 
Acetone 
Acetomtnle 
Acrylamide 
Ammonia Solution 
Biuret Reagent 
Bromophenol Blue 
Calcium Chlonde (CaCh) 
Citnc Acid
Dimethylsulphoxide (DMSO) 
Glacial Acetic Acid 
Glycerol
Hydrochlonc Aad
Iron (III) Chlonde (FeCl3 6H20 )
Polyethylene Glycol 6,000
Tnton X-100
Urea
Zinc Chlonde (ZnCl2)
Chelating Sepharose Fast Flow 
Phenyl Sepharose CL-4B 
Sephacryl S-200 HR
SP-Sepharose Fast Flow 
Q-Sepharose High Performance
A ldrich C hem ical Com pany (Poole. Dorset. England)-
1,7-Phenanthrolme 
4,7 -Phenanthroline
2-Pyrrohdone 
Tnfluoroacetic Acid (TFA)
C alhiochem -N ovahiochem  (UK) Ltd. (N ottingham . E ngland):
LHRH 1-5 LHRH 1-7
LHRH 1-6 pGlu-Pro-NH2
Penninsula Laboratories (B elm ont. CA.. USA): 
pGlu-His
pGlu-His-Pro-Gly-NH2
Pierce C hem ical C om pany (THinois. U SA )1
BCA Reagent
B oeh n n ger M annheim  (UK) Ltd (East Sussex. England)-
4-(2-Aminoethyl)-benzenesulfonyl fluoride (Pefabloc SC)
Papain
TnzmaBase
M ount Sm ai School o f M edicine (New York - Courtesy o f Dr. S. WilkV
Fmoc-Pro-Pro-Nitnle
Z-Pro-Prolinal
Trinity C ollege (D ublin - Courtesy of Dr. I .  KellvV.
pGIu-Phe-Pro-NH2
Kepak Ltd.. C lonee. Dublin
Bovine Brain and Blood
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2.2 Determination of Enzyme Activities
2.2.1 Pyroglutamyl Aminopeptidase Type II
Two fluonmetnc assays were employed for the detection of Pyroglutamyl Aminopeptidase Type II 
(PAPII) activity (see figure 2 2 1) Both assays are based on the cleavage of the substrate pGlu-His-Pro- 
MCA m the presence of a specific prolyl endopeptidase (PE) inhibitor, Z-Pro-Prolinal (Wilk and 
Orlowski, 1983) or finoc-Pro-Pro-Nitnle (Li et a l , 1996) and 2-pyrrolidone, a reversible pyroglutamyl 
ammopeptidase type I (PAPI) inhibitor (Armentrout and Doolittle, 1969)
Figure 2.2.1 Fluorimetric Assays o f  PAPII
pGlu-His-Pro-MCA
+ Z-Pro-Prolmal or fmoc-Pro-Pro-Nitnle (PE Inhibitor)
+ 2-Pyrrolidone (PAPI Inhibitor)
PAPII
pGlu + His-Pro-MCA
His-Pro + M C A  Cyclo His-Pro + M C A
Fluorescence of "Liberated" MCA Measured (Ex 370nm, Em 440nm)
2 .2 .1 .1  A Fluorimetric Coupled Enzyme Assay for PAPII
PAPII activity was determined by a modification of the method of Friedman and Wilk (1986) 400 |il of 
0 ImM pGlu-His-Pro-MCA in 20mM potassium phosphate buffer, pH 7 5 was added to a mixture of, 
100(4.1 of sample, 20jil of 100|iM Z-Pro-Prohnal or 26pM fmoc-Pro-Pro-Nitnle, 20(0.1 of 1 3M 2- 
Pyrrolidone and 20(0.1 of partially purified Dipeptidyl Aminopeptidase Type IV (DAPIV) (see section 2 5) 
The mixture was incubated for 1 hour at 37°C before the reaction was terminated by the addition of 940jj.1 
of 1 5M acetic acid All assays were performed m triplicate and suitable negative controls were prepared 
by incubating substrate separate from the other components of the incubation mixture for the hour, 
followed by the addition of acetic acid to the incubation mixture prior to the addition of substrate 
Liberated MCA was determined using a Perkin-Elmer LS-50 fluorescence spectrophotometer with
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excitation and emission wavelengths of 370nm and 440nm respectively Excitation and emission slit 
widths were adjusted as appropriate for the level of fluorescence produced Samples containing particulate 
material were centrifuged at 13,000 rpm for 10 minutes, using a Heraeus Sepatech Biofuge A, pnor to 
fluorescence reading
In addition to the above assay, a non-quantitative microplate assay was devised to facilitate the detection 
of PAPII m the large number of fractions generated by column chromatography lOOjJ.1 of 0 ImM pGlu- 
His-Pro-MCA in 20mM potassium phosphate buffer, pH 7 5 was added to a mixture of 50(xl of sample 
and 20(xl of a "cocktail" containing equal volumes of lOOpM Z-Pro-Prohnal or 26p.M fmoc-Pro-Pro- 
Nitnle, 1 3M 2-Pyrrolidone and DAPIV The mixture was incubated for 1 hour at 37°C before the 
reaction was terminated by the addition of 150(0.1 of 1 5M acetic acid A suitable negative control was 
included on each plate by replacing the enzyme sample with buffer Liberated MCA was detected in the 
same manner as above, using a Perkm-Elmer LS-50 fluorescence spectrophotometer fitted with a 
microplate-reader
2 .2 .1 .2  A N on-Enzym atic C ychsation F lu orim etn c Assay for PAPII
This assay was earned out as desenbed m section 2 2 1 1  with the following exceptions DAPIV was 
omitted from the incubation mixture and the volume of 1 5M acetic acid added was increased to 960(11, 
thus bnnging the final volume to 1 5ml Following addition of the acetic acid, the reaction mixture was 
incubated at 80°C for 30 minutes to facilitate the non-enzymatic cychsation of His-Pro-MCA to His-Pro 
diketopiperazine (cyclo His-Pro) and free MCA Liberated MCA was determined as outlined in section 
22  11
2.2.2 Pyroglutamyl Aminopeptidase Type I
Pyroglutamyl Aminopeptidase Type I (PAPI) activity was determined according to the method of 
Cummins and O'Connor (1996), a modification of the ongmal procedure of Fujiwara and Tsuru (1978) 
lOO^ il of sample was incubated for 1 hour at 37°C with 400|xl of 0 ImM pGlu-MCA m 20mM 
potassium phosphate buffer, pH 7 5 containing 2% v/v DMSO, 2mM DTT and 2mM EDTA The 
reaction was terminated by the addition of 1ml of 1 5M acetic acid All assays were performed in tnphcate 
and suitable negative controls were prepared by incubating substrate and sample separately for the hour, 
followed by the addition of acetic acid to the incubation mixture prior to the addition of substrate 
Liberated MCA was determined as outlined m section 2 2 1 1
2.2.3 Prolyl Endopeptidase
Prolyl endopeptidase (PE) activity was determined according to a modification of the ongmal procedure of 
Yoshimoto et al (1979) 100(4,1 of sample was incubated for 1 hour at 37”C with 400(1.1 of 0 ImM Z- 
Gly-Pro-MCA in 20mM potassium phosphate buffer, pH 7 5 containing 4% v/v DMSO, 2mM DTT and 
2mM EDTA The reaction was tenmnated by the addition of 1ml of 1 5M acetic acid All assays were 
performed in triplicate and suitable negative controls were prepared by incubating substrate and sample
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separately for the hour followed by the addition of acetic acid to the incubation mixture prior to the 
addition of substrate Liberated MCA was determined as outlined in section 2 2 1 1
A non-quantitative microplate assay was also developed in order to facilitate the detection of PE m the 
large number of fractions generated by column chromatography 100|xl of sample was incubated for 1
hour at 37°C with 100|il of 0 ImM Z-Gly-Pro-MCA in 20mM potassium phosphate buffer, pH 7 5
containing 4% v/v DMSO, 2mM DTT and 2mM EDTA The reaction was terminated by the addition of 
lOOjil of 1 5M acetic acid A suitable negative control was included on each plate by replacing the 
enzyme sample with buffer Liberated MCA was determined as outlined in section 2 2 1 1
2.2.4 Dipeptidyl Aminopeptidase Type IV
Dipeptidyl aminopeptidase type IV (DAPIV) activity was determined according to a modification of the 
original procedure of Kato et al (1978) 100|il of sample was incubated for 1 hour at 37°C with 400p.l of 
0 ImM Gly-Pro-MCA in 20mM potassium phosphate buffer, pH 7 5 The reaction was terminated by 
the addition of 1ml of 1 5M acetic acid All assays were performed m triplicate and suitable negative 
controls were prepared by incubating substrate and sample separately for the hour followed by the addition 
of acetic acid to the incubation mixture prior to the addition of substrate Liberated MCA was determined 
as outlined m section 2 2 1 1
A non-quantitative microplate assay using the substrate Gly-Pro-MCA (0 ImM) was used to facilitate the 
detection of DAPIV in the large number of fractions generated by column chromatography as described m 
section 2 2 3
2 .3  7-Am ino-4-M ethyl-Coum arin Standard curves
In order to quantify the activity of enzymes on "quenched" fluonmetnc substrates, 7-Ammo-4-Methyl- 
Coumann (MCA) standard curves were constructed lOmM MCA in 100% DMSO was diluted to a 
concentration of 200(iM using 20mM potassium phosphate buffer, pH 7 5, at 37°C This stock solution 
was stored at 4°C Lower concentrations of MCA were achieved using 20mM potassium phosphate 
buffer, pH 7 5 as diluent Standard curves were constructed by substituting the appropriate MCA standard 
for substrate under the assay conditions descnbed in section 2 2, 2 9 7 and 2 10 11 2 Ranges of 0- 
0 3(jM, 0-2|iM, 0-10|JM and 0-40jiM MCA were prepared Fluonmetnc intensity was measured using a 
Perkm-Elmer LS-50 fluorescence spectrophotometer with excitation and emission wavelengths of 370nm 
and 440nm respectively The excitation slit width was maintained at lOnm while the emission slit width 
was adjusted to produce fluonmetnc intensities appropnate for the range being analysed
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A unit of enzyme activity was defined as that which liberates one picomole of MCA per minute at 37°C 
Conversion of fluonmetnc intensities to units of enzyme activity was achieved using the following 
formulae
Units per ml = Fluonmetnc Intensity x 66 667
Slope
Units per mg = . Fluonmetnc .Intensity x 66 667 
Slope x Protein
where "Slope" is the slope of an appropnate MCA standard curve, "Protein" is the protein concentration, 
in mg/ml, of the sample being assayed The factor "66 667" considers the method of preparation of the 
standard curve, the conversion of |iM to picomoles, the conversion of hours to minutes and the 
conversion from "per 100(xl" to "per ml" of sample
2 .4  Protein Determination
Three methods were employed for the determination of protein concentration m samples Due to the 
difference in sensitivity of each of the assays and their susceptibility to mterfenng substances, no smgle 
method was suitable for all applications
2.4.1 Biuret Protein Assay
The biuret protein assay was used for the determination of protein concentration m samples containing 
high levels of protein such as serum and post cation exchange serum samples 50jj.1 of sample was 
incubated with 200|al of Biuret reagent for 30 minutes at 37°C after which the absorbance at 560nm was 
measured using a TiterTek Multiscan PLUS spectrophotometnc plate reader A O-lOmg/ml BSA standard 
curve was prepared in parallel with the assay each time it was performed
2.4.2 Bicinchoninic Acid (BCA) Protein Assay
The Bicinchoninic Acid (BCA) protem assay, based on the ongmal method of Smith et al (1985), was 
used for the determination of protem concentration in samples containing relatively low levels of protein 
Samples with protein concentrations above the range of the assay were diluted as appropriate while 
samples with protem concentrations below the range of the assay were concentrated by reverse-osmosis 
using polyethylene glycol (PEG) 6,000 Samples containing mterfenng substances such as imidazole, 
glycerol or PEG were dialysed extensively against distilled water pnor to assay Two distinct protocols 
were used as appropnate for the samples being assayed
2 .4  2 1 BCA assay Standard Protocol
lOfxl of sample was incubated with 200jil of BCA working reagent for 30 minutes at 37°C after which 
the absorbance at 560nm was measured using a TiterTek Multiscan PLUS spectrophotometnc plate 
reader A 0-2mg/inl BSA standard curve was prepared in parallel with the assay each time it was 
performed
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2 .4 .2 .2  BCA assay. Enhanced Protocol
20|il or 50|xl of sample was incubated with 200fxl of BCA working reagent for 30 minutes at 60°C after 
which the absorbance at 560nm was measured using a TiterTek Multiscan PLUS spectrophotometnc 
plate reader An appropriate BSA standard curve (0-0 5mg/ml BSA for assays incorporating 20jj.1 of 
sample and O-O 018mg/ml BSA for assays incorporating 50p.l of sample) was prepared m parallel with 
the assay each time it was performed
2.4.3. Absorbance at 280nm
The absorbance of proteins based on the Xmax of tryptophan residues at 280nm was used as a non- 
quantitative method of determining protein concentrations m post-column chromatography fractions A 
Shimadzu UV 160A Spectrophotometer was used to determine this absorbance usmg quartz cuvettes This 
method is only suitable for samples containing relatively high levels of protein
2 .5  Partial Purification of Dipeptidyl Aminopeptidase Type IV From  
Bovine Serum
Due to the fact that this enzyme is not commercially available, DAPIV was partially purified from 
bovine serum for use m the PAPII coupled enzyme assay described m section 2 2 1 1
2 .5 .1  Bovine Serum  Production
Bovme whole blood was collected from a freshly killed animal The whole blood was transported to a 4°C 
cold room and the clot allowed to shrink for 24 hours The remaining unclotted whole blood was then 
decanted and centrifuged at 6,000 rpm (4,100g) for 1 hour usmg a Beckman J2-MC refrigerated centrifuge 
fitted with a JA-21 rotor at 4°C The serum thus produced was divided mto 20mL aliquots and stored at 
-20°C
2 .5.2  S P  Sepharose Fast Flow  Cation-Exchange Chrom atography
A 20ml SP Sepharose Fast Flow cation-exchange column (2 5cm x 4 1cm) was equilibrated with 100ml 
of lOOmM potassium phosphate buffer, pH 5 5 20ml of bovme serum was dialysed for 12 hours at 4“C 
into 4L of lOOmM monobasic potassium phosphate buffer (KH2PO4) and was subsequently centrifuged 
for 30 minutes at 15,000 rpm (27,200g) usmg a Beckman J2-MC refrigerated centrifuge fitted with a JA- 
20 rotor at 4°C, to remove post-dialysis precipitate The resulting supernatant was applied to the column 
which was then washed with 40ml of the equilibration buffer Bound protein was eluted with 50ml of 
500mM NaCl m lOOmM potassium phosphate buffer, pH 7 5 4ml fractions were collected throughout 
the procedure which was earned out at 4°C at a flowrate of 2ml/min (24 4cm/hour) Fractions were 
assayed for PE and DAPIV activity usmg the microplate assays outlined m sections 2 2 3 and 2 2 4 
respectively Protein determinations for each fraction were achieved using the biuret assay as described in 
section 2 4 1 Fractions containing the highest DAPIV activity were pooled
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2.5.3 Phenyl Sepharose C L -4 B  H ydrophobic Interaction Chrom atography
A 20ml Phenyl Sepharose CL-4B hydrophobic interaction column (2 5cm x 4 1cm) was equilibrated with 
100ml of 1M ammonium sulphate m lOOmM potassium phosphate buffer, pH 7 0 6 607g of dry 
ammonium sulphate was added to the post-SP Sepharose DAPIV pool and the pH adjusted using 1M 
NaOH, resulting m a final volume of 50ml containing 1M ammonium sulphate m lOOmM potassium 
phosphate buffer at pH 7 0 Following the application of this sample, the column was washed with 60ml 
of the equilibration buffer Bound protein was eluted with 60ml of 5mM potassium phosphate buffer, pH 
7 5 5ml fractions were collected throughout the procedure which was earned out at 4°C at a flowrate of 
2ml/mm (24 4cm/hour) Fractions were assayed for PE and DAPIV activity using the microplate assays 
outlined in sections 2 2 3 and 2 2 4  respectively Protein determinations for each fraction were achieved 
using absorbance readings at 280nm as described in section 2 4 3 Fractions containing the highest 
DAPIV activity were pooled
2 .5.4  Concentration of Partially Purified D A P IV
Post-Phenyl Sepharose CL-4B DAPIV (partially Punfied DAPIV) was dialysed for 18 hours into 2L of 
lOOmM potassium phosphate buffer, pH 7 5 at 4°C, with buffer changes at 3 and 6 hours, to remove the 
ammonium sulphate The post-dialysis sample was concentrated by reverse osmosis with polyethylene 
glycol 6,000 The concentrated sample was dialysed for a further 9 hours into 2L of lOOmM potassium 
phosphate buffer, pH 7 5 at 4°C with buffer changes at 3 and 6 hours to remove polyethylene glycol 
which passed through the dialysis membrane dunng concentration Glycerol was added to the sample to a 
final concentration of 10% v/v and 1ml aliquots were stored at -20°C
2 .5.5  Investigation of Enzym atic Purity o f Partially Purified D A P IV
The enzymatic purity of the partially purified DAPIV was investigated in order to determine the 
suitability of this matenal for use m the PAPII coupled enzyme assay, desenbed m section 2 2 1 1  The 
activities of PAPII, PAPI and PE m the sample were determined as outlined m sections 2 2 1 2, 2 2 2 
and 2 2 3 respectively In addition, the sample was assayed for ammopeptidase activity using the 
substrates Pro-MCA and Ala-MCA The assay procedures are desenbed m section 2 10 101
2 .6  Determ ination o f Optimal Conditions for the Solubilisation o f
PAPII From the Particulate Fraction o f Bovine Brain
2.6.1 Preparation o f W ashed M em branes from  Bovine Brain
25g of bovine brain was homogenised in 100ml of 20mM potassium phosphate buffer, pH 7 5 with the 
aid of a Sorvall Omni Mixer Tissue was disrupted by three 5 second pulses at speed setting four with a 
10 second pause between pulses The crude homogenate was centrifuged for 1 hour at 15,000 rpm 
(27,200g) using a Beckman J2-MC refrigerated centrifuge fitted with a JA-20 rotor The supernatant (SI) 
was discarded while the pellet (PI) was resuspended to a volume of 125ml in 1M NaCl, 20mM 
potassium phosphate buffer at pH 7 5, using 5 up and down strokes of a 40ml Glas-Col hand held pestle 
and tube homogeniser I he resuspendcd pellet was centrifuged as before The resulting supernatant (S2)
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was discarded while the pellet (1*2) was resuspended as above, to a volume of 125ml in distilled water and 
recentnfuged as before Once again the supernatant (S3) was discarded The washed membranes, thus 
obtained m the pellet (P3), were resuspended to a final volume of 95ml with 20mM potassium phosphate 
buffer, pH 7 5 as previously described All procedures were earned out at 4°C or on ice
2.6.2 Investigation of Various M em brane Solubilisation Regimes
In order to determine the optimum method of PAPII solubilisation from the membranes, a range of 
detergents and proteases were tested
10% stock solutions of the detergents CHAPS, saponin, sodium deoxycholate and Tnton X-100 were 
prepared in 20mM potassium phosphate buffer at pH 7 5 A range of concentrations from 0 to 10% of 
each detergent were prepared using 20mM potassium phosphate buffer, pH 7 5 as diluent 300|Xl of each 
detergent concentration being tested was added to 2 7ml of the resuspended washed membranes, (prepared 
as outlined m section 2 6 1), resulting m final concentrations of 0-1% detergent Following incubation 
for 1 hour on ice with constant shaking, 500p.l of the incubation mixture was retained while the 
remainder was centnfuged at 13,000 rpm for 15 minutes usmg a Heraeus Sepatech Biofuge A
lmg/ml stock solutions of phospholipase C and the proteases papain (30 umts/mg), chymotrypsin (90 
umts/mg) and trypsin (10,500 umts/mg) were prepared m 20mM potassium phosphate buffer at pH 7 5 
A range of concentrations from 0 to lmg/ml of each was prepared usmg 20mM potassium phosphate 
buffer, pH 7 5 as diluent 300|il of each test concentration was added to 2 7ml of the resuspended washed 
membranes in duphcate, resulting in final concentrations of 0-100(ig/ml Incubations were for 1 hour on 
ice or at 25°C with constant shaking, following which the action of chymotrypsin and trypsin was 
terminated by the addition of 100|xl of lmg/ml Bowman-Birk, trypsm/chymotrypsm inhibitor in 20mM 
potassium phosphate buffer, pH 7 5 (32 3^g/ml final concentration) The action of papain was terminated 
by the addition of lOOfxl of 31mM îodoacetamide in 20mM potassium phosphate buffer, pH 7 5 (ImM 
final concentration) 500jli1 of each incubation mixture was retained while the remainder was centnfuged at
13,000 rpm for 15 minutes usmg a Heraeus Sepatech Biofuge A
Following centrifugation the pellets were discarded and the supernatants retained The coupled enzyme 
assay, desenbed in section 2 2 11, was used to determine PAPII activity m the supernatants and m the 
pre-centnfugation homogenates
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2.6.3 C om parison  of the Specific A ctiv ity  of P A P II R eleased b y  the V ariou s
Solubilisation Regimes
20ml of washed membranes, (prepared as outlined in section 2 6 1), were treated with 0 4% w/v CHAPS, 
0 4% v/v Triton X-100, and 0 4% w/v sodium deoxycholate, for 1 hour on ice Similarly, 20ml of 
washed membranes were incubated with 5(ig/ml papain and 5(ig/ml trypsin, for 1 hour at 25°C, using the 
same ratios as outlined m section 2 6 2 Samples were centrifuged for 1 hour at 15,000 rpm, (27,200g), 
at 4°C using a Beckman J2-MC refrigerated centrifuge fitted with a JA-20 rotor The non-enzymatic 
cyclisation fluonmetnc assay, descnbed in section 2 2 1 2 , was used to determine the PAPII activity m 
the resulting supernatants MCA standard curves were constructed for each sample in which standards were 
substituted for substrate m order to determine the effect of the samples on fluorescence The protein 
concentration of each sample was determined using the BCA assay descnbed m section 2 4  2 1 , thus 
allowing the specific activity of PAPII m each sample to be determined
2.6.4 Stability of P A P II Released by Various Solubilisation Regim es
500|il aliquots of each of the supernatants obtained by the procedure outlined m section 2 6 3 were stored 
at 4°C and at -20°C Over a fourteen day penod samples were removed and assayed for PAPE activity as 
descnbed m section 2 4  21
2 .7  Purification o f PAPII from the M em brane Fraction of Bovine
Brain
2 .7 .1  Solubilisation of P A P II from  the W ashed M em branes
To 95ml of resuspended washed membranes, prepared as outlined in section 2 6 1, 5ml of a 0 lmg/ml 
stock solution of trypsin m 20mM potassium phosphate buffer, pH 7 5 was added (final concentration 
5|xg/ml) Following incubation at 25 °C for 1 hour, the reaction was terminated by the addition of 3ml of 
a 0 12mg/ml stock solution of soybean trypsin inhibitor (final concentration 3 5(Xg/ml) The suspension 
was centnfuged for 1 hour at 20,000 rpm, (48,400g), at 4°C using a Beckman J2-MC refrigerated 
centnfuge fitted with a JA-20 rotor The resulting pellet was discarded while the supernatant was 
recentnfuged as above to remove any remaining particulate matter This clanfied trypsin solubilised 
supernatant was stored on ice for further use The entire membrane washing and solubilisation procedure 
is outlined in figure 2 71
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25g of Bovine Brain 
Homogenised in lOOmls 
of Potassium Phosphate Buffer, pH 7.5
F igu re 2 .7 .1  Washing and Solubilisation o f  Bovine Brain Membranes
Centrifuge @ 27,200g for 1 hour SI
Pellet Resuspended in lM  NaCl 
in Potassium Phosphate Buffer, pH 7.5
Centrifuge @ 27,200g for 1 hour S2
Pellet Resuspended 
in DistW ater.
Centrifuge @ 27,200g for 1 hour S3
Pellet Resuspended in 
Potassium Phosphate Buffer, pH 7.5.
t
Trypsin Added 
(5[ig/ml Final Cone)
Incubate @ 25°C for 1 hour
I
Trypsin Inhibitor Added 
(3.5|iig/ml Final Cone)
Centnfuge @ 27,200g for 1 hour P4
Trypsin Solubilised Supernatant
Centrifuge @ 48,400g for 1 hour h -  P5
Clarified Trypsin Solubilised 
Supernatant
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2 .7.2  Q -Sepharose H igh Perform ance A n ion-Exchange Chrom atography
78 5ml of clarified trypsin solubilised supernatant was applied to a 10ml Q-Sepharose column (2 5cm x 
2cm) which was equilibrated with 100ml of 20mM potassium phosphate buffer, pH 7 5 Following a 
50ml wash with equilibration buffer the bound protein was eluted isocratically with 50ml of lOOmM 
NaCl in 20mM potassium phosphate buffer at pH 7 5 4 5ml fractions were collected throughout the 
procedure which was earned out at 4°C at a flowrate of lml/min (12 2cm/hour) Fractions were assayed 
for PAPII activity usmg the non-enzymatic cyclisation fluonmetric assay, desenbed m section 2 2 1 2  
Protein determinations for each fraction were achieved usmg the BCA assay as described in section 
2 4  21  Fractions containing the highest PAPII activity were pooled
2 .7.3  Chelating-Sepharose Fast Flow Im mobilised M etal Ion Chrom atography
Two chelating Sepharose columns were connected in senes Zn2+ was immobilised on the first column, 
14ml bed volume (1 5cm x 8cm), by passing 30ml of 0 3M ZnCl2 through the column and followed by 
75ml of distilled water The second column, 5ml bed volume (1 5cm x 3cm), was not charged with metal 
ions Both columns were equilibrated with 150mM NaCl in 20mM potassium phosphate buffer at pH 7 5
The volume of the post-Q-Sepharose PAPII pool was increased to 110% of its onginal volume by the 
addition of 650mM NaCl in 20mM potassium phosphate buffer at pH 7 5, thus bnnging the final NaCl 
concentration to 150mM All of this sample was applied to the pre-equilibrated chelating-Sepharose 
columns Following a 45ml wash with equilibration buffer the bound protein was eluted with a 50ml 
linear gradient of 0-45mM imidazole m equilibration buffer at pH 7 5 4ml fractions were collected 
throughout the procedure which was carried out at 4°C A flowrate of 0 5ml/min (17cm/hour) was 
employed for regeneration, equilibration, loading and washing while a flowrate of lml/min (34cm/hour) 
was employed for the elution step Fractions were assayed for PAPII activity usmg the non-enzymatic 
cyclisation fluonmetnc assay, desenbed in section 2 2 1 2  Protein determinations for each fraction were 
achieved usmg 20jxl of sample m the enhanced BCA assay desenbed m section 2 4 2 2 Fractions 
containing the highest PAPII activity were pooled
2.7.4  Preparation of Calcium  Phosphate-Cellulose Resin
Calcium phosphate gel was prepared by a modification of the methods of Barranger (1976) and Donlon 
and Kaufman (1980) This procedure was earned out at room temperature Into 1 5L of 0 5M CaCl2, a 
volume of 1L of 0 5M Na2HPC>4 was added at a flowrate of lOml/min, while being stined continuously 
After mixing the final volume for a further 15 minutes, 1 5ml of concentrated ammonia solution was 
added and stimng continued for 10 minutes The precipitated gel was allowed to settle and the supernatant 
decanted The precipitate was then washed m 1L of distilled water and stirred for 5 minutes before 
allowing the gel to setUe and again decanting the supernatant This washing procedure was repeated eight 
times to remove all traces of ammonia, which was monitored usmg Nessler's reagent The washed gel 
was stored at 4°C in 1L of degassed, distilled water
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lOg of Sigmacell cellulose type-50 powder, to be used as a filter aid, was soaked overnight m 100ml of 
150mM KC1 in 500mM potassium phosphate buffer at pH 6 8 Following extensive washing, and 
removal of fines, with distilled water, the cellulose was dried overnight in a 70°C oven
Prior to column packing, lg  of washed, dried cellulose was suspended m 10ml of 20mM potassium 
phosphate buffer, pH 7 5 12ml of an even suspension of calcium phosphate m water was added to the 
cellulose in buffer suspension and the mixture was stirred gently until an even suspension was obtained
2 .7 .5  Calcium Phosphate-Cellulose Chrom atography
The post-chelating-Sepharose PAPII pool was dialysed for 12 hours into 2L of lOmM potassium 
phosphate buffer, pH 7 5, with one buffer change at 10 hours All of this dialysed sample was applied to 
a 9ml calcium phosphate-cellulose column (1 5cm x 5cm), prepared as outlined m section 2 7 4, which 
was pre-equilibrated with 60ml of lOmM potassium phosphate buffer, pH 7 5 Following a 30ml wash 
with equilibration buffer, the bound protein was eluted with a 40ml linear gradient from lO-lOOmM 
potassium phosphate buffer at pH 7 5 4ml fractions were collected throughout the procedure which was 
earned out at 4'C A flowrate of 0 3ml/mm (10 2cm/hour) was employed for regeneration, equilibration, 
loading and washing while a flowrate of 0 5ml/min (17cm/hour) was employed for the elution step 
Fractions were assayed for PAPII activity using the non-enzymatic cyclisation fluorunetnc assay, 
desenbed m section 2 2 1 2  Protein determinations for each fraction were achieved using 20jxl of sample 
in the enhanced BCA assay desenbed in section 2 4  2 2 Fractions containing the highest PAPII activity 
were pooled
2 .7 .6  Sephacryl S-200 H R  G el-Filtration C hrom atography
The post calcium phosphate-cellulose PAPII pool was concentrated to 1 7ml using an Amicon 
Centnplus-50 concentrator, at 4°C, m a Beckman J2-MC refngerated centnfuge fitted with a JA-20 rotor 
300p.l of glycerol was added to the concentrated sample, thus bringing the final concentration to 15% v/v 
This sample was applied, by submergence below the buffer head, to a 230ml Sephacryl S-200 HR gel 
filtration column (2 5cm x 47cm), which was pre-equilibrated with 400ml of 150mM KC1 m 20mM 
potassium phosphate buffer at pH 7 5 The column was eluted with 250ml of equilibration buffer After 
87ml had passed through the column, 3 7ml fractions were collected A flowrate of lml/min 
(12 2cm/hour) was employed throughout the procedure which was earned out at 4°C Fractions were 
assayed for PAPII activity using the non-enzymatic cyclisation fluonmetnc assay, desenbed m section 
2 2 1 2  Protein determinations for each fraction were achieved using 50|j.l of sample in the enhanced 
BCA assay described m section 2 4 2 2 Fractions containing the highest PAPII activity were pooled 
Unless otherwise indicated, an equal volume of 2% w/v protease free BSA was added to this purified 
enzyme and 3ml aliquots were stored at -20°C, for use in charactensation studies
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2 .8  Polyacrylamide Gel Electrophoresis
SDS polyacrylamide gel electrophoresis (SDS PAGE) was carried out on the purified PAPII (post 
Sephacryl S-200) sample, to assess the efficiency of the purification procedure, according to the method 
of Laemmh (1970) Deionised water was used throughout this procedure
2 .8 .1  Sam ple Preparation
Purified PAPII was concentrated by reverse osmosis, using PEG 6,000 Aliquots of purified PAPII 
concentrated 10-fold, 5-fold and un-concentrated were subsequently dialysed into 2L of 62 5mM Tns-HCl, 
pH 6 8, for 24 hours with buffer changes at 6 and 18 hours Dialysed samples were mixed with an equal 
volume of sample solubilisation buffer which consisted of 20% v/v glycerol, 8% w/v SDS, 10% v/v 2- 
mercaptoethanol and 0 01% w/v bromophenol blue m 62 5mM Tns-HCl at pH 6 8 Silver stain SDS 
molecular weight standards were prepared according to the manufacturers recommendations and 
subsequently diluted 1/2, 1/5 and 1/10 with solubilisation buffer Table 2 8 1 lists the molecular weight 
markers used All samples were incubated for 2 minutes in a boiling water bath and allowed to cool to 
room temperature pnor to loading onto the gel
Table 2.8.1 Molecular Weight Markers Used fo r SDS PAGE
Molecular Weight Standard Source Molecular Weight (Daltons)
ß-Galactosidase E coli 116,000
Phosphorylase b Rabbit muscle 97,000
Albumin Bovme Sérum 66,000
Fumarase Porcine heart 48,500
Carbonic Anhydrase Bovine Erythrocytes 29,000
2 .8 .2  Gel Preparation and Electrophoresis i
A 16cm x 16cm x 1mm, 7 5% resolving gel overlayed with a 3 75% stacking gel was cast m an Atto 
vertical electrophoresis Midi system The volumes of the vanous solutions used to prepare the gels are 
shown in table 2 8 2 20jil of each sample or molecular weight marker was loaded onto the gel which 
was electrophoresed in an electrode buffer consisting of 1 92M Glycine, 1% w/v SDS and 0 25M Tns at 
pH 8 3 Electrophoresis proceeded for approximately 3 hours at 25mA per gel
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Table 2.8.2 SDS PAGE Gel Preparation
Solution Volume Required for 7.5% 
Resolving Gel (ml)
Volume Required for 3.75% 
Stacking Gel (ml)
30% Acrylamide, 0.8% Bisacrylamide 7.5 2.5
3M Tris-HCl pH 8.8 3.75 -
0.5M Tris-HCl pH 6.8 - 5
10% v/v SDS 0.3 0.2
Deionised Water 17 11.3
1.5% w/v Ammonium Persulphate 1.5 1
TEMED 0.015 0.015
2.8.3 Silver Staining
A Sigma AG-25 Silver Stain kit was employed to perform the silver staining of SDS PAGE gels based 
on the method of Heukeshoven and Demick (1985). Table 2.8.3 outlines the recommended staining 
procedure. This procedure was followed for the staining of gels with the exception that the development 
time was extended to 20 minutes and the reducing step was deemed to be unnecessary. The relative 
mobility (Rf) of each of the molecular weight markers was determined by dividing the distance migrated 
by the standard by the distance migrated by the tracking dye. A plot of Logio of molecular weight versus 
Rf was constructed. This calibration curve facilitated the determination of the molecular weight of 
unknown protein bands. An image of the stained gel was recorded using black and white photography of 
the gel.
Table 2.8.3 Recommended Silver Staining Procedure fo r  SDS PAGE Gels
Step Reagent Volume Duration
1. Fixing 30% v/v EtOH /10% v/v Glacial Acetic Acid 300ml x 3 20 min. x 3
2. Rinsing Deionised Water 300ml x 3 10 min. x 3
3. Silver Staining Silver Nitrate 300ml 30 min.
4. Rinsing Deionised Water 300ml 10-20 sec.
5. Developing Sodium Carbonate / Formaldehyde 150ml x 2 5-8 min. x 2
6. Development Stop 1% v/v Glacial Acetic Acid 300ml 5 min.
7. Rinsing Deionised Water 300ml x 3 10 min. x 3
8. Reducing Potassium Ferricyanide / Sodium Thiosulphate 
/ Sodium Carbonate
300ml 10-30 sec.
9. Rinsing Tap Water Running Water 1 min.
10. Rinsing Deionised Water 300ml x 3 10 min. x 3
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2.9 Development of pGlu-His-Pro-MCA Based PAPII Assays
2.9.1 Inhibition of PE by Z-Pro-Prolmal and fmoc-Pro-Pro-Nitrile
16mM Z-Pro-Prolinal m 100% methanol was diluted to a final concentration of lOOfiM using 20mM 
potassium phosphate buffer, pH 7 5 A range of dilutions from O-lOOfiM Z-Pro-Prolmal were prepared 
using the same buffer as diluent 20(il of each test concentration was added to 100|il of the cytosolic 
fraction of bovine bram (SI fraction), obtained as outlined in section 2 61  2 4mM fmoc-Pro-Pro-Nitnle 
in 100% DMSO was diluted to a final concentration of 26|oM using 20mM potassium phosphate buffer, 
pH 7 5 A range of dilutions from 0-26|jM fmoc-Pro-Pro-Nitnle were prepared using the same buffer as 
diluent 20(xl of each test concentration was added to lOOfj.1 of the post-Q-Sepharose PAPII pool, obtained 
as outlined in section 2 7 2 The PE assay described in section 2 2 3 was carried out on all samples to 
determine the residual enzyme activity The final concentration ranges, under assay conditions, were 0- 
3 85|iM Z-Pro-Prolmal and 0-1|jM fmoc-Pro-Pro-Nitnle
2.9.2 Inhibition of PAPI by 2-Pyrroiidone
2-pyrrohdone was incubated at 37°C until a homogeneous solution was obtained A range of dilutions 
from 0-100% 2-pyrrolidone (0-13 16M) was prepared usmg 20mM potassium phosphate buffer, pH 7 5 
as diluent 20\il of each test concentration was added to lOOjLil of the cytosolic fraction of bovine brain 
(SI fraction), obtained as outlined m section 2 61 The PAPI assay descnbed in section 2 2 2 was earned 
out to determine the residual enzyme activity The final 2-pyrrolidone concentration range, under assay 
- conditions, was 0-0 51M
2.9.3 The Effect of DAPIV on MCA Release
The amount of partially purified DAPIV required to catalyse the liberation of MCA from all of the His- 
Pro-MCA produced by the action of PAPII, on the substrate pGlu-His-Pro-MCA, was investigated This 
study was performed on both a crude sample and a purified sample
IOOjj.1 of crude homogenate (see section 2 6 1), 20(il of 26|jM fmoc-Pro-Pro-Nitnle and 20j_tl of 1 32M 
2-Pyrrohdone was incubated for 1 hour at 37°C with 400(11 of 0 ImM pGlu-His-Pro-MCA The reaction 
was terminated by incubating the mixture at 80°C for 2 minutes When reaction mixture had cooled to 
37°C, a range of volumes from 0-150|Xl of partially punfied DAPIV (see section 2 5 4) was added The 
final volume of the incubation mixture was adjusted to 690(1.1 by the addition of 20mM potassium 
phosphate buffer, pH 7 5 Following further incubation for 1 hour at 37°C the reaction was terminated by 
the addition of 810)il of 1 5M acetic acid Liberated MCA was determined as outlined m section 2 2 1 1
80|xl of punfied PAPII containing 1% w/v BSA (see section 2 7 6), and 20|J.l of 26jiM fmoc-Pro-Pro- 
Nitnle was incubated for 1 hour at 37'C with 400|il of 0 ImM pGlu-His-Pro-MCA The reaction was 
terminated by incubating the mixture at 80°C for 2 minutes When the reaction mixture had cooled to 
37°C, a range of volumes from 0-300jil of partially purified DAPIV (see section 2 5 4) was added The 
final volume of the incubation mixture was ad|usted to 800(il by the addition of 20mM potassium
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phosphate buffer, pH 7 5 Following further incubation for 1 hour at 37°C the reaction was terminated by 
the addition of 700jLLl of 1 5M acetic acid Liberated MCA was determined as outlined m section 2 2 1 1
All assays were performed in triplicate A suitable negative control for each sample was prepared by 
incubating substrate separate from the other components of the incubation mixture for 1 hour at 37°C, 
and subsequently for 2 minutes at 80°C Following the addition of substrate, the appropriate volumes of 
DAPIV and buffer were added and following 1 hour further incubation at 37°C, acetic acid was added
2.9.4 The Effect of Time at 80°C on MCA Release
The length of time at 80°C required for the liberation of MCA from all of the His-Pro-MCA produced by 
the action of PAPII, on the substrate pGlu-His-Pro-MCA, was investigated This study was performed on 
both a crude sample and a purified sample
lOOjLtl of crude homogenate (see section 2 6 1), 20|il of 26fiM fmoc-Pro-Pro-Nitnle and 20jil of 1 32M 
2-Pyrrolidone was incubated for 1 hour at 37°C with 400(il of 0 ImM pGlu-His-Pro-MCA The reaction 
was terminated by the addiUon of 960(il of 1 5M acetic acid The reaction mixture was incubated at 80°C 
for a range of times from 0-50 minutes, following which the samples were cooled by incubation in an
ice-water bath Liberated MCA was determined as outlined in section 2 2 11
80|il of purified PAPII containing 1% w/v BSA (see section 2 7 6), and 20|il of 26jxM fmoc-Pro-Pro- 
Nitnle was incubated for 1 hour at 37°C with 400|j.l of 0 ImM pGlu-His-Pro-MCA The reaction was 
terminated by the addition of 1ml of 1 5M acetic acid The reaction mixture was incubated at 80°C for a 
range of times from 0-180 minutes, following which the samples were cooled by incubation m an tce- 
water bath Liberated MCA was determined as outlined in section 2 2 1 1
All assays were performed m triplicate A suitable negative control for each sample was prepared by
incubating substrate separate from the other components for the hour at 37°C, followed by the addition of 
acetic acid prior to the addition of substrate and subsequent incubation for the appropriate length of time 
at 80°C
2.9.5 Linearity of PAPII Activity With Respect To Time
The linearity of PAPII activity, against the substrate pGlu-His-Pro-MCA, with respect to time was 
investigated This study was performed on both a crude sample and a purified sample
lOOfxl of crude homogenate (see section 2 6 1) or 100(il of purified PAPII containing 1% w/v BSA (see 
section 2 7 6), 20|xl of 26nM fmoc-Pro-Pro-Nitnle and 20(il of 1 32M 2-Pyrrolidone was incubated for a 
range of times from 0-120 minutes at 37°C with 400|il oi 0 ImM pGlu-His-Pro-MCA The reacUon was 
terminated by the addition of 960|il of 1 5M acetic acid The reaction mixture was incubated at 80°C for 
30 minutes, following which the samples were cooled by incubation in an ice-water bath Liberated MCA 
was determined as outlined in section 2 2 11
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2.9.6 Linearity of the Non-Enzymatic Cyclisation PAPII Assay With Respect to 
Enzyme Concentration
A range of dilutions of purified PAPII (see section 2 7 6) were prepared using 20mM potassium 
phosphate buffer, pH 7 5 as diluent Each dilution was assayed for PAPII activity as outlined in section 
2 2 1 2 A range of dilutions of purified PAPII containing 1% w/v BSA was prepared using 1% w/v BSA 
m 20mM potassium phosphate buffer at pH 7 5 as diluent Each dilution was assayed for PAPII activity 
as outlined m section 2 2 1 2  This study was also earned out using a modification of the assay desenbed 
m section 2 2 1 2 in which the incubation time at 80°C was increased to 2 hours In each case, a standard 
curve of enzyme concentration versus fluorescence was constructed
2.9.7 A Quantitative Assay for the Determination of PAPII Activity
A modification of the assay desenbed m section 2 2 1 2, m which the incubation time at 80°C was 
increased to 2 hours, was employed for the quantitative determination of PAPII activity m crude or 
partially purified samples A further modification of this procedure, m which 2-pyrrohdone and Z-Pro- 
Pro-Prohnal or fmoc-Pro-Pro-Nitnle were omitted, and the volume of acetic acid added to terminate the 
reaction was increased to 1ml, was used for the charactensation of the purified enzyme Charactensation 
studies which required absolute values for PAPII activity employed a 2 hour incubation time at 80°C, 
while those requinng only relative values employed a 30 minute incubation time at 80°C
2 .1 0  Characterisation of PAPII 
2.10.1 Relative Molecular Mass Determination via Gel-Filtration Chromatography
A 230ml Sephacryl S-200 HR gel filtration column (2 5cm x 47cm) was employed for the determination 
of the relative molecular mass of PAPII under non-denaturing conditions A flowrate of lml/min 
(12 2cm/hour) was employed throughout the procedure which was earned out at 4°C
2 .1 0 .1 .1  Void V olum e D eterm ination
Blue dextran was prepared at a concentration of 2mg/ml in 20mM potassium phosphate buffer, pH 7 5 
containing 15% v/v glycerol 2ml of this solution was applied, by submergence below the buffer head, to 
the Sephacryl S-200 HR gel filtration column which was pre-equilibrated with 400ml of 150mM KCl in 
20mM potassium phosphate buffer at pH 7 5 The column was eluted with 150ml of the equilibration 
buffer 2ml fractions were collected throughout the run The presence of blue dextran m the post-column 
fractions was detected by measuring the absorbance at 620nm using a TiterTek Multiscan PLUS 
spectrophotometnc plate reader, and the void volume (Vo) of the column was thus determined
2 .1 0 .1 .2  Elution Volum e D eterm ination for Protein Standards
Five known molecular mass standards, provided by a Sigma MW-GF-200 Kit, were dissolved individually 
in 20mM potassium phosphate buffer, pH 7 5 containing 15% v/v glycerol The standards used and die
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concentrations at which they were prepared are shown in table 2 10 1 The standards were applied 
individually m a 2ml volume, by submergence below the buffer head, to the Sephacryl S-200 HR gel 
filtration column which was pre-equilibrated with 400ml of 150mM KC1 m 20mM potassium phosphate 
buffer at pH 7 5 The column was eluted with 200ml of equilibration buffer 2ml fractions were collected 
throughout each run The presence of cytochrome C in the post-column fractions was detected by 
measuring the absorbance at 405nm using a TiterTek Multiscan PLUS spectrophotometnc plate reader 
while the other standards were detected using the BCA protein assay described m section 2 4  21
The elution volume (Ve) of each standard was determined and a plot of Logio of molecular mass versus 
Ve/V0 was constructed Using this calibration curve, it is possible to estimate the relative molecular 
mass of PAPII since its elution volume (Ve) has already been determined as outlined m section 2 7 6
Table 2.10.1 Molecular Weight Standards Used fo r  Gel Filtration
Molecular Weight Standard Source Approx Molecular 
Weight (Daltons)
Concentration
(mg/ml)
ß-Amylase Sweet Potato 200,000 5
Alcohol Dehydrogenase Yeast 150,000 5
Albumin Bovme Sérum 66,000 5
Carbonic Anhydrase Bovine Erythrocytes 29,000 5
Cytochrome C Horse Heart 12,400 2
2.10.2 Stability of Purified PAPII Under Various Storage Conditions
Purified PAPII (see section 2 7 6), was diluted with an equal volume of 40% v/v glycerol m 20mM 
potassium phosphate buffer at pH 7 5, 2% w/v BSA in 20mM potassium phosphate buffer at pH 7 5 or 
20mM potassium phosphate buffer, pH 7 5 500}xl aliquots of each were stored at 4°C, -20°C and -80°C 
Over a three week penod aliquots were removed and assayed for PAPII activity as outlined in section 
2 9 7 A plot of enzyme activity versus time was constructed for each storage condition
2.10.3 The Effect of Assay Temperature on PAPII Activity
Purified PAPII containing 1% w/v BSA was assayed at 25, 37, 45, 50 and 60°C for 15 minutes, by a 
modification of the assay described in section 2 9 7 Both the enzyme and substrate were premcubated for 
2 minutes at the corresponding temperature, prior to assay A plot of enzyme activity versus assay 
temperature was constructed The linearity of enzyme activity with respect to time at 45°C was 
investigated by performing the assay over a range of times from 0-60 minutes
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2 .1 0 .4 The Effect of pH on PAPII Activity
2 .1 0 .4 .1  pH Activity Profile
7ml of purified PAPII containing 1% w/v BSA was dialysed for 12 hours into 4L of distilled water 50|il 
of dialysed enzyme was preincubated for 15 minutes at 37°C, with 50|il of 40mM buffer at a range of pH 
values from 2 6 to 10 5 The buffers used and their respective pH ranges are shown in table 2 1 0 4  Each 
sample was assayed for PAPII activity as described in section 2 9 7 The substrate used for each assay was 
prepared by diluting 0 2mM pGlu-His-Pro-MCA, prepared in distilled water, with an equal volume of the 
corresponding buffer at a concentration of 40mM, at the corresponding pH Hence the enzyme was 
preincubated and assayed m the same buffer and at the same pH in each case A plot of enzyme activity 
versus pH was constructed
MCA standard curves were prepared, as outlined in section 2 3, for each buffer at each pH m order to 
determine the effect of these conditions on fluoresence Due to the large number of samples, each curve 
was constructed using only two MCA standard concentrations and 1% w/v BSA, in 20mM potassium 
phosphate buffer at pH 7 5, was used in the place of purified enzyme
2 .1 0 .4 .2  pH Inactivation Curve
7ml of purified PAPII containing 1% w/v BSA was dialysed for 12 hours into 4L of distilled water 50(il 
of dialysed enzyme was preincubated for 15 minutes at 37°C, with 50|il of 40mM buffer at a range of pH 
values from 2 6 to 10 5 The buffers used and their respective pH ranges are shown m table 2 104 Each 
sample was assayed for PAPII activity as described m section 2 9 7 The substrate used for each assay was 
prepared by diluting 0 2mM pGlu-His-Pro-MCA, prepared in distilled water, with an equal volume of the 
40mM potassium phosphate buffer Samples which were preincubated m the pH range 2 6-4 0 were 
assayed usmg substrate at pH 8 0 Those which were preincubated m the pH range 9 0-10 5 were assayed 
using substrate at pH 7 2 while all others were assayed usmg substrate at pH 7 5 Hence the enzyme was 
preincubated at a wide range of pH values but all assays proceeded within the pH range 6 8-7 6 A plot of 
enzyme activity versus premcubation pH was constructed
MCA standard curves were prepared, as ou dined m section 2 10 4 1 m order to determine the effect of 
these conditions on fluoresence
Table 2 10 4 Buffering Systems Used to Determine the Effect o f  pH  on PAPII Activity
Buffer pH Range
Citric Acid / Di Basic Potassium Phosphate 2 6 - 7 5
Potassium Phosphate 6 0 - 8 0
Ins  / HCI 7 0 - 9 0
Glycine/NaOI I 8 5 - 1 0  5
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2.10.5 The Effect of Functional Reagents on PAPII Activity
Stock solutions of a range of functional reagents were prepared as outlined in table 2 10 5 Lower 
concentrations of each were achieved using 20mM potassium phosphate buffer, ± 5% v/v acetone, at pH 
7 5 as appropriate The pH of the stock solutions were adjusted to pH 7 5 using 20mM monobasic or 
dibasic potassium phosphate buffer as appropriate or by the addition of 1M NaOH where necessary
10ml of purified PAPII containing 1% w/v BSA was dialysed into 2L of 20mM potassium phosphate 
buffer at pH 7 5 for 18 hours with onc buffer change at 6 hours 50jil of dialysed PAPII was preincubated 
for 15 minutes at 37°C with an equal volume of each functional reagent to be tested The residual PAPII 
activity was then determined as outlined in section 2 9 7 A positive control for each buffer system (±5% 
v/v acetone) was prepared m which the appropriate buffer replaced functional reagents
MCA standard curves were prepared, as outlined in section 2 3, for each functional reagent m order to 
determine the effect of these conditions on fluoresence Due to the large number of samples, each curve 
was constructed using only two MCA standard concentrations and 1% w/v BSA, m 20mM potassium 
phosphate buffer at pH 7 5, was used in the place of purified enzyme
2.10.6 The Effect of Metal-Complexing Agents on PAPII Activity with Respect to 
Time
The effect of a range of metal-complexmg agents and the non-chelatmg 1,7- and 4,7-phenanthrolme on 
PAPII activity over time was investigated 1 5ml of purified PAPII containing 1% w/v BSA, dialysed as 
outlmed m section 2 10 5, was incubated on ice with an equal volume of each reagent to be tested at a 
concentration of 2mM (see section 2 10 5) A positive control for each buffer system (± 5% v/v acetone) 
was prepared m which purified PAPII was mcubated with an equal volume of the appropriate buffer Over 
a 24 hour period aliquots were removed and the residual PAPII activity m each sample was determined as 
outlmed m section 2 9 7 A plot of residual PAPII activity versus time for each reagent was prepared
MCA standard curves, which were prepared earlier (see section 2 10 5), were used to determine the effect 
of these conditions on fluoresence
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Table 2.10.5 Preparation o f  Functional Reagents
Compound Class Compound Name Concentration Preparation®
Cysteme Protease Iodoacetamide 20mM Buffer
Inhibitors Iodoacetate 20mM Buffer
/V-Ethylmalemide (NEM) 20mM Buffer
Dithiobisnitrobenzoic acid (DTNB) 2mM Buffer*
Cysteme Protease Dithiothreitol (DTT) 20mM Buffer
Activators 2-Mercaptoethanol 20mM Buffer
Thioglycohc acid 20mM Buffer
Senne Protease AEBSF (Pefabloc SC) 20mM Buffer
Inhibitors Phenylmethanesulfonylfluonde (PMSF) 2mM 5% v/v Acetonec
Metallopeptidase Imidazole 20mM Buffer
Inhibitors CDTA 20mM Buffer
EDTA 20mM Buffer
EGTA 20mM Buffer
8-Hydroxyquinohne 20mM 5% v/v Acetone*7
1,10-Phenanthrolme 20mM 5% v/v Acetone
1,7-Phenanthrohne 20mM 5% v/v Acetone
4,7-Phenanthrohne 20mM 5% v/v Acetone*
Other Substances 2-Pyrrohdone lOOmM Buffer
Baatracm 2mg/ml Buffer
Puromycin 2mM Buffer
Bcnzamidine 20mM Buffer
a Functional reagents were prepared in 20mM potassium phosphate buffer, or in 5% v/v acetone (initial 
dissolution in 100% acetone and subsequent addition of 20mM potassium phosphate buffer) The pH 
of the stock solution was adjusted to pH 7 5 using 20mM monobasic and dibasic potassium 
phosphate buffer as appropnate or by the addition of 1M NaOH where necessary 
b Dissolution was aided by heating in a boiling water bath 
c PMSF was freshly prepared immediately prior to use
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2.10.7 The Effect of Metal Ions on PAPII Activity
Stock solutions of a range of metal salts were prepared at a concentration of 2mM, as outlined m table 
2 10 7 Lower concentrations of each were achieved by dilution with 20mM potassium phosphate buffer, 
pH 7 0 or 20mM tris/HCl, pH 7 0 as appropriate The pH of the stock solutions was adjusted to pH 7 0 
using 20mM monobasic or dibasic potassium phosphate buffer as appropriate or by the addition of 1M 
HC1 when tns buffer was used
5ml aliquots of purified PAPII containing 1% w/v BSA were dialysed mto either 2 5L of 20mM 
potassium phosphate buffer at pH 7 0 or 2 5L of 20mM tns/HCl buffer at pH 7 0 for 18 hours, with one 
buffer change at 6 hours 50^1 of dialysed PAPII was incubated for 15 minutes at 37°C with an equal 
volume of each metal salt to be tested The residual PAPII activity was then determined as outlined m 
section 2 9 7 A positive control for each buffer system (potassium phosphate buffer and tns/HCl) was 
prepared in which the appropriate buffer replaced the metal salt The substrate used m the assay was 
prepared in 20mM potassium phosphate buffer at pH 7 0 or 20mM tns/HCl at pH 7 0 as appropriate
MCA standard curves were prepared, as outlined m section 2 3, for each metal salt in order to determine 
the effect of these conditions on fluoresence Due to the large number of samples, each curve was 
constructed using only two MCA standard concentrations 1% w/v BSA, m 20mM potassium phosphate 
buffer at pH 7 0 or tns/HCl pH 7 0, was used m the place of punfied enzyme
Table 2.10.7 Preparation o f  M etal Salts
Metal Salt Concentration
(mM)
Preparation 1^
CuS04 2 20mM potassium phosphate buffer
M gS04 2 20mM potassium phosphate buffer
FeCl3 2 20mM potassium phosphate buffer
CaS04 2 20mM tns / HC1
CdS04 2 20mM tris / HC1
CoS04 2 20mM tns / HCI*
HgS04 2 20mM tns / HC1C
MnS04 2 20mM tns / HC1
N iS04 2 20mM tns / HC1
ZnS04 2 20mM tris / HCI
a The pH of the stock solution was adjusted to pH 7 0 using 20mM monobasic and dibasic potassium 
phosphate buffer as appropriate or by the addition of 1M HC1 when ms buffer was used 
* Dissolution was aided by heating in a boiling water bath
c Dissolved initially in a small volume of 1M UC1 followed by the gradual addition of tns base
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2.10.8 Reactivation of EDTA-Inactivated PAPII by Metal Ions
2 .1 0 .8 .1  ED TA -Inactivation  o f  PAPII
Purified PAPII containing 1% w/v BSA was dialysed into 2 5L of 20mM tns/HCl buffer at pH 7 0 as 
outlined m section 2 10 7 500|il of 50mM EDTA in 20mM tns buffer, adjusted to pH 7 0 with 1M 
NaOH, was added to 4 5ml of dialysed PAPII thus resulting m a final concentration of lOmM EDTA 
The mixture was incubated for 7 hours at 25 “C A positive control was prepared m which tns/HCl at pH 
7 0 was added in place of EDTA Aliquots of the control and the EDTA-treated sample were assayed for 
PAPII activity, as outlined in section 2 9 7, using substrate which was prepared in 20mM tns/HCl at pH 
7 0
2 .1 0 .8 .2  EDTA Removal Using Sephadex G-25 Gel F iltration
EDTA was removed from the sample by a modificauon of the method of Salvesen and Nagase (1989) 
Four 10ml Sephadex G-25 columns (1 5cm x 5 7cm) were equilibrated with 50ml of tns/HCl at pH 7 0 
The columns were allowed to run dry under gravity before being centnfuged at 1,000 rpm (184g) for 30 
seconds using a Heraeus Sepatech Megafuge 1 0 1ml of EDTA-treated sample was applied to the top of 
each of three of the columns while 1ml of the control sample was applied to the top of the other The 
columns were centnfuged at 1,200 rpm (265g) for 1 mmute The eluant from each of the columns was 
collected and that from the three EDTA-treated samples combined Aliquots of the control and the EDTA- 
treated sample were assayed for PAPII activity as outlined in section 2 10 8 1
2 .1 0 .8 .3  R eactivation  U sing M etal Salts
50)0.1 of post-gel filtration, EDTA-treated PAPII was premcubated for 15 minutes at 37°C with an equal 
volume of each metal salt to be tested The PAPII activity in each sample was then determined as 
outlined in section 2 10 8 1 A positive control was prepared m which 50|_il of tns/HCl was added to 
50|ixl of the post-gel filtration control sample
MCA standard curves, which were prepared earlier (see section 2 10 7), were used to determine the effect 
of these conditions on fluoresence
2.10.9 The Effect of DMSO on PAPII Activity
3ml of punfied PAPII, containing 1% w/v BSA, was dialysed into 2 5L of 20mM potassium phosphate 
buffer at pH 7 5 for 18 hours at 4°C, with one buffer change at 6 hours PAPII activity was determined as 
outlined in section 2 9 7 using 0 ImM pGlu-His-Pro-MCA prepared m 20mM potassium phosphate 
buffer at pH 7 5 containing DMSO at a range of concentrations from 0-10% v/v MCA standard curves
were prepared as outlined in section 2 3 to detenmne the effect of these conditions on fluoresence A plot
of PAPII activity versus DMSO concentration in the substrate was constructed
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2.10.10 Investigation of the Substrate Specificity of PAPII
2 .1 0 .1 0 .1  T he A ctiv ity  o f  PA PII A gain st a R ange o f  Q uenched  F lu o n m e tr ic  
S u b stra tes
The activity of purified PAPII against a range of quenched fluorunetric substrates was tested m order to 
assess the enzymatic purity of the sample and its substrate specificity The substrates tested, their method 
of preparation and the enzymes which they are used to detect are listed in table 2 10 10 1 100pl of 
purified PAPII was incubated with 400|jl1 of each substrate, at a concentration of 0  ImM, for 1 hour at 
37°C The reaction was terminated by the addition of 1ml of 1 5M acetic acid All assays were performed 
in triplicate and suitable negative controls were prepared by incubating the substrate and the enzyme 
separately for the hour, followed by the addition of acetic acid to the incubation mixture prior to the 
addition of substrate Liberated MCA was determined as outhned m section 2 2 1 1
Table 2.10.10.1 Preparation o f Quenched Fluorimetrie Substrates
Substrate Preparation" Used to Detect Reference
Z-Gly-Pro-MCA 4% v/v DMSO PE Yoshimoto et al (1979)
Gly-Pro-MCA Buffer DAPIV Kato et al (1978)
Pro-MCA Buffer Proline Aminopeptidase Sandennk et al (1988)
Ala-MCA Buffer Alanine Aminopeptidase Mantle et al (1983)
pGlu-MCA 2% v/v DMSO PAPI Fujiwara and Tsuru (1978)
a Substrates were prepared m 20mM potassium phosphate buffer at pH 7 5 or by initial dissolution m
100% DMSO with subsequent addition of 20mM potassium phosphate buffer at pH 7 5
2 .1 0 .1 0 .2  The A ctivity o f  PAPII A gainst pGlu-M CA, pGlu-BNA and pGlu-pNA
The PAPI substrates pGlu-MCA, pGlu-BNA and pGlu-pNA were prepared at a concentration of 0 2mM 
m 2% v/v DMSO by initial dissolution in 100% DMSO and subsequent addition of 20mM potassium 
phosphate buffer at pH 7 5 60nl of 1 3M 2-pyrrolidone and 240|xl of purified PAPII, containing 1% w/v 
BSA, was premcubated to 37°C in a glass cuvette within the heated cuvette block of a Perkm-Elmer LS- 
50 fluorescence spectrophotometer or a Umcam uv/vis Spectrometer UV2, as appropriate The reaction 
was initiated by the addition of 1 2ml of the substrate being tested The contents of the cuvette were 
mixed and the liberation of MCA, BNA or pNA was measured continuously over a period of 1 hour 
Appropriate negative controls were prepared for each substrate by including 20mM potassium phosphate 
buffer at pH 7 5 m place of PAPII MCA was measured fluorimetncally using excitation and emission 
wavelengths of 370nm and 440nm respectively with excitation and emission slit widths of lOnm and 
20nm respectively BNA was measured fulonmetrically using excitation and emission wavelengths of 
340nm and 410nm respectively with excitation and emission slit widths of lOnm and 20nm respectively 
pNA was determined by monitoring the absorbance at 410nm
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2 1 0 .1 0 .3  Investigation  o f the Substrate Specificity of PAPII by HPLC
The use of HPLC facilitated the separation and identification of cleavage products resulting from the 
incubation of PAPII with a range of pyroglutamyl substrates The HPLC system used consisted of a 
Beckman System Gold™ Programmable Solvent Module 126 (dual pump), Diode Array Detector Module 
168 and Autosampler 507 A Beckman Ultrasphere™ (Octyl) C-8 reverse phase column (4 6mm x 20cm) 
fitted with a Beckman Ultrasphere™ C-18 reverse phase guard-column (4 6mm x 4 5cm) was used with 
the above system The buffers used were, buffer A 0 2% v/v TFA in deionised water and buffer B 0 2% 
v/v TFA + 70% v/v acetomtnle in deionised water
Purified PAPII containing 1% w/v BSA was dialysed as outlined m section 2 10 9 150pl of dialysed 
enzyme was incubated for 18hours at 37°C with an equal volume of the peptide under investigation, 
prepared at a specific concentration in 20mM potassium phosphate buffer at pH 7 5 The reaction was 
terminated by the addition of 12 5|il of 5% v/v TFA An appropnate negative control for each reaction 
was prepared by incubating substrate and enzyme separately over the 18 hours and adding the TFA 
immediately after the addition of substrate
20jxl of sample was injected onto the column which was pre-equihbrated for 5 minutes m buffer A 
Elution was achieved using buffer A for 5 minutes followed by a linear gradient of 0-80% buffer B A 
flowrate of lml/min was employed throughout the procedure The absorbance of the eluant was measured 
at 206nm in all cases with the exception of MCA containing peptides which were monitored at 342nm
Standard preparations of His-Pro-OH, Cyclo His-Pro and pyroglutamic acid, were run under the above 
conditions in order to facilitate the identification of the metabolites resulting from the incubation of 
peptides with PAPII
2 1 0 .1 0 .4  M on itorin g  the C leavage o f  S ubstrates O ver Tim e by P A P II, U sing  
H PLC
Pyroglutamic acid, TRH, pGlu-His-Gly-OH and pGlu-His-Pro-Gly-NH2 were prepared at a concentration 
of 0 5mM in 20mM potassium phosphate buffer, pH 7 5 + 0 2% v/v TFA Acid TRH was prepared at a 
concentration of 0 35mM m the same buffer Dilutions of each were prepared and run on the HPLC under 
the conditions described m section 2 10 10 3 Standard curves of peak area versus peptide concentration 
were constructed
lml of dialysed PAPII (see section 2 10 10 3) was incubated with an equal volume of TRH, acid TRH, 
pGlu-His-Gly-OH and pGlu-His-Pro-Gly-NH2, which were prepared at double the concentrations outlined 
above, in 20mM potassium phosphate buffer at pH 7 5 Over a 20 hour period 300(il aliquots of each 
were removed and the reaction was terminated by the addition of 5% v/v TFA Samples were run on the 
HPLC as outlined in section 2 10 10 3 The concentrations of peptide and pyroglutamic acid in the 
incubation mixtures were determined using die standard curves A plot ol concentration versus incubation 
time was constructed for each peptide
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2.10.11 Kinetic Studies
2 .1 0 .1 1 .1  K m D eterm ination for pG Iu-H is-Pro-M CA
The Michaelis Menten constant (Km) was detennmed for the reaction of PAPII with the fluonmetnc 
substrate pGIu-His-Pro-MCA A range of concentrations of the substrate from l-200|iM, was prepared m 
20mM potassium phosphate buffer at pH 7 5 Purified PAPII containing 1% v/v BSA, dialysed into 
20mM potassium phosphate buffer at pH 7 5 as outlined m section 2 10 9, was assayed using this 
substrate concentration range as outlined in section 2 9 7 The Km and Vmax values for the substrate were 
determined using Michaelis-Menten, Eadie-Hofstee, Lineweaver-Burk, Hanes-Woolf and Direct Linear 
Plot analysis
2 .1 0 .1 1 .2  K m D eterm ination for pGIu-MCA
The Michaelis Menten constant (Km) was determined for the reaction of PAPII with the fluonmetnc 
substrate pGIu-MCA Post Sephacryl S-200 PAPII (see section 2 7 6), diluted 1/5 with 5% v/v BSA in 
20mM potassium phosphate buffer at pH 7 5 (final concentration 1% w/v BSA), was dialysed into 
20mM potassium phosphate buffer at pH 7 5 as outhned m section 2 10 9
750|jM pGIu-MCA was prepared m 20mM potassium phosphate buffer at pH 7 5 containing 4% v/v 
DMSO by initial dissolution m 100% DMSO and subsequent addition of buffer which was warmed to 
37°C A range of concentrations of the substrate from 50-750pM, was prepared in the same buffer The 
activity of PAPII across this substrate range was tested 250|o.l of dialysed enzyme was added to 1ml of 
substrate Following incubation for 1 hour at 37°C the reaction was terminated by the addition of 250(0.1 
of 6M acetic acid All assays were performed in tnphcate and suitable negative controls were prepared by 
incubating substrate and sample separately for the hour and adding acetic acid to the incubation mixture 
pnor to the addition of substrate Liberated MCA was determined as outhned in section 2 2 1 1  The Km 
and Vmax values for the substrate were determined usmg a range of kinetic models
2 .1 0 .1 1 .3  K t D eterm ination for Pyroglutam yl Peptides
The inhibitor dissociation constant (K,) for a range of pyroglutamyl peptides with PAPII was determined 
using the substrate pGIu-His-Pro-MCA A range of concentrations of pGIu-His-Pro-MCA, from 2- 
400fiM, was prepared in 20mM potassium phosphate buffer at pH 7 5 1ml of each substrate dilution 
was mixed with an equal volume of the pyroglutamyl peptide being tested (prepared to a specific 
concentration in 20mM potassium phosphate buffer pH 7 5) Purified PAPII containing 1% v/v BSA, 
dialysed into 20mM potassium phosphate buffer at pH 7 5 as outhned m section 2 10 9, was assayed 
usmg this substrate concentration range as outlined in section 2 9 7 The values for the peptides and 
the type of inhibition, were determined using the kinetic models descnbed m section 2 10 11 2
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Results
3 .1  7-Amino-4-MethyI-Coumarin Standard curves
MCA standard curves were prepared as outlined in section 2 3 Plots of fluorimetric intensity versus 
MCA concentration are presented in figures 3 1 1 , 3 1  2, 3 1 3  and 3 14  The inner filter effect observed 
when serum or crude homogenate of bovme brain are used as the enzyme sample, is demonstrated in 
figures 3 11 and 3 1 2 It should be noted that the MCA concentration expressed on the X-Axis of these 
figures represents the concentration present m the 400p.l or 1ml of standard used to construct the curves
3 .2  Protein Standard Curves
Protein standard curves were prepared usmg BSA as outlined in section 2 4 Plots of absorbance at 560nm 
versus BSA concentration are presented Figure 3 2 1  shows the standard curve for the Biuret assay, while 
figures 3 2 2 and 3 2 3 show standard curves obtained for the standard and enhanced protocols of the BCA 
assay, respectively
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MCA Concentration (nM)
Figure 3.1.1 MCA Standard Curves. Plots of fluorimetrie intensity versus MCA concentration 
100(jI of buffer (o— o) or lOOjxl of serum(*—•) was combmed with 400|j.l of a standard concentration of 
MCA and 1ml of 1 5M acetic acid before being analysed fluonmetncally as outlined in section 2 3 The 
emission slit width was set at 2 5nm Error bars represent the SEM of triplicate readings
MCA Concentration (fiM)
Figure 3.1.2 MCA Standard Curves Plots of fluorimetrie intensity versus MCA concentration 
1 OOf-il of buffer (o— o) or 100)0,1 of crude homogenate of bovine brain (•— •) was combined with 400|i.l 
of a standard concentration of MCA, 20|ll1 of 100(iM Z-Pro-Prolinal, 20(xl of 1 3M 2-pyrrohdonc and 
960(il of 1 5M acetic acid Samples were analysed fluonmetncally as outlined in section 2 3 The 
emission slit width was set at 5 Onm Error bars represent the SEM of tnplicate readings
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MCA Concentration (|oM)
Figure 3.1.3 MCA Standard Curve. Plot of fluorimetrie intensity versus MCA concentration 
IOOjjI of buffer was combined with 400|xl of a standard concentration of MCA and 1ml of 1 5M acetic 
acid before being analysed fluonmetncally as outlined in section 2 3 The emission slit width was set at 
lOnm Error bars represent the SEM of triplicate readmgs
MCA Concentration (pM)
Figure 3.1.4 MCA Standard Curve. Plot of fluorimetnc intensity versus MCA concentration 
250fxl of 1% w/v BSA in 20mM potassium phosphate buffer was combined with 1ml of a standard 
concentration of MCA and 250|il of 6M acetic acid before being analysed fluonmetncally as outlined m 
section 2 3 The emission slit width was set at 20nm Error bars represent the SEM of tnphcate readmgs 
This standard curve relates to the conditions used for the determination of the Km value for the reaction of 
PAPII with the substrate pGlu-MCA, as outlined in section 2 10 112
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BSA Concentration (mg/ml)
Figure 3.2.1 BSA Standard Curve. Plot of absorbance at 560nm versus BSA concentration 
obtained using the Biuret assay as outlined in section 2 4 1  Error bars represent the SEM of triplicate 
readings
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BSA Concentration (mg/ml)
Figure 3.2.2 BSA Standard Curves. Plot of absorbance at 560nm versus BSA concentration 
obtained using the BCA assay as outlined in section 2 4 2 lOjal of a standard concentration of BSA was 
incubated for 30 minutes at 37°C with 200|il of BCA working reagent (o— o) as outlined m section 
2 4 2 2 or 20(xl of a standard concentration of BSA was incubated for 30 minutes at 60°C with 200|il of 
BCA working reagent (•— •) as outlined in section 2 4 2 2 Error bars represent the SEM of triplicate 
readings
BSA Concentration (ng/ml)
Figure 3.2.3 BSA Standard Curve. Plot of absorbance at 560nm versus BSA concentration 
obtained using the BCA assay as outlined in section 2 4 2 50|il of a standard concentration of BSA was 
incubated for 30 minutes at 60”C with 200(4.1 ot BCA working reagent as outlined m section 2 4 2 2 
Error bars represent the SEM of triplicate readings
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3 .3 Partial Purification of DAPIV From Bovine Serum
3.3.1 Bovine Serum Production
Serum was produced as outlined m section 2 5 1 From 4 5L of whole blood collected, 1L of unclotted 
blood was obtained after 24 hours at 4°C Following centrifugation, 800ml of serum was obtained
3.3.2 SP Sepharose Fast Flow Cation-Exchange Chromatography
Following dialysis of 20ml of bovme serum, the post-dialysis precipitate was removed by centrifugation 
as outlined in section 2 5 2, resulting in 21 5ml of clear supernatant at pH 5 3 The supernatant was 
applied to an SP Sepharose column as outlined in section 2 5 2 Bound protein was eluted isocratically 
with 500mM NaCI Fractions 3-11 were combined to form the post-SP Sepharose pool (35ml) The 
elution profile of this column is illustrated in figure 3 3 1
3.3.3 Phenyl Sepharose CL-4B Hydrophobic Interaction Chromatography
Dry ammonium sulphate was added to the post-SP Sepharose pool as outlined m section 2 5 3 
Following the addition of the ammonium sulphate a precipitate formed, however, the precipitate dissolved 
as the pH approached 7 0 with the addition of 1M NaOH The sample (50ml adjusted volume) was 
applied to a phenyl sepharose column as outlined m section 2 5 3 Bound protein was eluted isocratically 
with 5mM potassium phosphate buffer, pH 7 5 Fractions 11-20 were combined to form the post-phenyl 
Sepharose pool (45ml) The elution profile of this column is illustrated m figure 3 3 2
3.3.4 Concentration of Partially Purified DAPIV
As outlined in section 2 5 4, the post-Phenyl Sepharose pool was dialysed into lOOmM potassium 
phosphate buffer, pH 7 5 and concentrated to a final volume of 26ml by reverse osmosis with PEG
6,000 Following further dialysis into lOOmM potassium phosphate buffer at pH 7 5, glycerol was added 
to a final concentration of 10% v/v
Table 3 3 1 summarises the purification scheme
3.3.5 Investigation of Enzymatic Purity of Partially Purified DAPIV
The enzymatic punty of the partially purified DAPIV was investigated as outlined m section 2 5 5 No 
PAPII, PAPI or PE activity was detected in the sample No aminopeptidase activity was detected using 
the substrates Pro-MCA and Ala-MCA
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Figure 3.3.1 Elution Profile of DAPIV Activity and Z-Gly-Pro-MCA Degrading 
Activity from SP Sepharose Cation-Exchange Chromatography. 21 5ml of dialysed serum 
was applied to a 20ml SP Sepharose column as outlined m section 2 5 2 The column was eluted
isocratically with 500mM NaCl (------ ) Fractions were assayed for protem ( ) using the Biuret assay
as outlined in section 2 4 1 ,  Z-Gly-Pro-MCA degrading activity (o— o) as outlined in section 2 2 3 and 
DAPIV activity (•— •) as outlined m section 2 2 4 Fractions 3-11 were combined to form the post-SP
Sepharose pool (35ml) as indicated (<-»)
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Figure 3.3.2 Elution Profile of DAPIV Activity and Z-Gly-Pro-MCA Degrading 
Activity from Phenyl Sepharose Hydrophobic Interaction Chromatography. Post-SP 
Sepharose DAPIV, adjusted to 1M ammonium sulphate in a total volume of 50ml, was applied to a 
20ml Phenyl Sepharose column as outlined in section 2 5 3 The column was eluted isocratically with
5mM potassium phosphate buffer at pH 7 5 containing no ammonium sulphate (-------) Fractions were
assayed for protein ( ) using the absorbance at 280nm as outlined m section 2 4 3, Z-Gly-Pro-MCA
degradmg activity (o— o) as outlined in section 2 2 3 and DAPIV activity (•— •) as outlmed m section
2 2 4 Fractions 11-20 were combined to form the post-phenyl Sepharose pool (45ml) as indicated (<—>)
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Table 3.3.1 Partial purification o f  DAPIV from  bovine serum
Sample Total Activity Total Protein Specific Activity Purification Yield
(Units*) (mg) (Umts/mg) Factor (Fold) (%)
Serum 116,389 1,616 72 02 1 100
Post-Phenyl
Sepharose
(Concentrated)
73,253 205 7 356 12 4 9 62 9
* 1 Unit of enzyme activity is defined as that which releases 1 picomole of MCA per minute from
80nM Gly-Pro-MCA at 3T C
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3 .4  Determination of Optimal Conditions for the Solubilisation of 
PAPII From the Particulate Fraction of Bovine Brain
The optunal conditions for the solubilisation of PAPII were determined as outlined m section 2 6 
Washed membranes from bovine brain were obtained as outlined in section 2 6 1 and were treated with a 
range of detergents and proteases as outlined m section 2 6 2 Phosphohpase C and the detergent saponin 
had no solubilisation effect and are therefore not discussed further The PAPII activity m the supernatants 
represents the amount of enzyme released from the membranes while the activity in the pre-centnfugation 
homogenates represents the total activity remaining after treatment with the detergent / protease It should 
be noted that the non-quantitative, coupled enzyme assay described in section 2 2 1 1  was used to 
determine PAPII activity In addition, MCA standard curves were not prepared for each sample to account 
for the inner-filter effect
The effectiveness of the detergents Triton X-100, CHAPS and sodium deoxycholate in releasing PAPII is 
illustrated in figure 3 4 1  Triton X-100 and CHAPS solubilised 100% and 90% of enzyme activity 
respectively at a concentration of 1% No loss of total enzyme activity m the homogenates was observed 
with these detergents Sodium deoxycholate solubilised 73% of PAPII activity at a concentration of 0 4% 
w/v At sodium deoxycholate concentrations above 0 2% w/v a decrease in the total enzymatic activity in 
the homogenate was observed
The effectiveness of the proteases trypsin, chymotrypsin and papain at 25 °C and on ice are illustrated in 
figures 3 4 2 and 3 4 3 respectively Trypsin was found to be the most effective protease for the 
solubilisation of PAPII Following incubation for 1 hour at 25 °C and on ice, maximal amounts of the 
enzyme was released by 5|0.g/ml and 10ng/ml trypsm respectively and by 5(xg/ml and 50}J.g/ml papam 
respectively 100(ig/ml chymotrypsin released maximal amounts of the enzyme when incubated for 1 
hour at both temperatures At protease concentrations above l|j.g/ml a loss of total enzyme activity in the 
homogenates was observed
The PAPII activity, protem concentration and PAPII specific activity of supernatants, produced by the 
solubilisation regimes described m section 2 6 3, are presented m figure 3 4 4  Supernatants were 
obtained following 1 hour incubation at 25°C with 5|J.g/ml papam and trypsin, and following 1 hour 
incubation on ice with 4% (v/v or w/v) Triton X-100, CHAPS and sodium deoxycholate In each case the 
figures are presented relative to the highest value obtained It should be noted that the quantitative, non- 
enzymatic cyclisation assay described in section 2 2 1 2  was used for the determination of PAPII activity 
In addition, MCA standard curves were prepared as outlined in section 2 3 to account for the inner-filter 
effect of the samples
72
120
Detergent Concentration (%)
Figure 3.4.1 Solubilisation of PAPII by Detergents. 2 7ml of resuspended washed 
membranes from bovine brain was incubated on ice for 1 hour with 300|il of 20mM potassium 
phosphate buffer at pH 7 5 containing a range of concentrations of CHAPS (o— o), sodium deoxycholate 
(A—A) and Triton X-100 (o— o) as outlined in section 2 6 2 PAPII activity was determined as outlined 
in section 2 2 1 1  The pre-centnfugation homogenates (filled symbols) were assayed to determine the 
total activity remaining after treatment and the supernatants (hollow symbols) were assayed to 
determine the amount of activity solubilised by the detergent Error bars represent the SEM of triplicate 
readings
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Figure 3.4.2
Protease Concentration (ng/mL)
F igu re 3 .4 .3
Protease Concentration (ng/ml)
F igures 3 4.2 and 3 4.3 Solubilisation o f PAPII by Proteases 2 7ml of resuspended 
washed membranes from bovme bram was incubated for 1 hour at 25°C (figure 3 4 2) or on ice (figure 
3 4 3) with 300^1 of 20mM potassium phosphate buffer at pH 7 5 containing a range of concentrations 
of chymotrypsin (O— O), papain (A— A) and trypsin (o— o) as outlined m section 2 6 2 PAPII activity 
was determined as outlined in section 2 2 11 T he pre-centrifugation homogenates (Filled symbols) 
were assayed to determine the total activity remaining alter treatment and the supernatants (hollow 
symbols) were assayed to determine the amount ol activity solubilised by the protease
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Trypsin Papain Triton CHAPS Sodium 
5|ig/ml 5|ig/ml X-100 0 4%w/v Deoxycholate
0 4% v/v 0 4% w/v
PAPII Activity (Relative to that in the Trypsin Solubilised Supernatant)
Protein Concentration (Relative to that in the Sodium Deoxycholate Solubilised Supernatant) 
PAPII Specific Activity (Relative to that in the Trypsin Solubilised Supernatant)
Figure 3.4.4 Comparison of PAPII Activity, Protein Concentration and PAPII 
Specific activity in Supernatants Obtained by Various Solubilisation  Regimes
Washed membranes from bovme brain were solubilised as outlined in section 2 6 3 The resulting 
supernatants were assayed for PAPII activity as outlined in section 2 2 1 2 and for protein as outlined m 
section 2 4 2 1  Error bars represent the SEM of triplicate readings
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3.4.1 Stability of PAPII Released by Various Solubilisation Regimes
The stability of PAPII solubilised under the conditions outlined in section 2 6 3, was investigated as 
outlined in section 2 6 4 Plots of PAPII activity (relative to the initial activity), versus tune stored at 
4°C and -20°C are presented in figures 3 4 5 and 3 4 6 respectively The enzyme activity m the Triton X- 
100 and sodium deoxycholate solubilised supernatants, stored at 4°C, was not monitored beyond 3 and 6 
days respectively, due to microbial contamination
When stored at 4°C, no loss of PAPII activity was observed in the trypsin solubilised supernatant over a 
14 day period 90% and 33% enzyme activity remained after 14 days in the papain and CHAPS 
solubilised supernatants respectively 53% and 52% enzyme activity remained after 24 hours m the Triton 
X-100 and sodium deoxycholate solubilised supernatants respectively
When stored at -20°C for 14 days, the PAPII activity in all of the supernatants was abolished with the 
exception of the trypsin solubilised supernatant which retained 77% of the initial enzyme activity After 
24 hours at -20°C, 5% and 35% of the initial PAPII activity remained in the supernatants solubilised 
with Triton X-100 and sodium deoxycholate respectively After 3 days at -20°C, less than 50% of the 
initial PAPII activity remained in the supernatants solubilised with papain and CHAPS
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Figure 3.4.5
Time (Days)
I Figure 3.4.6
I(
Time (Days)
Figures 3.4.5 and 3 4.6 The Stability of PAPII Released by Various Solubilisation 
Regimes. Figures 3 4 5 and 3 4 6 illustrate the stability of PAPII stored at 4°C and -20°C respectively 
Washed membranes from bovine brain were solubilised, as outlined m section 2 6 3, by incubation with 
5(iig/ml trypsin (o — o), 5(ig/ml papain (V— V), 04%w/v CHAPS (□— □ ), 0 4%v/v Triton X-100 
(o— o) or 0 4%w/v sodium deoxycholate (A—A) Aliquots of the resulting supernatants were stored at 
4°C and -20°C as described in section 2 6 4 Over a fourteen day period, aliquots were withdrawn and 
assayed for PAPII activity as outlined in section 2 2 12 Error bars represent the SEM of triplicate 
readings
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3 .5  Purification of PAPII From the Membrane Fraction of Bovine Brain
3 .5 .1  Solubilisation o f P A P II from the W ashed M em branes of Bovine Brain
Washed membranes from 25g of bovine brain were prepared in a final volume of 95ml as outlined in 
section 2 6 1 72% of the total PAPII activity was recovered m this fraction Following solubilisation 
with 5|j.g/ml trypsin for 1 hour at 25°C, as outlined in section 2 7 1, 79ml of clarified trypsin solubilised 
supernatant was obtained 500(11 of this sample was retained for enzyme activity and protein 
determinations This solubilisation procedure released 92% of PAPII activity and 14 6% of protein from 
the washed membranes into the supernatant
3.5.2  Q-Sepharose H igh Perform ance A n ion-E xchange Chrom atography
78 5ml of clarified trypsin solubilised supernatant was applied to a Q-Sepharose column as outlined in 
section 2 7 2 Bound protein was eluted isocratically with lOOmM NaCl in 20mM potassium phosphate 
buffer at pH 7 5 Fractions 33-37 were combined to form the post-Q-Sepharose pool (22ml) 500jj1 of 
this pool was retained for enzyme activity and protein determinations 95% of PAPII activity was 
recovered from this step The elution profile of this column is illustrated in figure 3 5 1
3.5.3  Chelating-Sepharose Fast Flow Immobilised M etal Ion Chrom atography
21 5ml of 650mM NaCl in 20mM potassium phosphate buffer at pH 7 5 was added to the post-Q- 
Sepharose pool resulting in a final volume of 23 65ml, containing 150mM NaCl in 20mM potassium 
phosphate buffer at pH 7 5 This material was applied to two chelatmg-Sepharose columns connected m 
series, as outlined in section 2 7 3 Bound protein was eluted using a linear gradient from 0-45mM 
imidazole in 20mM potassium phosphate buffer at pH 7 5 Fractions 26-29 were combined to form the 
post-chelating-Sepharose pool (15 5ml) 500|xl of this pool was retamed for enzyme activity and protein 
determinations 86% of PAPII activity was recovered from this step The elution profile of this column is 
illustrated in figure 3 5 2
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Figure 3.5.1 Elution Profile of PAPII Activity from Q-Sepharose High Performance 
Anion-Exchange Chromatography. 78 5ml of clarified trypsin solubilised supernatant was applied 
to a 10ml Q-Sepharose column as outlined in section 2 7 2 TTie column was eluted isocratically with 
lOOmM NaCl (-  -  - )  Fractions were assayed for PAPII activity (•— •) as outlined m section 2 2 1 2  
and for protem ( ) usmg the standard BCA assay as outlined in section 2 4 2 1 Fractions 33-37 were
combined to form the post-Q-Sepharose pool (22ml) as indicated (<->)
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Figure 3.5.2 E lution Profile of PA PII Activity from  Chelatm g-Sepharose Fast 
Flow Immobilised Metal Ion Chromatography. 2 15ml of 650mM NaCl m 20mM potassium 
phosphate buffer at pH 7 5 was added to the post-Q-Sepharose pool resulting in a final volume of 
23 65ml, containing 150mM NaCl in 20mM potassium phosphate buffer at pH 7 5 This material was 
applied to two chelating Sepharose columns connected m series (19ml total volume) as outlined m
section 2 7 3 The column was eluted using a linear gradient from 0-45mM imidazole (------ ) Fractions
were assayed for PAPII activity (•—•) as outlined m section 2 2 1 2  and for protein ( ) using 20pl of
sample m the enhanced BCA assay as outlined in section 24  2 2 Fractions 26-29 were combined to form
the post-chelatmg-Sepharose pool (15 5ml) as indicated (<-»)
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3.5.4  Calcium  Phosphate-Cellulose Chrom atography
Following dialysis into lOmM potassium phosphate buffer at pH 7 5, the post-chelating Sepharose pool 
(18ml) was apphed to a calcium phosphate-cellulose column as outlined in section 2 7 5 Bound protein 
was eluted by the application of a linear gradient from 10-100mM potassium phosphate buffer at pH 7 5 
Fractions 15-20 were combined to form the post-calcium phosphate-cellulose pool (24 5ml) 500(J,1 of 
this pool was retained for enzyme activity and protein determinations 61% of PAPII activity was 
recovered from this step The elution profile of this column is illustrated in figure 3 5 3
3 .5.5  Sephacryl S200 H R  G el-Filtration Chrom atography
Following concentration by ultrafiltration and the addition of glycerol to a final concentration of 15% 
v/v, the post-calcium phosphate-cellulose pool (2ml) was applied to a Sephacryl S200 column as 
outlined in section 2 7 6 Fractions 12-17 were combined to form the post-Sephacryl S200 pool (22ml) 
66% of PAPII activity was recovered from this step The elution profile of this column is illustrated m 
figure 3 5 4
Table 3 5 1 summarises the purification scheme
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Figure 3.5.3 Elution Profile of PAPII Activity from Calcium Phosphate-Cellulose 
Chrom atography. Following dialysis into lOmM potassium phosphate buffer at pH 7 5 the post- 
chelatmg Sepharose pool (18ml) was applied to a 9ml calcium phosphate-cellulose column as outlined in 
section 2 7 5 The column was eluted using a linear gradient from 10-100mM potassium phosphate
buffer at pH 7 5 (------ ) Fractions were assayed for PAPII activity (•— •) as outlined m section 2 2 1 2
and for protein ( ) using 20^1 of sample m the enhanced BCA assay as outlined m section 2 4 2 2
Fractions 15-20 were combined to form the post-calcium phosphate-cellulose pool (24 5ml) as indicated
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Figure 3 5.4 E lution Profile of PA PII Activity from Sephacryl S200 HR Gel- 
Filtration Chromatography. Following concentration by ultrafiltration and the addition of glycerol 
to a final concentration of 15% v/v, the post-calcium phosphate-cellulose pool (2ml) was applied to a 
230ml Sephacryl S200 column as outlined m section 2 7 6 The column was eluted using 150mM KC1 
m 20mM potassium phosphate buffer at pH 7 5 Fractions were assayed for PAPII activity (•— •) as 
outlined in section 2 2 1 2  and for protein (* ) using 50JJ.1 of sample m the enhanced BCA assay as
outlined in section 2 4 2 2 Fractious 12-17 were combined to form the post-Sephacryl S200 pool (22ml)
as indicated (<->)
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Table 3.5.1 Purification o f  PAPII from  Bovine Brain
Purification Step Volume Total protein Total activity Specific Activity Purification Factor Yield For each individual step
(ml) (mg) (Units*) (Umts*/mg) (Fold) (%) Purification Factor 
(Fold)
Yield
(%)
Homogenate 125 1937 5 13290 6 86 1 100 — —
Particulate fraction 125 1450 0 12213 8 42 1 23 91 9 123 91 9
Salt washed pellet 125 1087 5 11504 10 58 1 54 86 6 1 26 94 2
Water washed pellet 95 1026 0 10442 10 18 148 78 6 0 96 90 8
Trypsin solubilised 
supernatant
79 150 1 9601 6 63 97 9 3 72 2 6 28 92 0
Post-Q-Sepharose
chromatography
22 20 46 9156 9 447 55 65 2 68 9 7 00 95 4
Post-chelating-Sepharose
chromatography
15 5 3 10 7901 5 2548 86 371 6 59 5 5 70 86 3
Post-calcium phosphate- 
cellulose chromatography
24 5 0 49 4847 4 9892 57 1442 36 5 3 88 61 3
Post-Sephacryl S200 
chromatography
22 0 0 154 3218 1 20896 75 3047 24 2 2 11 66 4
1 Unit of enzyme activity is defined as that which releases 1 picomole of MCA per mmute from 74|_lM pGlu-His-Pro-MCA at 37°C PAPII activity was determined using the 
quantitauve, non-enzymatic cyclisation assay, descnbed in section 2 9 7 with a 2 hour incubation period at 80°C
Polyacrylamide gel electrophoresis was carried out on post-Sephacryl S200 PAPII as outlined in section 
2.8. A photograph of the gel obtained following electrophoresis and silver staining (as outlined in section 
2.8.3) is shown in figure 3.6.1. Figure 3.6.2 shows a calibration curve of Logio of molecular weight 
versus Rf, constructed as outlined in section 2.8.3 Seven distinct bands, varying in molecular weight 
from 55-141 kDa, were visualised in the lanes containing the concentrated post-Sephacryl S200 PAPII. 
Two bands with molecular weights of 55 kDa and 70 kDa were visualised in the lane containing the un­
concentrated sample.
1 2 3 4 5 6 7
3 .6  Polyacrylamide Gel Electrophoresis
116.000 Da
97.000 Da
66.000 Da
48,500 Da
29,000 Da
Figure 3.6.1 SDS PAGE Silver Stained Gel. A 16cm x 16cm x 1mm, 7.5% resolving gel, 
overlayed with a 3.5% stacking gel, was electrophoresed as outlined in section 2.8.2. Silver staining was 
carried out as outlined in section 2.8.3. Samples which were prepared as outlined in section 2.8.1, were 
loaded in the following order:
Lane 1. Post-Sephacryl S200 PAPII (un-concentrated)
Lane 2. Post-Sephacryl S200 PAPII (concentrated 5-fold)
Lane 3. Post-Sephacryl S200 PAPII (concentrated 10-fold)
Lane 4. Molecular weight markers (diluted 1/10)
Lane 5. Molecular weight markers (diluted 1/5)
Lane 6. Molecular weight markers (diluted 1/2)
Lane 7. Molecular weight markers (neat)
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Figure 3.6.2 SDS PAGE Calibration Curve. Plot of Logio of molecular weight versus 
relative mobility (Rf) A 16cm x 16cm x 1mm, 7 5% resolving gel, overlayed with a 3 5% stacking gel, 
was electrophoresed as outlined m section 2 8 2 Silver stammg was earned out as outlined in section 
2 8 3 Molecular weight standards were prepared as outlined in section 2 8 1
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3 .7  Development of pGlu-His-Pro-MCA Based PAPII Assays
3 .7 .1  Inhibition o f PE by Z-Pro-Prolinal and fm oc-Pro-Pro-N itriie
The inhibition of PE by Z-Pro-Prolinal and fmoc-Pro-Pro-Nitnle was investigated as outlined in section
2 91 The inhibition of PE in bovine brain cytosol by Z-Pro-Prolinal is illustrated in figure 3 7 11 
100% inhibition was achieved by the addition of 20|xl of 100|iM Z-Pro-Prolinal (final concentration
3 85pM under assay conditions) The inhibition of PE in the post-Q-Sepharose PAPII pool by fmoc-Pro- 
Pro-Nitnle is illustrated in figure 3 7 12 The addition of 20(xl of 26(xM fmoc-Pro-Pro-Nitnle (final 
concentration lpM under assay conditions) resulted in 100% inhibition of the enzyme
3 .7 .2  Inhibition o f PAPI by 2-Pyrrolidone
The inhibition of PAPI in bovme brain cytosol by 2-pyrrolidone, investigated as outlined m section 
2 9 2, is illustrated in figure 3 7 2 Maximal inhibition (95%) was achieved by the addition of 20|il of 
1 316M 2-pyrrolidone (final concentration 51mM under assay conditions)
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Concentration of Z-Pro-Prolinal Added (|j M)
Figure 3.7.1.1 Inhibition of PE by Z-Pro-Prolinal. 20|il o f Z-Pro-Prolinal, at a range of
concentrations from 0-100pM, was added to 100|il o f bovine brain cytosol as outlined in section 2.9.1, 
resulting in a range of concentrations of Z-Pro-Prolinal from 0-3.85(xM under assay conditions. Samples 
were assayed for residual PE activity as described in section 2.2.3.
Concentration of fmoc-Pro-Pro-nitrile Added (nM)
Figure 3.7.1.2 Inhibition of PE by fmoc-Pro-Pro-Nitrile. 20|il of fm oc-Pro-Pro-N itrile, 
at a range of concentrations from 0-26(iM, was added to 100|il of the post-Q-Sepharose PAPII pool as 
outlined in section 2.9.1, resulting in a range of concentrations of fmoc-Pro-Pro-Nitrile from 0-l(jiM 
under assay conditions. Samples were assayed for residual PE activity as described in section 2.2.3.
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Concentration of 2-Pyrrolidone Added (M)
Figure 3.7.2 Inhibition of PAPI by 2-Pyrrolidone. 20(xl of 2-Pyrrolidone, at a range of 
concentrations from 0-13 16M, was added to 100(il of bovine brain cytosol as outlined in section 2 9 2, 
resulting m a range of concentrations of 2-Pyrrolidone from 0-0 51M under assay conditions Samples 
were assayed for residual PAPI activity as described m section 22  2
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3.7.3  The Effect of D A P IV  on M C A  Release
The amount of partially purified DAPIV (see section 2 5) required to catalyse the liberation of MCA from 
all of the His-Pro-MCA produced by the action of PAPII, on the substrate pGlu-His-Pro-MCA, was 
investigated as outlined m section 2 9 3 The effect of increasing volumes of DAPIV on the release of 
MCA following the incubation of pGlu-His-Pro-MCA with crude homogenate and purified PAPII is 
illustrated in figures 3 7 3 1 and 3 7 3 2 respectively Maximal amounts of MCA are released following 
incubation for 1 hour at 37°C with 20p.l and 250jil of DAPIV in the assays containing crude homogenate 
and purified PAPII respectively
3 .7.4  The Effect o f Tim e at 80°C on M C A  Release
The incubation time at 80°C required to catalyse the liberation of MCA from all of the His-Pro-MCA 
produced by the action of PAPII, on the substrate pGlu-His-Pro-MCA, was investigated as outlined in 
section 2 9 4 The effect of time at 80°C on the release of MCA following the incubation of pGlu-His- 
Pro-MCA with crude homogenate and purified PAPII is illustrated in figures 3 7 4 1 and 3 7 4 2 
respectively Maximal amounts of MCA are released following incubation for 20 minutes and 120 
minutes at 80°C of the assays containing crude homogenate and purified PAPII respectively
3 .7 .5  Linearity of P A P II A ctivity  with respect to Tim e
The linearity of PAPII activity with respect to time was investigated as outlined in section 29  5 The 
release of MCA following the incubation of pGlu-His-Pro-MCA with crude homogenate and purified 
PAPII for varying lengths of time, followed by a 30 mmute incubation at 80°C, is illustrated in figures 
3 7 5 1 and 3 7 5 2 respectively In both cases, the release of MCA with respect to time is linear over 2 
hours
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figu res 3.7.3.1 and 3.7 3.2 The Effect of DAPIV on MCA Release. Following the 
reaction of crude homogenate (•— •) or purified PAPII (o— o) with pGlu-His-Pro-MCA, a range of 
volumes of DAPIV was added as outlined in section 2 9 3 After incubation at 37°C for 1 hour liberated 
MCA was determined as outlined in section 2 211  Error bars represent the SEM of triplicate readings
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Figure 3.7.4.1
Time at 80°C (minutes)
F igure 3.7.4.2
Time at 80°C (minutes)
Figures 3.7.4.1 and 3.7.4.2 The Effect of Time at 80°C on MCA Release. Following 
the reaction of crude homogenate (•— •) or purified PAPII (o— o) with pGlu-His-Pro-MCA, samples 
were incubated for a range of times at 80°C as outlined in section 2 9 4 After cooling in an ice water- 
bath, liberated MCA was determined as outlined in section 2 21,1. Error bars represent the SEM of 
(riphcate readings
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Figure 3.7.5.1
Time (minutes)
F igure 3.7.5.2
Time (minutes)
Figures 3.7.5.1 and 3.7.5.2 Linearity of PAPII Activity with respect to Time Crude 
homogenate (•— •) or purified PAPII (o— o) was assayed over a range of times at 37°C as outlined in 
section 2 9 5 Liberated MCA was determined as outlined in section 2 2 11 Error bars represent the 
SEM of triplicate readings
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3.7.6 Linearity of the Non-Enzymatic Cyclisation PAPII Assay with respect to 
Enzyme Concentration
The linearity of the non-enzymatic cyclisation PAPII assay with respect to enzyme concentration was 
investigated as outlined in section 2 9 6 Figure 3 7 6 1 illustrates the relationship between PAPII 
activity and concentration of purified enzyme containing no BSA, usmg the non-enzymatic cyclisation 
assay described m section 2 2 1 2  The relationship between PAPII activity and concentration of purified 
enzyme containing 1% w/v BSA, using1 the non-enzymatic cyclisation assay with 30 minutes incubation 
at 80°C (see section 2 2 1 2 )  and 2 hours incubation at 80°C (see section 2 9 7) is illustrated m figures 
3 7 6 2 and 3 7 6 3 respectively A  non-linear relationship between enzyme activity and enzyme 
concentration was observed in the absence of BSA In the presence of 1%  w/v BSA a linear relationship 
was observed when either 30 minute or 2 hour incubations at 80°C were employed
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Figure 3.7.6.1
Relative Concentration of Purified PAPII
F igure 3.7 6.2
Relative Concentration of Purified PAPII
Figures 3.7.6.1 and 3.7.6.2 L inearity  of the Non-Enzymatic Cyclisation PA PII 
Assay with respect to Enzyme Concentration. Plots of PAPII activity versus enzyme 
concentration A range of dilutions of post-Sephacryl S200 PAPII containing no BSA (•—•) or 1% w/v 
BSA (o— o), were assayed using the non-enzymatic cyclisation assay, employing a 30 minute incubation 
at 80°C, descnbed m section 2 2 1 2  Error bars represent the SEM of triplicate readings
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Figure 3.7.6.3 L inearity  of the Non-Enzym atic Cyclisation PA PII Assay with 
respect to Enzyme Concentration. Plot of PAPII activity versus enzyme concentration A range 
of dilutions of post-Sephacryl S200 PAPII containing 1% w/v BSA was assayed using the non-enzymatic 
cyclisation assay, employing a 2 hour incubation at 80°C, as described in section 2 9 7 Error bars 
represent the SEM of triplicate readings
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3 .8  Characterisation of PAPII
3 .8 .1  Relative M olecular M ass Determ ination via Gel-Filtration Chrom atography
A 230ml Sephacryl S-200 HR gel-filtration column was calibrated as outlined in section 2 10 1 The 
void volume (V0) of the column (i e the elution volume of blue dextran) was determined to be 104ml as 
oudmed in section 2 10 1 1 The elution volumes (Ve) of a range of molecular mass standards were 
determined as described m section 2 10 1 2 A plot of Logio of molecular mass versus Ve/V0 yielded the 
calibration curve shown m figure 3 8 1 The elution volume of PAPII activity was determined to be 
138ml Based on the equation of the calibration curve,
Logio MW = 6 095 - 2 837 (Ve/V0) 
the molecular mass of PAPII was estimated to be 214,051 Da
3 .8 .2  Stability o f Purified PA PII Under Various Storage Conditions
Post-Sephacryl S-200 PAPII, in the presence of (i) 1% w/v BSA, (11) 20%v/v glycerol or (m) m the 
absence of stabilising agents, was stored at 4°C, -20°C and -80°C as outlined in section 2 10 2 Over a 
three week period, aliquots of enzyme were removed and assayed for residual PAPII activity as outlined in 
section 2 9 7 Enzyme stored at 4°C, in the presence of BSA was not assayed beyond the fourth day due 
to microbial contamination of the sample Plots of residual PAPII activity versus storage time are 
presented m figure 3 8 2
When stored at 4°C, total loss of activity was observed after 14 days m the sample containing no 
stabilising agents After 21 days, 7% of the initial activity remained m the sample containing glycerol 
88% of the initial activity remained in the sample containing BSA after 4 days (last day assayed)
When stored at -20°C, total loss of activity was observed m the sample containing no stabilising agents 
after 7 days After 21 days, 21% of the initial activity remained m the sample containing glycerol and 
81% of the initial activity remained m the sample containing BSA
When stored at -80°C, total loss of activity was observed m the sample containing no stabilising agents 
after 24 hours (earliest time assayed) After 21 days, 47% and 93% of the initial activity remained in the 
samples containing glycerol and BSA respectively
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Figure 3.8.1 Sephacryl S-200 M olecular Mass C alibration Curve. Plot of Logi o 
molecular weight versus Ve/V0 where Ve is the elution volume of molecular mass standards (•— •) or 
PAPII (o) and V0 is the void volume of the column (104ml), determined by the elution volume of blue 
dextran Based on linear regression analysis of the calibration curve, as outlined m section 2 10 1, the 
molecular mass of PAPII was estimated to be 214,051 Da
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Figure 3.8.2 Stability of Purified PAPII. Plots of relative PAPII activity versus time stored 
at 4°C, -20°C and -80°C Post-Sephacryl S-200 PAPII was stored in the presence of 1% w/v BSA 
(o— o), 20% v/v Glycerol (A—A) or without any additions (o— o) as outlined in section 2 10 2 Error 
bars represent the SEM of triplicate readmgs
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3.8.3 The Effect of A ssay Tem perature on P A P II A ctivity
Purified PAPII, containing 1% w/v BSA was assayed for 15 minutes at a range of temperatures as 
outlined m secuon 2 10 3 Figure 3 8 3 1 illustrates the effect of assay temperature on enzyme activity 
Maximal enzyme activity is observed at 45 °C Incubation at 60°C resulted in no observed enzyme 
activity
Purified PAPII, containing 1% w/v BSA was assayed over a range of times at 45°C as outlined in section 
210 3 The linear relationship between enzyme activity and time is illustrated m figure 3 8 3 2
3.8.4 The Effect of pH  on P A P II A ctivity
The effects of pH on PAPII activity was investigated as outlined in section 2 10 4 The pH activity 
profile, described in section 2 10 4 1, is presented m figure 3 8 41 The enzyme exhibits a pH optimum 
of 6 8 to 7 6 Withm the optimum pH range, maximal activity is observed in the citric acid / potassium 
phosphate buffering system
The pH inactivation curve, described in section 2 10 4 2, is presented in figure 3 8 4 2 Following 
preincubation for 15 minutes at 37°C, at a range of pH values, the enzyme assay was performed withm 
the optimal pH range of 6 8 to 7 6 At pH values above 9 2 and below 4 0 the enzyme is inactivated
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Figure 3.8.3.1 The Effect of Assay Tem perature on PA PII Activity. Plot of PAPII 
activity versus assay temperature Following a 2 mmute premcubation of substrate and sample, purified 
PAPII containing 1% w/v BSA was assayed for 15 minutes at a range of temperatures as outlined in 
section 210 3 Error bars represent the SEM of triplicate readings
Tune (minutes)
Figure 3.8.3.2 Linearity of PAPII Activity with respect to Time at 45°C. Plot of 
PAPII activity versus time at 45°C Following a 2 mmute preincubation of substrate and sample, purified 
PAPII containing 1% w/v BSA was assayed for a range of tunes at 45°C, as outlined m section 2 10 3 
Error bars represent the SEM of triplicate readings
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Figures 3.8.4.1 and 3.8.4.2 The Effect of pH on PAPII Activity. Plots of PAPII 
activity versus pH Figure 3 8 41 illustrates pH activity profile of PAPII as outlined in section 2 10 4 1 
Purified enzyme, containing 1% w/v BS A, was premcubated for 15 minutes at 37°C m a range of buffers 
at a range of pH values and was assayed with substrate prepared in the same buffer at the same pH The 
pH inactivation curve of the enzyme, prepared as described in section 2 10 4 2, is illustrated in figure 
3 8 4 2 Following a 15 minute preincubation at 37°C in a range of buffers at a range of pH values, 
punfied PAPII containing 1% w/v BSA was assayed using substrate prepared in potassium phosphate 
buffer within the pH range 6 8 to 7 6 The buffering systems used are citric acid / di-basic potassium 
phosphate (o— o), potassium phosphate (o— o), tris / HC1 (A—A) and glycine / NaOH (V—V) Error 
bars represent the SEM of triplicate readings
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3.8.5 The Effect of Functional Reagents on P A P II A ctivity
The effect of various functional reagents on purified PAPII activity was tested as outlined in section 
2 10 5 Table 3 8 5 presents the residual enzyme activity, as a percentage of that m an untreated sample, 
following 15 minutes preincubation at 37°C with functional reagents, at the concentrations indicated 
Total inhibition of enzyme activity was observed following treatment with lOmM 1,10-phenanthrolme 
Residual PAPII activities of 33 7% and 3 2% resulted from incubation with AEBSF (Pefabloc SC) at 
concentrations of ImM and lOmM respectively Significant inhibition of greater than 20% was observed 
following treatment with EGTA (lOmM), 8-hydroxyqumoline (ImM and lOmM), 1,7-phenanthroline 
(lOmM), 4,7-phenanthroline (10mM),Ar-EthylmaIeimide (lOmM) and dithiothreitol (lOmM)
3.8.6 T h e Effect of M etal-C om plexin g A gen ts on P A P II A ctiv ity  w ith respect to 
Time
The effect of various metal-complexing agents and the non-chelating 1,7- and 4,7- phenanthrolines on 
purified PAPII activity was tested, with respect to time, as outlined in section 2 10 6 Figures 3 8 6 1 
and 3 6 8 2 illustrate the effect of these compounds on enzyme activity when incubated on ice with 
purified PAPn, containing 1% w/v BSA, over a 24 hour period The residual activities after 24 hours are 
presented in'table 3 8 5 The inhibition by 1,7- or 4,7-phenanthrolme is not tune dependent Inhibition 
with imidazole increases over the initial 3 hour period but does not increase further, upon incubation 
beyond this tune 1,10-phenanthrolme, 8-hydroxyqumoline, EDTA, CDTA, and EGTA inhibit the 
enzyme m a tune dependent manner over the 24 hour period
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Com pound
C la ss .
Compound Name. Residual PAPII Activity as a Percentage of 
that in an Untreated Sample ± SEM
Concentration (mM) t 
1 .0  10
Cysteme Protease lodoacetamide 93 2 ± 0 3 89 8 ± 0 8
Inhibitors Iodoacetate 91 5 ± 27 89 1 ± 2 1
N-Ethylmaleimide 97 4 ± 0 8 78 3 ± 0  7^
Dithiobisnitrobenzoic acid 89 8 ± 0 5 -
Cysteine Protease Dithiothreitol 88 9 ± 1 3 5 2 1 ± i r '
Activators 2-Mercaptoethanol 95 0 ± 1 4 89 5 ± 1 6
Thioglycolic acid 914 ± 28 94 2 ± 3 1
Senne Protease AEBSF (Pefabloc SC) 33 7 ± 0 3 v 3 2 ± 0 6V
Inhibitors Phenylmethanesulfonylfluonde 97 9 ± 3 2 -
Metallopeptidase Imidazole 99 3 ± 2 6 [86 3 ± 1 l]*v 96 2 ± 1 0
Inhibitors CDTA 96 2 ± 28  [46 4 ± 1 7]*v 89 8 ± 0 9V
EDTA 97 7 ± 1 1 [52 8 ± 0 8]*v 95 9 ± 2 2
EGTA 92 5 ± 13 [461 ± 0  6]*v 70 7 ± 1 4V
8-Hydroxyquinoline 85 9 ± 1 0V [68 6 ± 2 6]*v 32 2 ± 2 5V
1,10-Phenanthrolme 90 6 ± 3 5 [59 1 ± 1 l]*v 0V
1,7-Phenanthroline 863 ± 3 6  [83 3 ± 23]* 33 1 ± 2 l v
4,7-Phenanthroline 82 9 ± 3 4 [83 4 ± 1 7]*v 44 1 ± 2 5V
Other Substances 2-Pyrrolidone (50mM)t 92 9 ± 2 8 - -
Bacitracm (lmg/ml)î 919 ± 1 1 - -
Puromycm 83 1 ± 1 l v -
-
Benzamidine 90 7 ± 3 2 94 4 ± 1 0
Table 3.8.5 The Effect of Functional Reagents on PAPII Activity The effect of 
functional reagents on PAPII activity was determined as outlined in section 2 10 5 Purified enzyme 
containing 1% w/v BSA was preincubated for 15 minutes at 37°C with the test compound at the 
concentration indicated (t) Residual PAPII activity was determined as outlined in section 2 9 7
* The number in square brackets refers to the residual activity following incubation for 24 hours on ice
 ^ Indicates P < 0 05, when statistical analysis of the results was performed using the paired Student's 
t-Test
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Figure 3.8.6.1
Time (hours)
&—A 4,7-Phenanthroline 
□—□ 1,7-Phenanthroline
O—O 1,10-Phenanthroline
Figure 3.8.6 .2
Imidazole
8-Hydroxyquinoline
EDTA
CDTA
EGTA
Time (hours)
Figures 3.8.6.1 and 3.6.8.2 The Effect of M etal-Complexing Agents on PAPII 
Activity with respect to Time. The effect of metal-chelators, and the non-chelating 1,7- and 4,7- 
phenanthrolines, on PAPII activity with respect to time was investigated as outlined in section 2.10.6. 
Purified PAPII containing 1% w/v BSA was incubated over a 24 hour period on ice with each of the test 
compounds at a concentration of ImM. Residual enzyme activity was determined as outlined in section 
2.9.7. Error bars represent the SEM of triplicate readings.
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The effect of various metal ions on purified PAPII activity was tested as outlined in section 210 7 Table 
3 8 7 presents the residual enzyme activity, as a percentage of that in an untreated sample, following 15 
minutes premcubation at 37°C with metal salts, at the concentrations indicated 50% inhibition or greater 
was observed following exposure to CdS04 (0 ImM and ImM), HgS04 (ImM) and ZnS04 (ImM) 
Significant inhibition was also observed with CUSO4 (0 ImM and ImM) and MgS04 (0 ImM) An 
enhancement of enzyme activity to 161% and 559% of the initial activity was observed following 
exposure to C0SO4 at 0 ImM and ImM respectively
3.8.7 The Effect of Metal Ions on PAPII Activity
M etal Salt Residual PAPII Activity as a Percentage of 
that in an Untreated Sample + SEM
Concentration (mM) t
0 .1 1 .0
CaS04 911 ± 2 5 96 0 ± 2 2
CdS04 50 0 ± 1 6V 1 6 ± 0 5V
C0SO4 161 3 ± 3 l v 559 1 ± 0 8V
CuS04 96 7 ± 0 9V 79 3 ± 0 5V
FeCl3 96 8 ± 2 5 98 7 ± 1 9
HgS04 914 ± 1 8 24 1 ± 1 8V
MgS04 93 3 ± 0 5^ 91 3 ± 14^
M nS04 1,12 0 ± 14 94 9 ± 3 0
NiS04 105 1 ± 2 4 125 0 ± 5 7
ZnS04 99 3 ± 1 2 39 1 ± 11 6V
Table 3.8.7 The Effect of Metal Ions on PAPII Activity. The effect of metal 10ns on 
PAPII activity was determined as outlined m section 2 10 7 Purified enzyme containing 1% w/v BSA 
was premcubated for 15 minutes at 37°C with the metal salt at the concentration indicated (t) Residual 
PAPII activity was determined as oudined in section 2 9 7
 ^ Indicates P < 0 05, when statistical analysis of the results was performed usmg the paired Student's 
t-Test
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3.8.8 Reactivation of E D T A -In activated  P A P II by M etal Ions
Purified PAPII containing 1% w/v BSA was incubated for 7 hours at 25°C with lOmM EDTA as 
outlined in section 2 10 8 1 Following this treatment, ¡6% of the enzyme activity remained when 
compared to the control sample Sephadex-G25 gel filtration, as outlined in section 2 10 8 2, resulted m 
an increase m volume from 1ml to 1 8ml for the control sample and 3ml to 5 4ml for the EDTA-treated 
sample Following EDTA removal, the EDTA treated sample displayed 32% of the activity found in the 
control sample
A range of metal salts were added to the post-gel filtration EDTA treated sample at final concentrations of 
0 ImM and lmM, as described in section 2 10 8 3 Figure 3 8 8 illustrates the PAPII activity, 
determined as outlined in section 2 9 7, following 15 mmutes preincubation at 37°C with the metal salts 
Reactivation to 67% was observed following incubation with ImM CaSC>4 Treatment with 0 ImM 
MnSC>4 and ZnS04 resulted m reactivation to 56% and 108% respectively No significant change in 
activity was observed following treatment with these metals at the higher concentration of ImM 
Reactivation to 587% and 185% was observed following treatment with ImM C0SO4 and N1SO4 
respectively
3.8.9 The Effect of D M S O  on P A P II A ctivity
The effect of DMSO on PAPII activity was investigated as outlined in section 2 10 9 Figure 3 8 9" 
illustrates the effect of increasing concentrations of DMSO m the substrate, on the punfied enzyme The 
activity expressed using substrate containing 2% v/v DMSO, is 5% higher than that using substrate 
containing no DMSO 4% v/v and 6% v/v DMSO in the substrate has no significant effect on enzyme 
activity A decrease of 10% and 21% of enzyme activity is observed when the substrate contains 8% v/v 
and 10% v/v DMSO respectively
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* P<0 05, ** P<0 01 ( Statistical Analysis Using Paired Student's t-Test)
Figure 3.8.8 Reactivation of EDTA-Inactivated PAPII by Metal Ions Purified PAPII 
containing 1% w/v BSA was incubated for 7 hours at 25°C with lOmM EDTA as outlined m section 
2 10 8 1 EDTA was removed by Sephadex G-25 gel filtration as described m section 2 10 8 2 A range 
of metal salts were added to the post-gel filtration EDTA treated sample as outlined m section 2 10 8 3 
Following 15 minutes preincubation at 37°C with the metal salts, at the concentrations mdicated, the 
residual PAPII activity was determined as outlined in section 2 9 7 Error bars represent the SEM of 
triplicate readings
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Figure 3.8.9 The Effect of DMSO on PAPII Activity Plot of relative PAPII activity, as a 
percentage of that expressed using substrate containing no DMSO, versus DMSO concentration Purified 
PAPII containing 1% w/v BSA was assayed using 0 ImM pGlu-His-Pro-MCA containing various 
concentrations of DMSO as outlined in section 2 10 9 Error bars represent the SEM of triplicate 
readings
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3.8.10 Substrate Specificity of PAPII
3 .8 .1 0 .1  The Activity of PA PII Against a Range of Quenched F luo rim etnc  
S ubstra tes
The ability of PAPII to hydrolyse a range of quenched fluorimetnc substrates was tested as outlined m 
section 2 10 10 1 Table 3 8 10 1 illustrates that none of the substrates were cleaved by the punfied 
enzyme with the exception of the PAPI substrate pGlu-MCA
Substrate Whether Hydrolysed
Z-Gly-Pro-MCA No
Gly-Pro-MCA No
Pro-MCA No
Ala-MCA No
pGlu-MCA Yes
Table 3.8.10.1 Cleavage of Quenched Fluorim etnc Substrates by PAPII 100 .^1 of 
punfied PAPII was incubated with 400(Xl of each substrate (at a concentration of 0 ImM), for 1 hour at 
37°C The reaction was terminated by the addition of 1ml of 1 5M acetic acid Liberated MCA was 
determined as outlined in section 2 2 1 1  All assays were performed in tnplicate with suitable negative 
controls as descnbed m section 2 10 10 1
3 .8 .1 0 .2  The activity of PAPII Against pGlu-MCA, pGlu-BNA and pGlu-pNA
The activity of punfied PAPII against the PAPI substrates pGlu-MCA, pGlu-BNA and pGlu-pNA was 
investigated as outlined in section 2 10 10 2 No activity was observed towards the substrate pGlu-pNA 
Figures 3 8 10 1 and 3 8 10 2 show the effect of incubating PAPII (+ 2-pyrrolidone), over 1 hour at 
37°C, with pGlu-MCA and pGlu-BNA respectively Also shown on these plots is the breakdown of the 
substrates m the absence of enzyme when 20mM potassium phosphate buffer at pH 7 5 is included m 
place of PAPII Both plots illustrate that the substrates are hydrolysed by the enzyme and that the 
reactions proceed m a linear fashion over 1 hour
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Figure 3.8.10.1
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Figures 3.8.10.1 and 3.8.10.2 Cleavage of pGlu-BNA and pGIu-MCA by PAPI1.
60(il of 1 3M 2-pyrrohdone and 240|J.l of purified PAPII containing 1% w/v BSA (-----) or 240(il of
20mM potassium phosphate buffer at pH 7 5 (—), was incubated for 1 hour at 37°C with 1 2ml of 
0 2mM pGlu-BNA (Figure 3 8 10 1) or pGIu-MCA (Figure 3 8 10 2) Liberated BNA or MCA was 
monitored continuously over 1 hour as outlined in section 2 10 10 2 Both substances were monitored 
fluonmetncally with excitation and emission wavelengths of 370nm and 440nm respectively for MCA 
and 340nm and 410nm respectively for BNA Excitation and emission slit widths of lOnm and 20nm 
respectively were used throughout
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3 .8 .1 0 .3  Investigation of the Substrate Specificity of PAPII by HPLC
The ability of purified PAPII to hydrolyse a range of synthetic pyroglutamic acid containing substrates 
was investigated using HPLC, as oudined m section 2 10 10 3 The HPLC chromatograms illustrating 
the cleavage of acid TRH, pGlu-Phe-Pro-NH2, pGIu-His-Pro-Gly-OH and pGlu-His-Pro-Gly-NH2 are 
shown m figures 3 8 10 3 to 3 8 10 6 The cleavage of TRH is illustrated on the HPLC chromatograms 
shown m figure 3 8 10 7 In each case, cleavage of the peptide is determined by a reduction of, or total 
elimination of the substrate peak and the formation of a pyroglutamic acid peak In the case of acid TRH 
cleavage, His-Pro-OH and a small amount of cyclo-His-Pro were identified as the other cleavage products 
(figure 3 8 10 3) Cyclo-His-Pro was identified as a minor cleavage product following pGlu-His-Pro-Gly- 
OH and pGlu-His-Pro-Gly-NH2 hydrolysis (figures 3 8 10 5 and 3 8 10 6) His-Pro-NH2 and cyclo-His- 
Pro were identified as the other cleavage products following TRH degradation (figure 3 8 10 8) Other 
cleavage products could not be conclusively identified due to the fact that standard fragments were not 
available Table 3 8 10 2 lists the peptides which were tested and whether or not they were cleaved by the 
enzyme
3 .8 .1 0 .4  Monitoring the Cleavage of Substrates over Time by PAPII, Using HPLC
Standard concentrations of pyroglutamic acid, TRH, acid TRH, pGlu-His-Pro-Gly-NH2 and pGlu-His- 
Gly-OH were prepared as outlined m section 2 10 10 4 Following application to, and elution from the 
HPLC column under the conditions outlined in section 2 10 10 3, plots of peak area versus peptide 
concentration were constructed The standard curves thus obtained are presented m figure 3 8 10 8
The peptides listed above were incubated with purified PAPII at 37°C for a range of times as outlined m 
section 210 104 Following HPLC analysis, the concentrations of pyroglutamic acid and peptide m the 
incubation mixture were determined using the standard curves Plots of peptide and pyroglutamic acid 
concentration, versus incubation time are presented m figures 3 8 10 9 to 3 8 10 12 Total exhaustion of 
substrate coupled with an increase of the concentration of pyroglutamic acid, to a level equivalent to the 
initial substrate concentration, was observed after incubation for 6 hours in the cases of TRH and acid 
TRH and after incubation for 10 hours in the case of pGlu-His-Pro-Gly-NH2 After 20 hours incubation, 
approximately 30% of the pGlu-His-Gly-OH was hydrolysed (figure 3 8 10 12)
The cleavage of TRH over time is illustrated by the HPLC chromatograms shown m figure 3 8 10 8 
After 6 hours all of the TRH has been hydrolysed resulting in the formation of pyroglutamic acid, His- 
Pro-NH2 and cyclo His-Pro Following 20 hours incubation, the pyroglutamic acid peak remains the 
same size, the His-Pro-NH2 peak has disappeared and the cyclo His-Pro peak has increased in size A 
similar pattern of degradation was observed for pGlu-His-Pro-Gly-NH2 After 10 hours, all of the 
substrate was hydrolysed resulting m the formation of pyroglutamic acid and two other metabolites, (i) a 
major peak with a retention time of 10 5 minutes and (n) a small amount of cyclo-His-Pro Following a 
further 10 hours incubation, the major peak is reduced m size while the cyclo-His-Pro peak is increased m 
size
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Figure 3.8.10.3 Cleavage of Acid TRH by PAPII. Plot of absorbance at 206nm versus 
retention tune Substrate specificity studies using reverse phase HPLC were earned out as outlined in
section 2 10 10 3 Plots present data obtained from the negative control (------ ) and following the
incubation, for 18 hours at 37°C, of acid TRH (0 35mM) with purified PAPII ( ) A linear gradient
from 0 to 80% buffer B is illustrated (— )
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Figure 3.8.10.4 Cleavage of pG lu-Phe-Pro-N H ? by PAPII. Plot of absorbance at 206nm 
versus retention time Substrate specificity studies using reverse phase HPLC were earned out as outlined
m section 2 10 10 3 Plots present data obtained from the negative control (------ ) and following the
incubation, for 18 hours at 37°C, of pGlu-Phe-Pro-NH2 (0 375mM) with punfied PAPII ( ) A linear
gradient from 0 to 80% buffer B is illustrated (— )
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Figure 3.8.10.5 Cleavage of p G lu -H is-P ro -G lv -O H  by PAPII. Plot of absorbance at 
206nm versus retention time Substrate specificity studies using reverse phase HPLC were earned out as
outlined in section 2 10 10 3 Plots present data obtained from the negative control (------) and following
the incubation, for 18 hours at 37°C, of pGlu-His-Pro-Gly-OH (0 5mM) with punfied PAPII ( ) A
linear gradient from 0 to 80% buffer B is illustrated (— )
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Figure 3 8.10.6 Cleavage of p G lu -H is-P ro -G lv -N H ^  by PAPII. Plot of absorbance at 
206nm versus retention tune Substrate specificity studies using reverse phase HPLC were earned out as
outlined m section 2 10 10 3 Plots present data obtained from the negative control (------) and following
the incubation, for 18 hours at 37°C, of pGlu-His-Pro-Gly-NH2 (0 5mM) with punfied PAPII ( ) A
linear gradient from 0 to 80% buffer B is illustrated (— )
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Figure 3.8.10.7 Cleavage of TR H  by PAPII. Plots of absorbance at 206nm versus retention 
time The cleavage of TRH by PAPII was monitored over a 20 hour period using reverse phase HPLC, as 
outlined m section 2 10 10 4 Plots present data obtained following the incubation of TRH (0 5mM) 
with purified PAPII for 0,6  and 20 hours at 37°C- A linear gradient from 0 to 80% buffer B is illustrated 
( . . . )
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Peptide Peptide Concentration (mM)'l' Whether Hydrolysed
pGlu-Ala-OH 05 No
pGlu-His-OH 05 No
pGlu-Gly-OH 05 No
pGlu-Phe-OH 05 No
pGlu-Val-OH 05 No
pGlu-Pro-NH2 05 No
pGlu-His-Gly-OH 05 Yes
pGlu-His-Gly-NH2 05 Yes
pGlu-His-Pro-OH (Acid TRH) 0 35 Yes
pGlu-His-Pro-NH2 (TRH) 05 Yes
pGlu-Phe-Pro-NH2 0 375 Yes
pGlu-His-Pro-Gly-OH 05 Yes
pGlu-His-Pro-Gly-NH2 05 Yes
pGlu-Glu-Pro-NH2 05 No
LHRH 1-5 05 No
LHRH 1-6 05 No
LHRH 1-7 05 No
LHRH 05 No
Eledoisin 0175 No
Neurotensm 0 175 No
pGlu-MCA 0 375 Yes
Table 3.8.10.2 Investigation of the substrate Specificity of PA PII Purified PAPII 
containing 1% w/v BSA was incubated at 37°C for 18 hours with a range of peptides Following analysis 
of the incubation mixture by reverse-phase HPLC as outlined m section 2 10 10 3, cleavage of the 
peptide was determined by a reduction (or elimination) of the peptide peak coupled with the production of 
pyroglutamic acid (t) The concentration of the peptides under assay conditions is indicated
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Figure 3.8.10.8 Peptide Standard Curves. Plots of peak area (* Absorbance Units) versus 
peptide concentration Standard concentrations of peptides were prepared and run on the HPLC system as 
outlined in section 2 10 10 4 Plots present data obtained from acid TRH (o— o), pyroglutamic acid 
(•—•). pGlu-His-Pro-Gly-NH2 ( ° — o), TRH (♦— ♦) and pGlu-His-Gly-OH (A—A)
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Figure 3.8.10.9 Cleavage of T R H  by PAPII over Time. Plots of peptide concentration 
versus incubation tune at 37°C The cleavage of TRH by PAPII was monitored over a 20 hour period 
using reverse phase HPLC, as outlined in section 2 10 10 4 Plots present the decrease m TRH 
concentration (•—•) and the increase pyroglutamic acid concentration (o o) over tune
Incubation Time (Hours)
Figure 3 8.10.10 Cleavage of Acid TRH by PAPII over Time. Plots of peptide 
concentration versus incubation tune at 37 °C The cleavage of acid TRH by PAPE was monitored over a 
20 hour period using reverse phase HPLC, as outlined in section 2 10 10 4 Plots present the decrease in 
acid TRH concentration (•—•) and the increase pyroglutamic acid concentration (o o) over time
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Figure 3.8.10.11 Cleavage of pG lu-FTis-Pro-G lv-N H ? by PAPII over Time. Plots of 
peptide concentration versus incubation tune at 37°C The cleavage of pGlu-His-Pro-Gly-NH2 by PAPII 
was monitored over a 20 hour period using reverse phase HPLC, as outlined m section 2 10 10 4 Plots 
present the decrease in pGlu-His-Pro-Gly-NH2 concentration (•—•) and the mcrease pyroglutamic acid 
concentration (o o) over tune
Incubation Tune (Hours)
Figure 3.8.10.12 Cleavage of pG lu-H is-G lv-O H  by PAPII over Time Plots of peptide 
concentration versus incubation tune at 37°C The cleavage of pGlu-His-Gly-OH by PAPII was 
monitored over a 20 hour period using reverse phase HPLC, as outlined in section 2 10 10 4 Plots 
present the decrease m pGlu-His-Gly-OH concentration (•— •) and the mcrease pyroglutamic acid 
concentration (o o) over time
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3.8.11 Kinetic Studies
3 .8 .1 1 .1  Determination of Km of PAPII for pGlu-MCA and pGlu-His-Pro-MCA
A Km value was determined for the reaction of purified PAPII with pGlu-His-Pro-MCA and pGlu-MCA 
as outlined in section 2 10 111 and 2 10 11 2 respectively The data obtained is presented as Michaelis- 
Menten, Eadie-Hofstee, Lmeweaver-Burk and Hanes-Woolf plots, m figures 3 8 1 1 1  t o 3 8 1 1 4 f o r  
pGlu-His-Pro-MCA and m figures 3 8 1 1 5  to 3 8 1 1 8  for pGlu-MCA The Km and Vmax values for the 
substrates were determined from these plots and also from Direct Linear Plot analysis (plot not presented) 
The values obtained are presented in table 3 8 111 Km values of 419 8|xM and 2 53|jM and Vmax 
values of 2,815 umts/mg and 36,144 umts/mg, were determined for pGlu-MCA and pGlu-His-Pro-MCA 
respectively, using the Direct Linear Plot analysis
Kinetic Analysis pGlu--His-Pro-MCA pGlu-MCA
Km (|iM) Vmax (Umts/mg)'!’ Km (MM) Vmax (Umts/mg)’!’
Michaelis-Menten 2 46 36,584 3514 2,582
Eadie-Hofstee 2 63 36,954 412 2 2,801
Lmeweaver-Burk 2 76 37,573 448 8 2,964
Hanes-Woolf 167 35,358 385 4 2,677
Direct Linear Plot 2 53 36,144 419 8 2,815
Table 3.8.11.1 K m and Vmax Values for the Reaction of Purified PAPII with the 
Substrates pGlu-His-Pro-MCA and pGlu-MCA.
 ^ Vmax values are presented in Umts/mg, defined as that which liberates 1 picomole of MCA per 
minute at 37°C, per mg of purified protein (not including the BSA added to the purified enzyme)
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Figure 3.8.11.1 M ichaehs-M enten Plot for pGlu-His-Pro-M CA.
Data was obtained as outlined in section 2 10 111 Km and Vmax values for the substrate were 
determined to be 2 46|iM and 36,584 umts/mg respectively Error bars represent the SD of triplicate 
readings
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Figure 3.8.11.2 Eadie-Hofstee Plot for pGlu-His-Pro-MCA.
Data was obtained as outlined in section 2 10111 Km and Vmax values for the substrate were 
determined to be 2 63|xM and 36,954 umts/mg respectively Error bars represent the SD of triplicate 
readings
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Figure 3.8.11.3 Lmeweaver-Burk Plot for pGLu-His-Pro-MCA.
Data was obtained as outlined in section 2 10 11 1 Km and Vmax values for the substrate were 
determined to be 2 76fiM and 37,573 units/mg respectively Error bars represent the SD of triplicate 
readings
Substrate Concentration (|iM)
Figure 3.8.11.4 Hanes-Woolf Plot for pGlu-His-Pro-MCA.
Data was obtained as outlined in section 2 10 11 1 Km and Vmax values for the substrate were 
determined to be 1 67|iM and 35,358 umts/mg respectively Error bars represent the SD of triplicate 
readings
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Substrate Concentration (jiM)
Figure 3.8.11.5 M ichaehs-M enten Plot for pGlu-MCA.
Data was obtained as outlined in section 2 10 11 2 Km and Vmax values for the substrate were 
determined to be 351 4|iM and 2,582 umts/mg respectively Error bars represent the SD of triplicate 
readings
Rate / Substrate Concentration (Units ng 1 nM ’)
Figure 3.8.11.6 Eadie-Hofstee Plot for pGlu-MCA.
Data was obtained as outlined in section 2 10 11 2 Km and Vmax values for the substrate were 
determined to be 412 2joM and 2,801 units/mg respectively Error bars represent the SD of triplicate 
readings
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Figure 3.8.11.7 Lineweaver-Burk Plot for pGlu-MCA
Data was obtained as outlined m section 2 10 112 Km and Vmax values for the substrate were 
determined to be 448 8(oM and 2,964 umts/mg respectively Error bars represent the SD of triplicate 
readings
Substrate Concentration (|aM)
Figure 3.8.11.8 Hanes-Woolf Plot for pGlu-MCA.
Data was obtained as outlined in section 2 10 11 2 Km and Vmax values for the substrate were 
determined to be 385 4pM and 2,677 umts/mg respectively Error bars represent the SD of triplicate 
readings
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3 .8 .1 1 .2  Determination of K, values for Pyroglutamyl Peptides on PAPII Activity
The inhibitor constant (KJ for a range of pyroglutamyl peptides on purified PAPII activity was 
determined as outlined in section 2 10 11 3 The data obtained was analysed using the Michaelis-Menten, 
Eadie-Hofstee, Lmeweaver-Burk, Hanes-Woolf and Direct Linear Plots models The nature of inhibition 
observed, when pyroglutamyl peptides were introduced into reactions between purified enzyme and pGlu- 
His-Pro-MCA, was determined using the Lmeweaver-Burk plot Figures 3 8 1 1 9  to 3 8 1 1  12 
demonstrate the competitive nature of the inhibition observed with all of the peptides tested The Kj 
values for the peptides are presented in table 3 8 112
Peptide Concentration
(mM)
Type of 
Inhibition
M-M E-H
K ,(mM)
L-B H-W DLP
None* - - (2 3) (2 5) (2 7) (1 1) (24)
pGlu-His-Pro-OH (AcidTRH) 05 C 233 7 254 6 283 7 101 1 236 7
pGlu-His-Pro-NH2 (TRH) 05 C 43 9 45 1 57 0 18 9 40 3
pGlu-Phe-Pro-NH2 0 1 c 67 8 76 7 87 7 316 73 1
pGlu-His-Gly-OH 05 c 2,347 1,506 1,043 908 1,671
pGlu-His-Gly-NH2 05 c 6021 606 8 634 0 296 2 582 2
pGlu-His-Pro-Gly-OH 05 c 58 1 60 0 54 4 25 8 58 8
pGlu-His-Pro-Gly-NH2 0 325 c 32 3 32 3 37 4 14 2 29 6
LHRH 1-5 0 175 c 10 1 113 10 3 4 7 10 8
LHRH 1-6 0 175 c 19 1 215 31 0 8 6 19 4
LHRH 1-7 0175 c 61 3 61 5 69 1 28 1 60 3
LHRH 0175 c 9 1 75 7 6 3 2 8 1
Table 3.8.11.2 Kj Values for a Range of Pyroglutamyl Peptides in the Reaction of 
Purified PAPII with pGlu-His-Pro-MCA. Kt values foi a range of pyroglutamyl peptides were 
determined as outlined in section 2 10 11 3 Data was analysed usmg Michaelis-Menten (M-M), Eadie- 
Hofstee (E-H), Lmeweaver-Burk (L-B), Hanes-Woolf (H-W) and the Direct Linear Plot (DLP) models
The figures m brackets represent the Km values obtained for the substrate pGlu-His-Pro-MCA in the 
absence of peptide / inhibitor
C Indicates competitive inhibition
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Figure 3.8.11.9 Lmeweaver-Burk Plot for Pyroglutamyl Peptides
The effect of pyroglutamyl peptides on the reaction of purified PAPII with pGlu-His-Pro-MCA, was 
investigated as outlined m section 2 10 11 3 Lineweaver-Burk plots are presented for assays 
incorporating TRH (A—A), pGlu-His-Pro-Gly-NH2 (o— o), acid TRH (V— V) or buffer (•— •) 
Competitive inhibition is indicated by the intersection of the lines on the Y-axis values are presented 
in 3 8 11 2 Error bars represent the SD of triplicate readings
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Figure 3.8.11.10 Lmeweaver-Burk Plot for Pyroglutamyl Peptides.
The effect of pyroglutamyl peptides on the reaction of purified PAPII with pGlu-His-Pro-MCA, was 
investigated as outlined m section 2 10 11 3 Lmeweaver-Burk plots are presented for assays 
incorporating LHRH (o— o), LHRH 1-5 (A— A), LHRH 1-6 (V— V), LHRH 1-7 (o — o) or buffer 
(•— •) Competitive inhibition is indicated by the intersection of the lines on the Y-axis Kt values are 
presented m 3 8 11 2 Error bars represent the SD of triplicate readmgs
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Figure 3.8.11.11 Lineweaver-Burk Plot for Pyroglutamyl Peptides.
The effect of pyroglutamyl peptides on the reaction of purified PAPII with pGlu-His-Pro-MCA, was 
investigated as outlined in section 2 10 11 3 Lmeweaver-Burk plots are presented for assays 
incorporating pGlu-His-Pro-Gly-OH (V—V), pGlu-Phe-Pro-NH2 (A—A) or buffer (•—•) Competitive 
inhibition is indicated by the intersection of the lines on the Y-axis values are presented m 3 8 11 2 
Error bars represent the SD of triplicate readings
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Figure 3.8.11.12 Lineweaver-Burk Plot for Pyroglutamyl Peptides.
The effect of pyroglutamyl peptides on the reaction of purified PAPII with pGlu-His-Pro-MCA, was 
investigated as outlined in section 2 1011 3 Lmeweaver-Burk plots are presented for assays 
incorporating pGlu-His-Gly-NH2 (V— V), pGlu-His-Gly-OH (A—A) or buffer (•— •) Competitive 
inhibition is indicated by the intersection of the lines on the Y-axis Kj values are presented m 3 8 11 2 
Error bars represent the SD of triplicate readings
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Discussion
4.1  MCA Standard Curves: The Inner Filter Effect
Fluonmctric assays offer increased sensitivity over colounmetnc assays (Blackmon et al 1992, Lloyd 
1981, Rendell 1987) Due to the fact that all of the enzyme assays described m section 2 2 are based on 
the release of MCA from specific substrates, a brief discussion on fluorescence spectrometry is warranted 
Liberated MCA was quantified by reference to standard curves, prepared as outlined m section 2 3 Figures 
3 11 to 3 1 4 are samples of the standard curves obtained The inclusion of biological samples such as 
bovme serum or crude homogenate of bovine brain in the standards, results m a decrease in the slope of 
the curve, as illustrated in figures 3 1 1  and 3 1 2  This decrease is due primarily to two factors, the inner 
filter effect and quenching It is not always clear from the literature, whether or not these phenomena have 
been taken into consideration by other investigators using fluonmetnc enzyme assays
The inner filter effect occurs whenever there is a compound present m the sample with an absorption band 
which overlaps either the excitation or emission band of the fluorescent analyte Radiation at the 
excitation wavelength (370nm for MCA) may be absorbed before it can excite the fluorescent species 
There may also be absorption of the emitted radiation (440nm for MCA) before it leaves the cell Other 
terms used to describe this effect include self-absorption, screening, prefilter and pastfilter effects and the 
trivial effect It becomes a problem when the absorption is high or when the concentration of the 
absorbing species, and therefore its absorbance, vanes from sample to sample
Quenching involves the removal of energy from a molecule m the excited state, by another molecule, 
usually as the result of a collision This can be important in fluorescence spectrometry since the 
fluorescence of the analyte may be quenched by the molecules of other compounds present m the 
incubation mixture Compounds containing heavy atoms (especially the heavier halogens) are effective 
quenchmg agents Compounds containing unpaired electrons, such as molecular oxygen m aerated buffers, 
can also act as efficient quenching agents However, it is apparent that the most common source of error 
and misinterpretation is the inner filter effect (Lloyd, 1981)
Considenng the purification of DAPIV from serum illustrates an example of how failure to consider the 
inner filter effect, could lead to misinterpretation of results If a standard curve incorporating serum (figure 
3 11) had not been prepared the total DAPIV activity m serum would have been calculated to be 86,128 
units, 26% lower than the actual value of 116,389 units (table 3 3 1) Similarly, if a standard curve 
incorporating the partially punfied sample had not been prepared the total DAPIV activity m this sample 
would have been calculated to be 69,078 units, 5 7% lower than the actual value of 73,253 units (table 
3 3 1) As a result of this, an erroneous yield of 80 2% would have been determined instead of the actual 
yield of 62 9%
Preparation of a standard curve, consisting of 10 MCA concentrations, cach in triplicate and incorporating 
enzyme, requires 3ml of enzyme sample Although the presence of a biological sample causes a decrease 
m the slope, the standard curve remains linear over the MCA concentration range (figures 3 11 and 
3 12) Therefore, in order to minimise the amount of sample required, mini-standard curves were prepared
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which incorporated only 2 standard MCA concentrations (OpM MCA and a top standard) This reduced the 
amount of sample required to 600|J.l per curve In addition, it was found that 1% w/v BSA in 20mM 
potassium phosphate buffer at pH 7 5 could be used instead of purified PAPII containing 1% w/v BSA 
This greatly reduced the amount of purified enzyme required for standard curve preparation during 
characterisation studies
It should be noted that compounds other than biological samples were found to contribute to the inner 
filter/quenching effects Buffers have a significant effect on fluorescence, with tns / HC1 at pH 7 5 
causing a 13% decrease in slope when compared to a corresponding standard curve prepared m 20mM 
- potassium phosphate buffer at pH 7 5 Decreasing the pH of the buffer used to prepare the standard curve 
causes a corresponding decrease in slope (see section 2 10 4) Functional reagents also contribute to the 
inner filter effect A decrease m the slope of 46% was observed when sample containing lOmM 8- 
hydroxyqumohne (0 67mM m the assay mixture) was incorporated into the standard curve
The final factor to be discussed in relation to fluorescence spectrometry is the geometry of the sample­
cell The magnitude and characteristics of inner filter effects depends strongly on sample-cell geometry 
(Lloyd, 1981) The cuvette based assays (1 5ml final volume) employ perpendicular geometry In this 
case, the fluorescence emitted is collected along an axis at right angles to the excitation beam Because of 
its freedom from the effects of scattered and transmitted excitation, this is the preferred arrangement 
(Lloyd, 1981) All quantitative assays were performed m this manner, using glass cuvettes The 
microplate assays, described in section 2 2, employ front surface geometry In this arrangement, the 
fluorescence is collected and measured through the illuminated surface Front surface geometry is 
particularly prone to inner filter effects and a high level of scattered light is diverted to the detector As a 
result of these factors, coupled with the loss of sensitivity, due to the optical fibres contained m the 
microplate reader accessory, microplate enzyme assays were used only for non-quantitative determinations 
The exaggerated inner filter effect observed with microplate assays is illustrated m the elution profile of 
DAPIV from SP-Sepharose chromatography (figure 3 3 1) The DAPIV run-through peak appears to be 
split into two peaks, due to drop in activity in fractions 4-8 This apparent drop in activity is m-fact due 
to the increased inner filter effect m these fractions as a result of their high protein concentration and/or 
colour
4 .2  Partial Purification of Dipeptidyl Aminopeptidase Type IV (DAPIV) 
From Bovine Serum
DAPIV is required for the coupled enzyme assays for PAPII described m sections 2 2 1 1 and 2 9 3 Due 
to the fact that the enzyme is not commercially available it was necessary to punfy DAPIV m the 
laboratory Bovine serum was chosen as the source of the enzyme since it is readily available m large 
quantities and is rich m DAPIV activity
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As illustrated in figure 3 3 1, the majority of DAPIV activity does not bind to the SP-Sepharose column 
under these conditions, but merely runs through with the bulk of the protein The bulk of the Z-Gly-Pro- 
MCA degrading activity, however, is bound to the column and is eluted with 500mM NaCl It should be 
noted that two distinct Z-Gly-Pro-MCA degrading activities are represented here That which co-elutes 
with DAPIV can be totally inhibited by Z-Pro-Prolmal and on this basis is identified as prolyl 
endopeptidase The second Z-Gly-Pro-MCA degrading activity, which binds to the column, is totally 
insensitive to Z-Pro-Prolmal and appears to be a distinct proline specific peptidase These activities will 
not be discussed here since they have been studied in detail by other workers in our laboratory
Phenyl Sepharose hydrophobic interaction chromatography (figure 3 3 2) successfully removes the 
remaining Z-Gly-Pro-MCA degrading activity (PE) from the greater part of the DAPIV activity which, 
once again, runs through the column Despite the co-elution of the major DAPIV peak with the major 
protein peak from both columns, thus reducing the purification factors, it was decided that removal of 
contaminating Z-Gly-Pro-MCA degrading activity was the most important consideration An overall 
purification factor of only 4 9 fold was achieved usmg this procedure, however, a relatively high yield of 
62 9% was obtained
Due to the fact that this partially purified DAPIV activity was shown to be free from aminopeptidase 
activity and enzymes capable of pGlu-His-Pro-MCA hydrolysis, PAP and PE, it was decided that this 
material was suitable for use m the coupled enzyme assays for PAPII
4 .3  Determination of Optimal Conditions for the Solubilisation of PAPII 
from the Particulate Fraction of Bovine Brain
PAPII is an ectoenzyme, i e an integral plasma membrane enzyme with an extracellularly localised active 
site (Charli et a l , 1988) Analysis of the ammo acid sequence, deduced from cDNA encoding PAPII, 
reveals a transmembrane-spannmg domain, consisting of 22 amino acids, near the ammo terminus of the 
enzyme (Schauder et a l , 1994) Integral membrane proteins may be classified into four groups depending 
on the proportion of their structure that is m contact with the hydrophobic part of the lipid bilayer (see 
figure 4 3) (Findlay, 1990) Class I proteins traverse the bilayer several times and have the bulk of their 
total structures within the hydrophobic phase Class II proteins are bound to the bilayer via a 
phosphotidyl mositol-carbohydrate moiety attached to the C-terminus of the polypeptide chain Class III 
protems are anchored m the bilayer by a smgle transmembrane segment Class IV proteins are associated 
with the bilayer via fatty acyl and / or diacylglycerol moieties covalently attached to the N-terminus of 
the polypeptide chain The latter three categories contain most or all of their mass in the aqueous phase
The first step in the purification of a particular membrane protein involves the isolation of a membrane 
fraction enriched in the protein The next step involves the solubilisation of the protein This may be 
achieved usmg detergents or enzymes Detergents are amphiphilic molecules (i e they contain spatially 
distinct hydrophobic and hydrophilic regions) which are soluble m aqueous conditions on account of their 
hydrophilic regions If sufficient amounts of a suitable detergent is present, the membrane solubilises
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into its lipid and protein components The former generally form mixed micelles with the amphiphile, 
while the latter exist surrounded by a monomolecular layer of the detergent which intercedes between the 
hydrophobic surface of the protein and the bulk aqueous medium The problems of obtaining amphiphihc 
protems in aqueous solution using detergents can be circumvented in the case of protems belonging to 
classes II, III and IV Protems of this type can often be liberated from the membranes by the use of 
proteases or phospholipases to release the soluble hydrophilic fragment, bearing biological activity, from 
its protem or lipid membrane anchor, which remains behind in the bilayer
Class II
Class I Class IV
Figure 4.3 Structural Types o f  Integral Membrane Proteins
Following homogenisation of bovine brain, the particulate fraction was washed with a high ionic 
strength buffer (1M NaCl) to remove loosely bound peripheral proteins Subsequent washing with low 
ionic strength (distilled water), osmotically shocked the membranes to remove occluded protem Greater 
than 90% of enzyme activity was recovered following each of these steps, resulting m an overall recovery 
of 78 6% with only 53% of the total protein remaining These findings are in agreement with other 
reports which have demonstrate conclusively that PAPII is a class III ectoenzyme which, within the 
CNS, is located on the synaptosomal membranes (O’Connor and O'Cuinn, 1984, Horsthemke et a l , 
1984, Friedman and Wilk, 1986, Charli et a l , 1988, Wilk and Wilk, 1989a, Bauer, 1994, Schauder et 
a l , 1994, and O'Leary and O'Connor, 1995a)
It was attempted to solubilise PAPII from the washed membranes using a range of detergents and 
proteases The enzyme was not solubilised when membranes were incubated for 1 hour with up to 
100(ig/ml phospholipase C, indicating that the enzyme is not anchored by a phosphatidylinositol-glycan 
residue (see figure 4 3, class II protem) This is in agreement with the findings of Bauer (1994)
The detergents tested were shown to solubilise the enzyme with variable efficiency (see figure 3 4 1) At a 
concentration of 1%, Tnton X-100 and CHAPS released 100% and 90% of enzyme activity respectively
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However, it should be noted that at detergent concentrations above 0 4%, the supernatant obtained 
following centrifugation was not totally clear This may indicate membrane disruption rather than true 
solubilisation at high detergent concentrations
The enzyme was successfully solubilised usmg proteases (figures 3 4 2 and 3 4 3), with trypsin being the 
most- and chymotrypsin the least efficient Maximal solubilisation was obtained following incubation of 
the membranes with 5fig/ml trypsin for 1 hour at 25°C Solubilisation of the enzyme with proteases 
suggests that the enzyme belongs to class III integral membrane proteins as presented in figure 4 3 This 
agrees with the structure proposed by Schauder et al (1994)
The final choice of an enzyme solubilisation regime was based on two further factors, (i) the PAPII 
specific activity in the supernatant and (u) the stability of the solubilised enzyme Figure 3 4 4 shows a 
comparison of the specific activities m supernatants obtained from various solubilisation regimes 
Solubilisation with trypsin results m the highest enzyme activity, lowest protein concentration and 
therefore, the highest specific activity The values obtained for papain are not significantly different from 
those for trypsin However, m the case of the three detergents tested, significantly lower enzyme activity, 
higher protein concentration and therefore lower specific activity is observed Sodium deoxycholate, being 
the worst of the detergents yields a specific activity 75% lower than that of the trypsin solubilised 
supernatant
The stability of the enzyme, at 4°C and -20°C, following solubilisation by various regimes, is illustrated 
in figures 3 4 5 and 3 4 6 At both temperatures, the trypsm solubilised enzyme was the most stable with 
no loss of activity following storage at 4°C for 14 days and only 23% loss of activity after 14 days at 
-20°C PAPII solubilised with Triton X-100 and sodium deoxycholate was extremely unstable with 95% 
and 65% of activity respectively being abolished after 24 hours at -20°C In both cases, almost 50% of 
activity was destroyed after 24 hours at 4°C Although the enzyme solubilised by papain and CHAPS was 
relatively stable at 4°C, there was a marked decrease m their stability at -20°C, with greater than 50% of 
activity being destroyed after 3 days The instability of PAPII solubilised by detergents has been reported 
previously by O'Connor and O'Cuinn (1984), Wilk and Wilk (1989a) and Bauer (1994) Although non- 
lomc detergents, m general, have a less destructive effect on biological activity (Findlay, 1990), this was 
not found to be so m this case The non-ionic detergent, Triton X-100, had an equally detrimental effect 
on PAPII activity as the anionic detergent sodium deoxycholate and was considerably more destructive 
than the zwittenonic detergent CHAPS The instability of the solubilised enzyme may be due to 
proteolytic attack since membrane disruption is often accompanied by protease activation (Findlay, 1990) 
However, this is unlikely to be the case since the enzyme is less stable when frozen at -20°C where 
proteolytic action would not occur Although the role of phospholipids m stabilising membrane protems 
is not fully understood, complete removal of lipids from biological membranes inactivates most 
membrane proteins, even m the presence of detergents (Jones et a l , 1987) This problem may be 
overcome by the addition of ’protective' lipids to the solubilised protein and to all buffers during the 
purification procedure Of the detergents tested, CHAPS had the least detrimental effect on PAPII
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stability This may be due to the fact that this steroid derivative has the ability to substitute for 
cholesterol, a lipid which may stabilise the structures of certain membrane structures (Jones et a l , 1987), 
thus indicating that delipidation is the reason for the poor stability following solubilisation with 
detergents
On the basis of the high specific activity and adequate stability, solubilisation with trypsin was accepted 
as the method of choice Proteolytic enzymes have been used previously by other researchers for the 
solubilisation of PAPII O'Connor and O'Cuinn (1984) used papain, while trypsin has been employed by 
Wilk and Wilk (1989a), (4 3fxg of trypsin per mg of membrane protein for 2 hours at 37°C) and Bauer 
(1994), (0 05|J.g of trypsin per mg of membrane protein for 15 minutes at 4°C) In this study, 5|ig/ml 
trypsm (0 46p.g of trypsin per mg of membrane protein) for 1 hour at 25 °C was used Under these 
conditions 92% of enzyme activity and only 15% of total membrane protein was solubilised, thus 
producing a purification factor of 6 28 fold
4 .4  Purification of PAPII from the Membrane Fraction of Bovine Brain
PAPII was further purified from the trypsm solubilised supernatant using a range of conventional 
chromatographic techniques which exploit the physiochemical properties of the enzyme The entire 
purification procedure was earned out at 4°C and the pH was maintained at 7 5 in order to minimise the 
loss of activity Adsorption processes were used early in the procedure due to their high capacity while 
gel-filtration, which has a much lower capacity, was used as the final step The sequence in which the 
chromatographic steps were arranged served to minimise the number of intermediate conditioning stages 
such as buffer / ionic strength changes (by dialysis) and concentration
4.4.1 Q -Sepharose H igh Perform ance Anion Exchange Chrom atography
Following the application of the trypsm solubilised supernatant to a Q-Sepharose column, the bulk of 
the contaminating protein (86%) was not retained by the anion exchange resin while all of the PAPII 
activity was bound (see figure 3 5 1) Isocratic elution with lOOmM NaCl resulted in excellent recovery
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of enzyme activity (95 4%) and a 7-fold purification factor This punfication step also serves as a 
concentration step since it reduces the sample volume from the 78 5ml loaded, to only 22ml in the post 
Q-Sepharose pool, thus making the product stream easier to handle
4.4.2 Chelatm g-Sepharose Fast Flow  Im mobilised M etal Ion Chrom atography
Metal chelate chromatography is a useful technique for the separation of high molecular weight and 
conformationally unstable biopolymers Protein sorption occurs by the coordination of surface histidine, 
cysteine and tryptophan residues to transition metal ions such as Cu2+ or Zn2+ (Roe, 1989) Initial 
attempts to purify PAPII using a chelating sepharose column charged with Zn2+ were only partially 
successful since a large portion of the activity (approximately 40%) failed to bind to the resin and merely 
ran through the column This run-through was not due to column overloading since increasing the size of 
the column or decreasing the volume of sample applied failed to resolve the problem Moreover, raising 
the pH of the sample and of the equilibration buffer to pH 8 0, which would be expected to promote
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stronger adsorption (Roe, 1989), also failed to reduce the run-through of enzyme activity The inclusion 
of a small column of uncharged chelatmg-Sepharose, connected in series after the mam column which 
was saturated with Zn2+, successfully eliminated the run-through of activity This configuration 
essentially produced a 19ml column of which only the top 74% was charged with metal ions Metal 
chelate chromatography is not usually recommended for the purification of metalloproteins as they tend to 
scavenge the metal ions from the column (Pharmacia, 1993) It is likely that the second uncharged 
column prevents the leakage of metal ions which have been scavenged from the upper portion of the 
column by PAPII
As described in section 27 3 ,150mM NaCl is included m the sample and the running buffers m order to 
minimise non-specific electrostatic interactions Under these running conditions PAPII activity is 
successfully resolved from the bulk of the contaminating protein (see figure 3 5 2) As with the ion- 
exchange step, a good recovery of enzyme activity (86 3%) was achieved resulting m a 5 7-fold 
purification factor Dialysis of the post chelatmg-Sepharose pool served two important functions, (1) 
removal of imidazole which inhibits PAPII activity in a time-dependent manner (see section 3 8 6) and 
(u) preparation of the sample for calcium phosphate-cellulose chromatography
4.4.3 Calcium  Phosphate-Cellulose Chrom atography
Calcium phosphate resin was prepared as outlined in section 2 7 4 The addition of Na2HP04  to CaCl2 
results in the formation of a precipitate which consists mainly of brushite (CaHP04 2H2O) At pH 
values above 7 0, brushite is unstable and may be transformed into hydroxylapatite (Ca5(P04)30H) with 
the liberation of phosphoric acid This may even happen during chromatography and thus lead to 
complications and inconsistent chromatographic properties Treatment of brushite with ammonia causes a 
transformation to a more stable product which probably consists largely of hydroxylapatite (Tisehus et 
a l , 1956) The material produced by this procedure is quite fine grained and must be mixed with a filter- 
aid such as cellulose prior to column packing in order to improve the flow characteristics of the column
The exact mechanism of protein adsorption onto calcium phosphate / hydroxylapatite is not fully 
understood, however, it is thought to involve both Ca2+ and PO43' groups on the resm surface Since 
these charged groups are closely arranged on the resm it is likely that dipole-dipole interactions exist 
between adsorbent and protem (Roe, 1989) A drawback to the use of calcium phosphate prepared in the 
laboratory over commercially available hydroxylapatite is the potential for batch to batch or even 
laboratory to laboratory variations and therefore inconsistent chromatographic properties However, it 
should be noted that commercial hydroxylapatite may be inferior to fresh laboratory prepared material 
(Roe, 1989)
Calcium phosphate-cellulose chromatography of the post chelatmg-Sepharose pool, under the conditions 
outlined in section 2 7 5 successfully resolved PAPII activity from almost 85% of contaminating protein 
(see figure 3 5 3) However, a relatively low recovery of enzyme activity (61 3%) gives rise to a modest 
purification factor of 3 88-fold
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4.4.4 Sephacryl S-200 Gel-Filtration Chromatography
Sephacryl S-200 gel-filtration chromatography was used as a final clean-up step in the purification 
procedure An un-exceptional purification factor of 2 11-fold was achieved using this technique This is 
due, in part, to a relatively low recovery of enzyme activity (66 4%)
An overall purification factor o f 3,047-fold with a 24 2% recovery was obtained for the purification of the 
enzyme from bovine whole brain (see table 3 5 1) These figures compare favourably with those obtained 
by other investigators for the purification o f PAPII O'Connor and O'Cumn (1985) (3,558-fold  
purification, 17% recovery from guinea pig whole brain), Wilk and Wilk (1989a) (5,266-fold purification, 
12 5% recovery from washed membranes o f rabbit brain), O'Leary and O’Connor (1995a) (600-fold 
purification, 17% recovery from washed membranes of bovme bram) However, the purification factor is 
considerably lower than that obtained by Bauer (1994) (201,272-fold purification, 20% recovery) for the 
purification o f PAPII from the washed membranes of porcine bram
4 .5  Assessment of the Effectiveness of the PAPII Purification
Procedure
4 . 5 . 1  Polyacrylam ide Gel E lectrophoresis
Multiple bands were visualised by silver staining following SDS PAGE of post Sephacryl S-200 PAPII 
(see figure 3 6 1) The presence o f multiple bands suggests that the enzyme was not purified to 
homogeneity It is possible that at least some of the bands occurred as a result of fragmentauon of the 
enzyme Bauer (1994) demonstrated a similar banding pattern following 200,000-fold purification o f  
trypsm solubilised PAPII from porcine brain The author demonstrated that membrane solubilisation 
using milder conditions and subsequent purification of the enzyme resulted in a single band This proved 
that the enzyme had been cleaved by trypsm at several peptide bonds during solubilisation but the overall 
structure o f the enzyme was maintained by non-covalent protein-protem interactions Treatment of washed 
membranes from bovme brain using milder condiUons (5(ig/ml for 1 hour on ice) resulted in only 20% of  
PAPII activity being solubilised Following enzyme purification as outlined in section 2 7 and 250-fold 
concentration o f the purified sample, only very faint bands were visualised by silver staining following 
SDS PAGE There was however no reduction in the number of bands observed following electrophoresis 
of this sample compared to that produced by harsher trypsin treatment
Despite the failure to conclusively demonstrate that the presence of multiple bands is due to PAPII 
fragmentation, there is some evidence to suggest that this may be the case From the Sephacryl S-200 
elution profile illustrated in figure 3 5 4, it can be seen that the PAPII pool contains only protein which 
eluted between 130ml and 150ml From the Sephacryl S-200 calibration curve shown m figure 3 8 1, it 
can be determined that proteins with an elution volume greater than 150ml have a relative molecular mass 
of less than 100,000 Da It is therefore reasonable to assume that, following SDS PAGE, protein bands 
which have molecular weights less than 100,000 Da are fragments or subunits of larger proteins More 
than half of the bands observed following electrophoresis of the post Sephacryl S-200 pool have such a 
molecular weight
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4 . 5 . 2  D eterm ination of the Enzym atic Purity o f the PA PII Preparation
The enzymatic punty of the PAPII preparation obtained following Sephacryl S-200 chromatography was 
investigated as outlined in section 2 10 10 1 Table 3 8 10 1 illustrates that this preparation is free from 
contamination by PE and DAPIV, enzymes capable of primary and secondary hydrolysis o f TRH and the 
fluonmetnc substrate pGlu-His-Pro-MCA No ammopeptidase activity was detected usmg the substrates 
Ala-MCA and Pro-MCA Aminopeptidases, if present, may have led to inaccurate results when 
investigating the substrate specificity o f PAPII It should be noted that contaminating ammopeptidase 
activity was detected m some BSA preparations (Sigma - A7906) Since BSA was used to stabilise the 
purified enzyme (see sections 3 8 2 and 3 7 6) it was important to ensure that protease free BSA (Sigma - 
A3294) was used for this purpose
4 .6  Development of pGlu-His-Pro-MCA Based PAPII Assays
Assays based on the hydrolysis of radiolabelled TRH have been used by many researchers for the 
determination of PAPII activity Although sensitive and accurate for the quantitation o f enzyme activity, 
these assays are also labour-intensive and expensive (see section 1 2  2 4) In 1986, Friedman and Wilk 
developed a colounmetric, coupled enzyme assay for the detection o f PAPII activity, based on the 
cleavage o f the substrate pGlu-His-Pro-2NA m the presence of excess DAPIV A modification o f this 
assay was described by O'Leary and O'Connor (1995a), who used the quenched fluonmetnc substrate 
pGlu-His-Pro-MCA These coupled enzyme assays are less expensive and labour-intensive than the 
radiolabelled assays and have the added advantage that the use of radioactivity is avoided
4.6.1 Inhibition of PE and PAPI
In order for assays based on the cleavage of TRH or the TRH substrate analogue, pGlu-His-Pro-MCA, to 
be specific for PAPII, it is important to ensure that other enzymes capable of its hydrolysis (PE and 
PAPI) are inhibited under assay conditions Figures 3 7 1 1  and 3 7 1 2  illustrate the total inhibition of 
PE by the specific inhibitors Z-Pro-Pro-Prohnal and fmoc-Pro-Pro-Nitnle respectively Figure 3 7 2 
illustrates the inhibition o f PAPI by 2-pyrrohdone The inhibition o f PAPI is particularly important 
when assaying crude samples which contain high levels o f the cytosolic enzyme Washed membrane 
preparations and further punfied samples are less likely to contain PAPI activity, however, bactenal 
contamination o f samples, thereby resulting m the presence o f the bacterial PAP has been observed 
(results not shown)
4.6.2 Development of Coupled Enzyme Assays for PAPII
Two variations of the pGlu-His-Pro-MCA based coupled enzyme assay were used in the course of this 
work In the first, descnbed m section 2 2 1 1 ,  DAPIV is included in the assay mixture at the same time 
as the PAPII containing sample This procedure is similar to that descnbed by Friedman and Wilk (1986) 
and assumes that as His-Pro-MCA is being produced by the action o f PAPII on the substrate, DAPIV
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simultaneously catalyses the liberation of MCA from this metabolite, thus allowing PAPII activity to be 
quantified fluonmetncally This assay represents a fast and simple method for the detection o f enzyme 
activity The microplate assay described m section 2 2 1 1 ,  which used this methodology, proved to be 
especially useful for the detection of PAPII activity m the large number of fractions generated during the 
development o f the purification procedure
The second variation o f the coupled enzyme assay is described in section 2 9 3 In order to ensure that 
MCA is liberated from all o f the His-Pro-MCA produced by the action of PAPII, the two enzyme 
reactions were performed separately Following the termination o f the PAPII reaction by heating the 
reaction mixture to 80°C, DAPIV was added to catalyse the liberation of MCA from His-Pro-MCA This 
reaction was subsequently terminated by the addition of aceuc acid This assay procedure is a modification 
of that described by O'Leary and O'Connor (1995a)
Figures 3 7 3 1 and 3 7 3 2 illustrate the effect o f increasing the amount o f DAPIV added following the 
reaction of crude homogenate or purified PAPII with pGlu-His-Pro-MCA The addition of 25|xl of 
DAPIV is sufficient to catalyse the liberation of all MCA following the reaction of crude homogenate 
with the substrate The DAPIV reaction increases the concentration of MCA by only 4% The liberation 
of such a high concentration o f MCA without the addition o f DAPIV can be explained by the fact that 
crude homogenate of brain contains relatively high levels o f endogenous DAPIV and DAPII activity (see 
section 1 3  8)
Following the reaction o f purified PAPII with pGlu-His-Pro-MCA, 250|il o f DAPIV must be added to 
catalyse the complete hydrolysis o f  His-Pro-MCA Since the purified PAPII preparation contains no 
DAPIV activity (see section 4 5 2), it is likely that the low concentration of MCA observed when no 
exogenous DAPIV is added, occurs as a result o f non-enzymatic cyclisation of His-Pro-MCA to cyclo 
His-Pro and free MCA dunng the two hour incubation
4.6.3 Development of a Non-Enzymatic Cyclisation Assay for PAPII
Although the coupled enzyme assays described have distinct advantages over radiolabelled assays, there are 
nonetheless some disadvantages As mentioned previously, since DAPIV is not commercially available it 
must therefore be purified m the laboratory Moreover, the use o f a coupled enzyme assay may cause 
complications m some o f the PAPII characterisation studies For instance, m the investigation of the 
effect of pH, functional reagents or metals on enzyme activity or m tbe determination of Kj values of 
peptides, it may be difficult to determine whether an observed result is due to the effect on PAPII, DAPIV 
or both For these reasons m was decided to develop a fluorimetnc assay based on the non-enzymatic 
cyclisation o f His-Pro-MCA to cyclo His-Pro and free MCA
The non-enzymatic cyclisation of His-Pro-NH2 to cyclo His-Pro has been shown to occur in aqueous 
solution at pH 2-10 at 37°C (Moss and Bundgaard, 1990) Following the termination of the PAPII
139
reaction by the addition of acetic acid, the cyclisation of His-Pro-MCA was promoted by heating the 
incubation mixture at 80°C The effect o f incubation tune at 80°C on MCA release, following the 
reaction of crude homogenate or purified PAPII with pGlu-His-Pro-MCA, is illustrated in figures 3 7 4 1  
and 3 7 4 2 Following the reaction of crude homogenate with the substrate, only a short incubation of 
15-20 minutes at 80°C is required to promote the complete cyclisation of His-Pro-MCA An increase in 
the MCA concentration of only 10% was observed as a result of this incubation, indicating that 90% of 
His-Pro-MCA was already hydrolysed by endogenous DAP activity m this sample
An incubation of 2 hours at 80°C was required for the complete cyclisation of His-Pro-MCA produced by 
the reaction of purified PAPII with pGlu-His-Pro-MCA In the absence of endogenous DAP activity in 
this purified sample, the extremely low concentration of MCA observed when the reaction mixture was 
not incubated at 80°C can be accounted for by a slow rate o f cyclisation of His-Pro-MCA during the 
initial reaction at 37°C
The possibility of shortening the incubation time necessary for the complete cyclisation of His-Pro-MCA 
was considered In view of the fact that the cyclisation of His-Pro-NH2 has been shown to occur more 
rapidly at pH 6-7 (Moss and Bundgaard, 1990), the possibility of terminating the PAPII reaction by 
means other than the addition of acetic acid, which reduces the pH o f the reaction mixture to 
approximately 2 2, was considered The PAPII reaction could be terminated by transferring the reaction 
mixture directly to an 80°C water-bath where the cyclisation reaction could proceed at pH 7 5 However, 
this option was not pursued further since it was decided that the addition of acetic negated the possibility 
of inter-sample pH variations affecting the rate of cyclisation Slight pH variations within the pH range 
6-8 have profound effects on the rate o f cyclisation of His-Pro-NH2 while slight pH variations within the 
pH range 2-3 have little or no effect on the rate of cyclisation (Moss and Bundgaard, 1990) Moreover, it 
was shown that the incubation time at 80°C could be shortened from 2 hours to 30 mmutes with no loss 
of assay-hneanty with respect to enzyme concentration (section 3 7 6)
4 . 6 . 3 . 1  L inearity o f the N on-E nzym atic C yclisation  Assay with respect to Tim e  
and Enzym e Concentration
The progress curves of most enzyme reactions are o f the form shown in figure 4  6 3, in which the 
velocity decreases with time Various factors may contribute to this decrease For instance, (l) the 
products of the reaction may inhibit the enzyme, (u) the degree of substrate saturation o f the enzyme may 
decrease due to a fall in substrate concentration as the reaction proceeds, (ui) the reverse reaction may 
become more important as the product concentration increases or (iv) the enzyme may undergo some 
inactivation at the temperature or pH of the reaction Enzyme activity is therefore usually quantified by 
measunng the initial velocity of the reaction It is only at the initial point that the conditions are known 
and the factors just mentioned have not yet had time to operate (Dixon and Webb, 1979a) The initial 
velocity of the reaction can be obtained simply by drawing a tangent, through the origin, to the early, 
linear part of the progress curve as illustrated m figure 4 6 3 Due to the nature of the assays described for
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the detection o f PAPII activity, both of which require a second step after the initial reaction o f the enzyme 
with the substrate, continuous monitoring of activity is not possible These methods therefore represent 
discontinuous assays in which the amount of product formed by the enzyme is measured at one discrete 
point on the reaction curve With such assay systems it is important to ensure that the measurement is 
taken from the linear part o f the progress curve thereby representing the initial velocity of the reaction
  Actual Velocity
  Initial Velocity
Figure 4.6.3 Schematic o f  progress curves with two different amounts o f  enzyme (A and B)
The progress curves, A and B, illustrated m figure 4 6 3 might represent experiments at two different pHs 
or with two different substrates or with two different amounts of enzyme Assuming, for simplicity, that 
the curves represent two different amounts of enzyme Single point measurement of product formed at 
time T i gives a true indication of the miual acttvity of both samples since the amount of product formed 
is proportional to the amount of enzyme present The amount of product formed at tune T2, however, is 
far from being proportional to the amount of enzyme present m either sample The apparent velocities, 
obtained by dividing these values by the time (T2), give quite misleading results Not only would the 
absolute values for the activity of each sample be incorrect, but the apparent activity o f  each sample 
would also be disproportionate
Progress curves of PAPII activity against the substrate pGlu-His-Pro-MCA are illustrated in figures 
3 7 5 1 and 3 7 5 2 These curves illustrate that whether crude homogenate or purified PAPII is used as 
the enzyme source, the reaction proceeds m a linear fashion over a 2 hour period It is therefore safe to 
assume that the assays described in sections 2 2 1 , 2 9 3  and 2 9 7  give a true measurement the initial 
activity of PAPII since an incubation tune of 1 hour is employed
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In order to ensure that the non-enzymatic cyclisation assay is quantitative for the measurement of PAPII 
activity, standard curves of enzyme concentration versus MCA released, were constructed Figure 3 7 6 1  
illustrates a non-linear relationship between MCA released and the concentration of post Sephacryl S-200 
PAPII An upward curvature such as this is usually indicative of the presence of an activator Dilution of 
the enzyme sample reduces the concentration of the activator below that at which optimal enzyme activity 
is expressed (Dixon and Webb, 1979b) In this case protein can be considered to be the enzyme activator 
or perhaps more correctly, the absence of protein-protein interactions in the dilute sample causes enzyme 
inactivation The presence of 1% w/v BSA m the enzyme results in a linear relationship between product 
formed and enzyme concentration as illustrated m figures 3 7 6 2 and 3 7 6 3
In view o f the facts presented here the non-enzymatic cyclisation assays described in section 2 9 7 were 
deemed to be suitable for the quantitative determination of PAPII activity A 2 hour incubation period at 
80°C was employed for studies which required absolute values of PAPII activity such as construction of 
the purification table or kinetic studies for the determination o f Vmax values Where relative values of 
enzyme activity were required, the shorter assay in which the reaction mixture is mcubated for 30 minutes 
at 80°C, was employed
4.6.4 Development of a Continuous PAPII Assay
Although a number of investigators have reported that the PAPI substrates pGlu-BNA, pGlu-pNA and 
pGlu-MCA are not cleaved by PAPII (O'Connor and O'Curnn, 1985, Wilk and Wilk, 1989a), it has 
recently been demonstrated that the purified enzyme is capable of pGlu-BNA hydrolysis (Czekay and 
Bauer, 1993, Bauer, 1994) The results presented in section 3 8 10 2 clearly illustrate that the purified 
bovme brain enzyme is capable of cleaving pGlu-BNA and pGlu-MCA, even m the presence of the PAPI 
inhibitor 2-pyrrolidone Hydrolysis o f the colourimetric substrate pGlu-pNA was not observed It is 
possible that the failure to detect hydrolysis of this substrate can be attributed to the lower sensitivity of 
the spectrophotometnc method employed for the detection of pNA compared to the fluonmetnc methods 
of BNA and MCA detection
The ability o f  the enzyme to hydrolyse these substrates offers a simple method to conunuously monitor 
PAPII activity It should be noted that these assays can only be used to detect enzyme activity m 
relatively pure samples which contain high levels o f PAPII activity, and are much less sensitive than the 
aforementioned pGlu-His-Pro-MCA based assays This fact can be explained by the kinetic characteristics 
o f the enzyme for the substrates pGlu-His-Pro-MCA and pGlu-MCA, presented in section 3 8 111 and 
summarised m table 3 8 111 For reasons which will be discussed m section 4 7 9, the Km and Vmax 
values referred to here will be those derived from the Direct Linear Plot The affinity of the enzyme for 
pGlu-MCA is 165-times lower than for pGlu-His-Pro-MCA (Km values of 420|iM  and 2 5[iM 
respectively) Furthermore, the Vmax value for pGlu-MCA (2,815 U/mg protein) is almost 13-tunes 
lover than that of pGlu-His-Pro-MCA (36,144 U/mg protein) These two factors combined, indicate that 
pGlu-MCA is an extremely poor substrate for the enzyme
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4.7.1 Stability of PAPII under Various Storage Conditions
Purified bo vine brain PAPII appears to be less stable than PAPII purified from other sources Bauer 
(1994) reported that, irrespective o f protein concentration, the purified porcine bram enzyme remained 
fully active for more than 2 months at 4°C In the absence o f stabilising agents the bovine brain enzyme 
is extremely labile with more than 50% of activity bemg abolished after only 24 hours at 4°C (see figure 
3 8 2) Freezing the enzyme at -20°C destroys 90% of activity whrie freezing at -80°C results m total loss 
of activity A similar effect was observed by Bauer (1994) who reported that at protem concentrations 
below lmg/ml the porcine bram enzyme was sensitive to freezing and thawing
The addition o f 20% v/v glycerol affords only moderate protection to the enzyme upon freezing and little 
or no stabilising effect when stored at 4°C This finding contrasts with those of O'Connor and O'Cuinn 
(1985) who reported the punfied guinea pig brain enzyme to be extremely stable at -20°C or 15°C m the 
presence o f 30% glycerol Bauer (1994) demonstrated that m the presence of 25% glycerol, sucrose or 
trehalose, more than 90% of activity could be recovered after freezing and thawing the porcine bram 
enzyme at -80°C
The inclusion of 1% w/v BSA in the purified enzyme preparation greatly improves the stability o f the 
bovine bram PAPII at each of the storage temperatures tested After 3 weeks at -80°C the BSA containing 
sample retained 93% of the initial activity A similar effect of BSA on the stability of the enzyme upon 
freezing and thawing was reported by Bauer (1994) The unproved stability of the punfied enzyme m the 
presence of BSA lends credence to the suggestion that protein-protem interactions are important for the 
stability / activity o f PAPII (see section 4 6 3 1)
4.7.2 Relative Molecular Mass Determination
The relative molecular mass o f PAPII was determined via gel-filtration chromatography as outlined in 
section 2 10 1 The results o f this study are presented m section 3 8 1 A relative molecular mass o f  
approximately 214,000 Da was determined for the trypsin solubilised enzyme This value is slightly 
lower than estimates of 230,000 - 240,000 Da reported for previously charactensed PAPIIs (O'Connor and 
O'Cumn, 1984, Wilk and Wilk, 1989a, Bauer, 1994, O'Leary and O'Connor, 1995a) There are a number 
of possible explanations for this discrepancy Following solubilisation of the enzyme with trypsin, the 
molecular mass presented here represents that of a truncated enzyme since the transmembrane spanning 
domain and intracellular domain have been cleaved from the extracellular part of the enzyme This is an 
attractive hypothesis when the value obtained here is compared to a value of 240,000 Da obtained by 
O'Leary and O'Connor (1995a) for the intact, Triton X-100 solubilised enzyme from bovine bram 
However relative molecular weights o f approximately 230,000 Da have been reported by other 
investigators for protease solubilised PAPII (O'Connor and 0'Cumn, 1984, Wilk and Wilk, 1989a, 
Bauer, 1994)
4 .7  Characterisation of PAPII
143
It is possible that the lower molecular mass obtained in this study is a reflection on the inaccuracies of 
the method used Close examination of the Sephacryl S-200 calibration curve illustrated in figure 3 8 1 
and the calibration equation presented m section 3 8 1, reveals that a 1ml difference in the elution volume 
of a protem results m a difference of approximately 13,000 Da in the estimation of its molecular mass In 
view o f this relatively large potential for error, the relative molecular mass o f the enzyme presented here 
does not differ considerably from previous estimates
As mentioned previously m section 4 5 1 , SDS PAGE analysis of the purified PAPII preparation resulted 
in the visualisation of multiple bands, thereby making it impossible to determine the subunit structure of 
the enzyme It is clear however, that the enzyme does not exist as a monomer since the highest molecular 
weight band visualised was at 141,000 Da (see section 3 6) Suen and Wilk (1990) reported a 48,000 Da 
subunit structure of PAPII from Y-79 human retinoblastoma cells Bovine brain PAPII does not appear 
to contain such a subunit since the lowest molecular weight band visualised was at 55,000 Da Bauer
(1994) demonstrated that the porcine brain enzyme exists as a dimer consisting of two identical subunits 
o f 116,000 Da The possibility that bovine brain PAPII exists as a dimer is supported by the 
visualisation of a band with a molecular weight of approximately 114,000 Da following SDS PAGE of 
the purified enzyme
4.7.3 The Effect of Assay Temperature on PAPII Activity
The effect o f assay temperature on PAPII activity was investigated as outlined m section 2 1 0  3 Samples 
were preincubated for 2 minutes at each temperature prior to assay in order to ensure that the observed 
activity genuinely reflected the activity of the enzyme at the temperature under investigation Failure to 
preincubate the samples would result in the observed activity representing the activity as the sample 
reached thermal equilibrium and the activity at the temperature under investigation The assay tune was 
shortened to 15 minutes in order to ensure that the measurement of enzyme activity represented the initial 
activity of the sample (see figure 4 6 3) The results o f this study are presented in section 3 8 3 Optimal 
activity was observed at 45°C The activity at 45°C was approximately 30% higher than at 37°C At 
55 °C the enzyme is partially inactivated, while 2 minutes preincubation at 60°C results in total 
inactivation o f the enzyme This temperature profile is similar to that observed for serum PAP (Bauer and 
Nowak, 1979)
In addition to displaying optimal activity at 45 °C, the enzyme was shown to be stable at this temperature 
for at least 1 hour This is illustrated by the progress curve m figure 3 8 <3 2 which demonstrates a linear 
relationship between enzyme activity and reaction time at 45 °C
4.7.4 The Effect of pH on PAPII Activity
The effect of pH on PAPII activity was investigated as outlined m section 2 10 4 The results o f  this 
study are presented m section 3 8 4 A narrow pH optimum of 6 8-7 6 was observed for the enzyme as
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illustrated m figure 3 8 4 1 A similar pH optimum of 7 0-7 5 was reported for the rabbit brain enzyme 
by Wilk and Wilk (1989a,b) Withm this pH range, highest activity was observed using the citric 
acid/potassium phosphate buffering system, with only slightly lower activity being observed in 
potassium phosphate buffer At pH 7 0, the activity of the enzyme in tns/HCl was only 50% of that in 
citric acid/potassium phosphate buffer This low activity may reflect a genuine preference of the enzyme 
for citnc acid/potassium phosphate buffer over tns/HCl or it may be caused by the effect o f the buffers on 
the rate o f His-Pro-MCA cyclisation during the assay The latter possibility is supported by the 
observation that His-Pro-NH2 cyclisation proceeds at a faster rate m the presence of phosphate buffer than 
in the presence of tns, acetate, or borate buffers (Moss and Bundgaard, 1990) Further investigation is 
necessary to determine the reason for the difference m the levels o f activity, however, it is clear that in 
each of the buffenng systems highest enzyme activity is observed in the pH range 6 8-7 6
The pH inactivation curve o f PAPII is presented in figure 3 8 4 2 This curve differs from the pH activity 
profile m that the former is prepared by preincubatmg the enzyme at a wide range of pH values and 
performing the assay at the optimum pH while the latter is prepared by preincubatmg and assaying the 
enzyme at a range of pH values From the pH inactivation curve it can be seen that the enzyme is almost 
totally inactivated below pH 4 0 Enzyme inactivation also occurs above pH 9 2 and exposure to pH 10 5 
results m almost total inactivation of the enzyme
By comparing the two curves it can be deduced that the observed pH activity profile is due to kmetically 
important ionisations rather than the effect o f pH on enzyme structure Although pKas are dependent on 
temperature, ionic strength and microenvironment of the lomsable group, the pH activity profile indicates 
the presence of a cntical group which must be m the basic form for activity (pKa =  6 0), possibly due to 
imidazole groups (histidine) and a group which must be m the acidic form for activity (pKa =  8 5), 
possibly due to hydroxyl groups (tyrosine or senne) (Dunn, 1989) The presence of histidine and tyrosine 
residues as catalytically important elements of PAPII has been clearly demonstrated by O'Connor and 
O'Cumn (1987) and Czekay and Bauer (1993)
4.7.5 The Effect of Functional Reagents on PAPII Activity
The effect of functional reagents on PAPII activity was investigated as outlined in section 2 10 5 The pH 
of all stock solutions was adjusted to pH 7 5 m order to ensure that any observed effects were not simply 
due to pH effects on the enzyme The results of this study are presented m section 3 8 5
The cysteine protease inhibitors had a slightly inhibitory effect on enzyme activity The cysteine protease 
activators were also found to inhibit PAPII activity A significant inhibition of 48% was observed with 
lOmM DTT The mild inhibition of the enzyme by cysteine protease inhibitors and the inhibition by 
DTT is consistent with previously charactensed PAPIIs (O'Connor and O'Cuinn, 1984, Wilk and Wilk, 
1989a, Bauer, 1994, O'Leary and O'Connor, 1995a), and clearly demonstrates that this enzyme is not a 
member of the family of cysteine proteases
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The effect o f two senne protease inhibitors on PAPII activity yielded conflicting results In agreement 
with previous reports (O'Connor and O'Cumn, 1984, Wilk and Wilk, 1989a, Bauer, 1994, O'Leary and 
O'Connor, 1995a), PMSF was shown to have no inhibitory effect on enzyme activity AEBSF however, 
was found to be a potent inhibitor of the enzyme resulting m 63% and 97% inhibition at ImM and 
lOmM respectively Further work is necessary to determine the mechanism of inhibition with this 
reagent
Since 2-pyrrolidone was used m the PAPII assays, it is important to note that at a concentration of 
50mM, this compound did not significantly inhibit the enzyme The microbial protease inhibitors 
bacitracin and benzamidine produced no significant effect on enzyme activity while, m agreement with the 
findings of O'Connor and O'Cumn (1984), puromycin was found to be inhibitory
4.7.6 The Effect of Metal-Complexing Agents on PAPII Activity
PAPII has recently been identified as a zmc metallopeptidase (Czekay and Bauer, 1993, Schauder et a l , 
1994) Initial studies on the inhibition o f the purified enzyme by metal chelators were carried out as 
outlined in section 2 10 5 The results o f this study are presented in section 3 8 5 At a concentration of 
ImM, only 8-hydroxyqumolme had a significant inhibitory effect o f 14% on the enzyme At a 
concentration of lOmM, no inhibition by imidazole or EDTA was observed and only modest inhibition 
of 10% and 29% was observed with CDTA and EGTA respectively Strong inhibition o f 68% was 
observed with 8-hydroxyqumoline at a concentration of lOmM Exposure to the chelator 1,10- 
phenanthrohne at this concentration resulted in total inhibition o f the enzyme However, the non- 
chelatmg compounds 1,7-phenanthroline and 4,7-phenanthroline, also resulted in strong inhibition of the 
enzyme
The degree o f enzyme inhibition by metal chelators is considerably lower than that reported previously for 
PAPII (O'Connor and O'Cumn, 1984, Wilk and Wilk, 1989a, Bauer, 1994, Czekay and Bauer, 1994, 
O'Leary and O'Connor, 1995a) It should be noted that the results obtained in this study relate specifically 
to the method employed thereby making direct comparison with previous studies difficult For instance, a 
pH o f 7 5 was maintained throughout these experiments A lower pH would favour metal removal owing 
to competition between H+ ions and metal ions for the enzyme ligands, therefore stronger inhibition by 
metal chelators would be observed (Auld, 1995) It is also possible that the presence o f l%w/v BSA in 
the enzyme preparation affords some protection to the enzyme from these compounds
To further investigate the effect of metal chelators and the non-chelating phenanthrolmes, their effect on 
enzyme activity was monitored over time as outlined in section 2 10 6 The results o f this study are 
presented in section 3 8 6 It can be seen from figures 3 8 6 1 and 3 8 6 2 that inhibition of the enzyme 
by the chelators occurs in a time-dependent manner while inhibition by the non-chelating 1 ,7 - 
phenanthrolme and 4,7-phenanthrohne is independent o f time A time-dependent inhibition of
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metallopeptidases by chelators is not unprecedented and has been previously reported for many enzymes, 
including PAPII (Czekay and Bauer, 1993) These authors also reported the inhibition of the enzyme by 
the non-chelating phenanthrolines to be independent of time They therefore suggested that this inhibition 
was due to non-specific hydrophobic interactions of the enzyme with the aromatic structures of these 
compounds It is interesting that in the initial study which employed a 15 mmute preincubation of 
enzyme with the test compound, 8-hydroxyqmnolme and 1,10-phenanthroline were found to be the most 
inhibitory chelators (see table 3 8 5) However, following 24 hours premcubation, the chelators CDTA, 
EDTA and EGTA resulted m the strongest inhibition o f PAPII activity (see figures 3 8 6 1 and 3 8 6 2) 
The initial, rapid inhibition of the enzyme by 8-hydroxyquinohne and 1,10-phenanthrolme may occur as a 
result o f the aforementioned non-specific hydrophobic interactions o f the enzyme with the aromatic 
structures o f these compounds, with the subsequent time-dependent inhibition resulting from their metal- 
complexmg abilities It is also possible that the initial inhibition occurs as a result o f the formation o f a 
ternary enzyme / metal /  chelator complex which is followed by dissociation of the chelator-bound metal 
m a time dependent manner This mode of inhibition by 1,10-phenanthrolme has been observed for other 
enzymes including astacrn (Stocker et a l , 1988) In the absence of chelators, the half life of metal release 
from enzymes can vary from seconds to years, for example angiotensin converting enzyme t i/2 = 36 
seconds, carbonic anhydrase tt/2 = 3 years (Auld, 1995) This fact explains the time-dependent inhibition 
of metallopeptidases by chelators
While EDTA is a universal complexmg agent which chelates most divalent ions, EGTA is reported to be 
specific for Ca2+ 1,10-phenanthrolme has a much higher affinity for Zn2+ than for Ca2+ and inhibition 
of an enzyme by this compound is usually indicative o f a zinc metallopeptidase (Salvesen and Nagase,
1989) Since PAPII is inhibited by all of these chelators, further studies were necessary to confirm the 
identity of the metal at its active site
4.7.7 The Effect of Metal Ions on PAPII Activity
The effect o f metal ions on PAPII activity was investigated as outlined in section 2 10 7 This study was 
performed at pH 7 0 since many of the metal salts were found to be insoluble at higher pH values No 
single buffer was found to be suitable for the dissolution o f all o f the metal salts, therefore tris and 
potassium phosphate buffers were used as descnbed in table 2 1 0  7 Since all attempts to dissolve FeS04  
at pH 7 0 were unsuccessful, FeCl3 was used in its place Sulphate salts o f all other metals were used so 
as to ensure that observed effects were due to metal ions rather than their countenons The results of this 
study are presented in section 3 8 7 The enzyme was not affected by Ca2+, Fe3+ or Mn2+, however, 
significant inhibition was observed following exposure to Zn2+, Hg2+ and Cd2+ Inhibition by Zn2+ and 
other transition metals has been reported for most metallopeptidases (Auld, 1995), including PAPII (Wilk 
and Wilk, 1989a, Bauer, 1994, Czekay and Bauer, 1994)
Exposure o f the enzyme to N i2+ caused a slight increase in PAPII activity while exposure to ImM Co2+ 
caused an increase in activity to more than 5-tunes that in the control Cobalt has been shown to be the
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one metal that substitutes for zinc m carboxypeptidases, endopepudases and aminopeptidases In some 
cases, cobalt has been shown to cause up to a 10-fold enhancement o f the activity o f zinc 
metallopeptidases (Auld, 1995) In 1993, Czekay and Bauer reported that the addition of 15|iM C0SO4 to 
purified PAPII resulted in a slow increase m the reaction rate to 170% of the control In a subsequent 
report, Bauer (1994) showed the enzyme to be inhibited by 71% following 15 minutes premcubation with 
ImM C0SO4 This inhibition with ImM C0SO4 contrasts sharply with the large increase m activity 
observed under similar conditions in this study It is possible that the presence of 1% w/v BSA in this 
enzyme preparation necessitates a higher concentration o f the metal (mM rather than }xM range) to 
enhance enzyme activity
The effect o f metal 10ns on EDTA-treated PAPII was investigated as outlined m section 2 10 8 Figure 
3 8 8 illustrates that the enzyme was only partially reactivated m the presence of Ca2+ or Mn2+ while 
full enzymatic activity could be restored by the addition o f ImM Z nS04 As expected from previous 
studies on the native enzyme, Co2+ or N i2+ were shown to be capable of restoring activity to levels 
greater than the control value These results correlate well with previous PAPII reactivation studies by 
Czekay and Bauer (1993) with the exception that these authors showed Zn2+ to be more efficient in the 
reactivation o f the enzyme than Ni2+ This inconsistency may be explained by the differences m the 
methodologies used As outlined m sections 2 10 8, following the inactivation of the enzyme with 
EDTA, the chelator was removed by gel filtration Addition of metal salts to the EDTA free enzyme 
ensures that only the ability of the metal ion to reactivate the enzyme is reflected in the resulting activity 
In their study, Czekay and Bauer inhibited the enzyme m the presence of EDTA and subsequently added an 
equimolar amount of the metal under investigation Under these conditions, the observed effect on enzyme 
activity reflects both the affinity of EDTA for the metal and the ability of the metal to reactivate the 
enzyme Since the binding strength of EDTA for N i2+ has been shown to be stronger than for Zn2+ 
(Auld, 1995), the concentration o f N i2+ available to the enzyme would be lower that o f  Zn2+ It is 
possible that the relative abilities of these metals to reactivate the enzyme is not truly represented
4.7.8 The Effect of DMSO on PAPII Activity
DMSO is necessary for the dissolution of the substrate pGlu-MCA (see sections 2 2 2 and 2 10 10 1) but 
is not necessary for the dissolution o f pGlu-His-Pro-MCA (see section 2 2 1 )  Before direct comparisons 
could be made between the kinetic characteristics of PAPII for these two substrates, it was necessary to 
determine the effect of DMSO on PAPII activity as outlined m section 2 10 9 The results o f this study 
are presented in section 3 8 9 The presence of 2% v/v DMSO in the substrate causes the enzyme activity 
to increase to 105% of the control While the activity is not significantly affected by 4% or 6% v/v 
DMSO, increasing the concentration to 8% and 10% v/v causes the activity to decrease by 10% and 21% 
respectively In view of the fact that PAPII activity is not affected by the presence of 4 %v/v DMSO, 
direct comparisons can be made between the Km and Vmax values of the substrates pGlu-MCA and pGlu- 
His-Pro-MCA, as presented in section 3 8 111 and discussed in section 4 6 4
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The notion that nature intended enzymes to be cataly tically active in water and that organic solvents serve 
only to destroy their catalytic power is incorrect (Dordick, 1989) Many enzymes, such as PAPII, 
function m naturally hydrophobic environments, usually m the presence of, or immobilised m a lipid 
membrane While water is an absolute requirement for the catalytic function of enzymes, it is unlikely 
that the bulk water concentration of 55M m aqueous solutions is necessary It is more likely that just a 
monolayer of water around the enzyme is necessary and therefore, it is not surprising that enzymes are 
catalytically active m organic solvent systems (Klibanov, 1986) The enhancement of PAPII activity in a 
low concentration of DMSO followed by its inactivation at higher concentrations represents a commonly 
reported effect of organic solvents on enzyme activity Some examples o f the effects of organic solvents 
on enzyme activity include, increased trypsm activity m 10% v/v acetomtnle (Batra and Gupta, 1994) and 
a 2-fold increase m the esterase activity of a-thrombin in the presence o f 20% v/v DMSO (Neidleman,
1990)
4.7.9 Substrate Specificity of PAPII
The ability o f PAPII to hydrolyse a range o f pyroglutamyl peptides was monitored by reverse phase 
HPLC as outlined in sections 2 10 10 3 and 2 10 10 4 The standard curves presented in figures 3 8 10 3 
to 3 8 10 7, illustrate the quantitative nature of the system for the detection of peptides and the metabolite 
pyroglutamic acid The HPLC profiles presented m figures 3 8 10 3 to 3 8 10 7, illustrate the cleavage of  
pyroglutamyl peptides by the enzyme, while figures 3 8 10 9 to 3 8 10 12 illustrate the cleavage of some 
of these peptides over time These figures clearly show hydrolysis of the peptides, indicated by a reduction 
in peak area, coupled with simultaneous increase in pGlu concentration The results o f this study are 
summarised m table 3 8 10 2
In agreement with previous studies on PAPII (O'Connor and O'Curnn, 1985, Wilk and Wilk, 1989a, 
Elmore et a l , 1990, O'Leary and O'Connor, 1995a), the enzyme was shown to be specific for only TRH 
and closely related peptides In addition to the peptides which these investigators showed to be hydrolysed, 
the enzyme was also shown to cleave pGlu-His-Gly-OH (anorexogemc peptide / colon mitosis inhibitor), 
pGlu-His-Gly-NH2 and pGlu-His-Pro-Gly-NH2
A number o f TRH-like peptides have recently been identified m mammalian semen (Cockle, 1995) pGlu- 
Glu-Pro-NH 2 (fertilisation promoting peptide) originates m the prostate and is involved in sperm 
maturation (Linden et a l , 1996) This peptide has also been found to be present in the CNS and anterior 
pituitary where it may function as a paracrine or autocrine modulator of pituitary function (Cockle, 1995, 
Rondeel et a l , 1995) In agreement with a recent report that PE is the enzyme responsible for the 
degradation of this tripeptide (Siviter and Cockle, 1995), no cleavage by PAPII was observed pGlu-Phe- 
Pro-NH2 originates m the testes and is also secreted into the semen Although its function has not yet 
been elucidated, it is thought to have a role distinct from that of pGlu-Glu-Pro-NH2 (Lmden et a l , 1996) 
In contrast with the findings of Lanzara et al (1989) and Elmore et al (1990), PAPII was shown to be 
capable o f hydrolysing pGlu-Phe-Pro-NH2 Since PAPII has been shown to be present in rabbit testes
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(Vargas et a l , 1992a) and is regulated by sex hormones (see section 1 4  2 3), it is possible that the 
enzyme plays a part in the regulation o f this tripeptide in vivo Previous studies on the substrate 
specificity o f PAPII have suggested an absolute requirement for the N-terminal pGlu-His sequence 
(Elmore et a l , 1990) The ability o f the enzyme to hydrolyse pGlu-Phe-Pro-NH2 demonstrates that the 
enzyme tolerates substitution of the penultimate His residue
Figure 3 8 10 7 illustrates the cleavage of TRH by PAPII over tune From these plots the non-enzymatic 
cyclisation of His-Pro-NH2 to cyclo His-Pro, after cleavage o f the pGlu-His bond by PAPII, is clearly 
demonstrated Figures 3 8 10 3, 3 8 10 5 and 3 8 10 6 demonstrate that cyclo His-Pro is formed 
following the metabolism of acid TRH, pGlu-His-Pro-Gly-OH and pGlu-His-Pro-Gly-NH2 It is clear, 
however, that the rate o f cyclisation in each of these cases is slower than that of His-Pro-NH2, since 
cyclo His-Pro represents only a minor metabolite after 18 hours incubation at 37°C The TRH precursor 
pGlu-His-Pro-Gly-OH has recently been shown to interact directly with TRH-Rs (Yamada et a l , 1995) It 
is possible that PAPII plays a part m the regulation o f this tripeptide in vivo, and in doing so it may 
contribute to in vivo levels o f cyclo His-Pro The conversion of His-Pro-Gly-OH to cyclo His-Pro, 
following the in vitro action o f PAPI on pGlu-His-Pro-Gly-OH, has previously been demonstrated by 
Miyashita et al (1993)
In view of the fact that the enzyme has been shown to hydrolyse pGlu-BNA and pGlu-MCA, albeit at a 
low rate and with low affinity (see sections 3 8 1 0  2, 3 8 1 1  1 and 4 6 4), it would be expected that some 
pGlu-Xaa dipeptides, such as pGlu-His or pGlu-Phe, might be cleaved However none of the dipeptides 
tested were hydrolysed by the enzyme It is possible that limited hydrolysis of these dipeptides does occur, 
but a more sensitive method such as capillary electrophoresis is necessary for its detection However, 
even if such hydrolysis was to be observed, it is unlikely to be of physiological importance
The kinetic characteristics of purified PAPII towards a range of pyroglutamyl peptides were determined as 
outlined m section 2 10 11 The Km, and Vmax values for these peptides were determined using a 
range o f kinetic models based on the Michaehs-Menten equation Henderson (1992) has reviewed the 
suitability of these models for the determination o f Km, Kv and Vmax values While very useful for 
display purposes, because of their linearity and familiarity, the reciprocal plots (Eadie-Hofstee and Hanes- 
Woolf plots) and especially the double reciprocal plot (Lineweaver-Burk plot), are statistically unsound 
for the determination of Km and Vmax The author has suggested that one reason for the continued 
popularity of the Lmeweaver-Burk plot, is that it conceals a poor fit between the data and a straight line 
Using a computer to calculate the least-squares fit o f the data points to a rate  versus su bstra te  
concentration hyperbola (Michaehs-Menten curve) provides statistically sound estimates of Km and Vmax 
Although not suitable for display purposes, the most statistically sound method for the determination of 
these values is the Direct Linear Plot (Eisenthal and Comish-Bowden, 1974) This method uses a non- 
parametric criterion of best-fit, m which the median value of a series of estimates of Km and Vmax is 
taken (Henderson, 1992) In view o f these facts, K, and Km values referred to hereafter are those 
determined from the Direct Linear Plot The Lmeweaver-Burk plots illustrated m figures 3 8 119  to
1 5 0
3 8 11 12 were used to determine the mode of inhibition of the peptides All o f the peptides tested were 
found to act as competitive inhibitors of the enzyme as summarised m table 3 8 112
In agreement with previous reports (O'Connor and O'Cuinn, 1985, Elmore et a l , 1990, O'Leary and 
O'Connor, 1995a), a K, o f 40{iM was obtained for the reaction of the enzyme with TRH The Km value 
determined for the TRH analogue, pGlu-His-Pro-MCA, (2 4-2 5nM), is considerably lower than for TRH 
itself, indicating that the enzyme has a preference for a large, hydrophobic group such as MCA, at the 
carboxy-termmus of the substrate This finding contrasts sharply with the findings of O'Leary and 
O'Connor (1995a), who reported a Km of 100|xM for this substrate The reason for (his discrepancy is not 
clear, however, it is possible that the presence of 0 3% v/v Triton X-100 in the enzyme preparation 
described by these investigators is responsible for this, and other, differences m the biochemical 
characteristics displayed by1 the enzyme It is also possible that the mtact, Triton X-100 solubilised 
enzyme behaves differently to the truncated, trypsin solubilised enzyme
In agreement with the findings of Elmore et al (1990), the peptides pGlu-His-Pro-OH, pGlu-His-Gly-OH 
and pGlu-His-Pro-Gly-OH each displayed higher Kj values than the corresponding amides, suggesting that 
the enzyme prefers an amide group at the carboxy-termmus of peptide substrates It is interesting to note 
that the enzyme has a higher affinity for pGlu-His-Pro-Gly-NH2 (K, = 30(JM), than for TRH (KL = 
40|XM) However, the rate of TRH hydrolysis by the enzyme is faster than that of pGlu-His-Pro-Gly-NH2 
as illustrated by the HPLC time-courses presented in figures 3 8 10 9 and 3 8 1011
The cleavage o f pGIu-His-Trp (LHRH 1-3), with a Kj of 130-170}xM, has previously been demonstrated 
by O'Connor and O'Cuinn (1985), Elmore et al (1990), and O'Leary and O'Connor (1995a) As expected, 
extending this sequence to LHRH 1-5,1-6,1-7 or to the complete decapeptide LHRH (pGlu-His-Trp-Ser- 
Tyr-Gly-Leu-Arg-Pro-Gly-NH2)> abolishes the ability of the enzyme to remove the N-termmal pGlu The' 
Kj values obtained for these peptides display an interesting trend The enzyme displays a marked increase 
in affinity for LHRH 1-5 (K* of lljiM ) over LHRH 1-3 Extending the sequence further to LHRH 1-6 
and 1-7 causes an increase in the Kxs to 19|iM and 60pM respectively This indicates that elongation of 
the peptide causes the affinity of the enzyme to be reduced Based on this trend, the Kj of the enzyme for 
the complete decapeptide LHRH would be expected to be even higher than 60|aM However, this was not 
found to be the case In fact, LHRH, with a Ki of only 8|iM, was found to be the most potent peptide 
inhibitor tested It is possible that this higher than expected affinity is due, at least in part, to the 
previously mentioned preference of the enzyme for peptide substrates with an amidated carboxy-termmus 
This result compares well with the findings of O'Connor and O'Cuinn (1985) who reported LHRH to be a 
potent competitive inhibitor of PAPII (Kt = 20(iM) However, it contrasts sharply with the findings of 
O'Leary and O'Connor (1995a), who reported the enzyme to be non-competitively inhibited by LHRH 
with an extremely high K, of 820|jM The reason for this discrepancy is not clear
In view of the facts presented herein, it is clear that the substrate specificity of PAPII is not as narrow as 
previously believed It is nonetheless clear that only TRH and closely related peptides are hydrolysed by
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the enzyme The physiological significance, if  any, of the enzymes abihty to hydrolyse peptides other 
than TRH remains to be elucidated
4 .8  Sum m ary
PAPII was solubilised from the membrane fraction of bovine bram by treatment with trypsin The 
enzyme thus released, was found to be considerably more stable than that obtained by solubilisation using 
a range of detergents The trypsin solubilised enzyme was further purified by Q-Sepharose amon- 
exchange, immobilised Zn-affimty, calcium phosphate cellulose and Sephacryl S200 gel filtration 
chromatography, resulting in a 3,047-fold purification with a 24% recovery of enzyme activity
A number of fluonmetnc assays for the detection of PAPII were developed, two of which are based on the 
TRH substrate analogue pGlu-His-Pro-MCA The first of these is a coupled enzyme assay Following the 
removal o f  the N-terminal pGlu by PAPII, liberation o f MCA from the metabolite His-Pro-MCA is 
catalysed by the addition of, partially purified, bovine serum DAPIV The second assay is based on the 
non-enzymatic cyclisation of His-Pro-MCA to cyclo His-Pro and free MCA This cyclisation is catalysed 
by incubation of the reaction mixture for up to 2 hours at 80°C A third assay, based on the ability of the 
enzyme to hydrolyse the substrate pGlu-MCA, facilitated the continuous monitoring of PAPII activity in 
purified samples containing relatively high levels o f activity These fluonmetnc assays offer expeditious 
alternatives to the existing radiolabelled TRH assays, for the detection of PAPE activity
A relative molecular mass o f 214,000 Da was determined for the enzyme, by gel filtration 
chromatography However, the subunit structure could not be determined due to the visualisation of 
multiple bands following SDS PAGE
The punfied enzyme was found to be relatively labile However, the presence of 1% v/v BSA was shown 
to greatly improve its stability The enzyme exhibits optimal activity in the pH range 6 8-7 6 and was 
found to be stable over a wide pH range of 4 0-9 0 Optimal enzyme activity was observed at 45°C
The enzyme was identified as a metallopeptidase on the basis of its inhibition, m a time dependent 
manner, by metal-complexing agents and its subsequent reactivation m the presence o f metal ions, 
including Zn2+, Ni2+ and Co2+ Enzyme inhibition by cysteine protease activators and inhibitors and by 
the senne protease inhibitor AEBSF, was also observed
TRH and a number of closely related peptides, including pGlu-His-Gly-OH, pGlu-His-Gly-NH2> pGlu- 
His-Pro-Gly-NH2 and pGlu-Phe-Pro-NH2, were hydrolysed by the punfied enzyme LHRH and LHRH 
1-5, although not substrates for the enzyme, were shown to be potent, competitive inhibitors o f the 
enzyme, with Kt values of 8(iM and 11 ¡iM respectively
In conclusion, the charactenstics o f the PAPII activity punfied from bovine bram are similar to those 
reported for previously charactensed PAPIIs It can therefore be assumed that this enzyme represents a 
"classical" pyroglutamyl ammopeptidase type-II (EC 3 4 1 9  6)
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Appendices
A . I .  Kinetic Analysis
Data obtained from kinetic investigations was analysed using the following models based on the 
Michaelis-Menten equation In these equations, V = initial velocity, Vmax = maximal velocity, [S] = 
substrate concentration, [I] = inhibitor concentration, Km = Michaelis constant and = inhibitor 
dissociation constant
A . 1 .1  M ichaelis M enten Analysis
The rate equation for the Michaelis-Menten model of enzyme catalysed reactions is as follows
y _ Vmax [S]
Km +[S]
A plot o f V versus [S] yields a rectangular hyperbola At V -  Vmax/2, [S] -  Km
A .1 .2  Lmeweaver-Burk Analysis
The Michaelis-Menten equation can be rearranged to yield the following equation
1 Km 1
V Vmax [S] Vmax
A double reciprocal plot o f 1/V versus 1/[S] yields a straight line The Y-Axis intercept represents 
1/Vmax and the X-Axis intercept represents -1/Km
A .1 .3  Eadie-H ofstee Analysis
The Michaelis-Menten equation can be rearranged to yield the following equation
v - v  VKmisf
A reciprocal plot of V versus V/[S] yields a straight line The Y-Axis intercept represents Vmax and the 
slope of the line represents -Km
A 1 .4  H anes-W oolf Analysis
The Michaehs-Menten equation can be rearranged to yield the following equation
B] Km | [S]
V Vmax Vmax
A reciprocal plot of [S]/V versus [S] yields a straight line The X-Axis intercept represents -Km and the 
slope of the line represents 1/Vmax
A1
A . 1 .5  Direct Linear Plot
This method is based on plotting substrate concentration and initial velocity values as lines in m 
parameter space rather than as points m observation space Where as in the previously mentioned 
models, substrate concentration and initial velocity values were used to place a point m observation space 
at particular X, Y coordinates, in this model a line is constructed by joining a point at a distance of -[S] 
from the origin on the X-axis to a point at a distance V from the origin on the Y-axis and extending that 
line into positive X and Y space Plotting multiple lines using multiple substrate concentration and 
initial velocity combinations will lead ideally to a unique intersection point, whose X and Y coordinates 
represent Km and Vmax respectively
In practise, many intersection points are obtained and the Km and Vmax parameters are represented by the 
median values Beacuse the median value of the list of possible determinations is used, the Direct Linear 
Plot is less sensitive to the effects of outliers, making it statistically better than the previouly described 
models A simple BASIC program was created to take data obtained from kinetic investigations and 
calculate the mtesection point of lines created as described, and to determine the median values
A2
In the presence of a competitive inhibitor the Michaelis Menten equation is replaced by following 
equation
A. 1 .5  Determination of K, V alues
V
On the basis o f this equation, the IQ value can be determined from the following equation m which Km is 
determined in the absence o f inhibitor and Kapp is the apparent Km in the presence of the inhibitor at a 
concentration [I] are determined usmg the kinetic models described previously
Kt - ®
Kapp - Km
m which Km is determined m the absence of inhibitor and Kapp is the apparent Km m the presence of the 
inhibitor at a concentration [I] are determined usmg the kinetic models described previously
A . 2. Statistical Analysis
Most results are presented as the mean of three individual determinations, (a, b and c), ± the standard 
deviation (SD) or ± the standard error of the mean (SEM) These values are calculated as follows
Mean = a + b + c
Variance = a2 + b2 + °2 . Mean2
SD = \J Variance 
SD
SEM =
\fT
A3
